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Abstract 
The assessment of skeletal muscle toxicity is important in the safety evaluation of 
new chemical entities, particularly those used as lipid-lowering agents. As current 
strategies for assessing myopathy are based on in vivo measurements, which 
sometimes lack sensitivity and specificity, there is a need for biomarkers that better 
predict myopathy and also for an approach that is more amenable to high-
throughput screening. Here, the use of cultured rat L6 myoblasts and myotubes 
was explored in combination with a variety of techniques to identify potential 
biomarkers, following exposure to a known experimental myotoxicant, 2,3,5,6 
tetramethyl-p-phenylenediamine (TMPD), or a highly selective peroxisome 
proliferator-activated receptor δ agonist, 4-[2-(3-fluoro-4-trifluoromethyl-phenyl)-4-
methyl-thiazol-5-ylmethylsulfanyl]-2-methyl-phenoxy-acetic acid (GWδ).  
 
The use of candidate biomarkers, based on the utilisation of a variety of established 
and putative markers of myopathy, proved to be of little additional value in 
myoblasts treated with low concentrations of TMPD. In myotubes, however, 
intracellular levels of aldolase and creatine kinase appeared to be responsive 
markers. Proteomic analysis of TMPD and GWδ-treated skeletal muscle cells using 
surface-enhanced laser desorption/ionization-time of flight-mass spectrometry 
(SELDI-TOF-MS) showed changes in the levels of 16 protein ions in myoblasts and 
12 changes in myotubes, although SELDI-TOF-MS did not lend itself to the 
conclusive identification of these ions. Analysis of the muscle cell proteins using 
label-free quantitative proteomics was able to simultaneously quantify TMPD-
induced changes and identify the proteins involved. In this way, 8 proteins in 
myoblasts and 10 proteins in myotubes were discovered to be the most responsive 
proteins to treatment. Changes in the levels of Rho GDP dissociation inhibitor (GDI) 
alpha in myoblasts and Myosin light chain 2 in myotubes were confirmed by 
immunoblotting, and these proteins were also responsive to treatment with GWδ 
and pravastatin.   
 
In conclusion, cultured skeletal muscle cells were responsive to the effects of 
potentially myotoxic agents, and proteomics was successful in identifying and 
quantifying proteins that may act as biomarkers of effect. 
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Chapter 1 
1. Introduction 
1.1 Pharmaceutical safety assessment  
The process of taking a compound from synthesis in the laboratory to the 
treatment of patients in the clinic, otherwise known as drug development, is a 
lengthy, complex and often ethically-questioned process, which takes place at 
huge costs to research and development (R&D) companies1-6. Despite the fact 
that advances in high-throughput technologies (e.g. combinatorial chemistry) 
have facilitated the identification of a large number of chemical targets in the 
early stages of drug development, the number of new compounds making it 
through to successful product launch has reduced significantly over the past few 
years, whilst the costs of research have increased7-13. These costs are 
exacerbated by the fact that only a small percentage of drugs initially evaluated 
make it through the approval process, due to unexpected findings in the later 
stages of drug development.  
 
Late stage drug attrition is combined with the fact that only a small proportion of 
drugs that complete the regulatory process make sufficient profits to recover the 
huge investments made by research companies. This could lead to sponsors 
investing in drugs that are not necessarily in the therapeutic areas of greatest 
need but that have the highest likelihood of being profitable14-16. As such, the 
rigorous safety assessment of new drugs is paramount, as adverse drug 
reactions (ADRs) are most frequently to blame for the failure of new compounds 
to be registered for clinical use. In addition to the duty of drug manufacturers to 
the protection of potential patients, research companies must also protect 
themselves (and the industry) against negative public perception and possible 
litigation arising from unexpected ADRs when new compounds are licensed for 
general use17-21. 
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Drug development is highly regulated by authorities such as the Food and Drug 
Administration (FDA) and guided by title 21 of the code of federal regulations 
(also known as 21CFR), which ensures that qualified investigators produce 
appropriate regulatory data and documents in a manner compliant with good 
clinical practice (GCP). In combination, scientific investigators, the FDA and 
institutional review boards (IRBs) certify the credibility of research work 
contributing to the registration of a novel chemical entity (NCE). Together, they 
provide the public with a measure of confidence in the science behind drugs 
available for clinical therapeutics22-24. Before an NCE is approved by the FDA, 
pharmacology and toxicology data is generated through a series of preclinical 
and clinical experiments in order to identify the most appropriate chemical 
targets, and also to test the effects of potential therapeutic drugs. Information on 
the efficacy of a molecule must be considered whilst, at the same time, ensuring 
that there is a sufficient therapeutic index (the ratio between the toxic dose and 
the therapeutic dose) so that the drug is most likely to be safe in humans during 
clinical trials and also post-marketing. 
 
The safety assessment of new compounds is typically conducted using a 
combination of disciplines looking at the chemistry of the molecule during 
candidate selection and the pharmacological interactions between the molecule 
and its intended or unintended targets. Complications that may arise from the 
bioavailability and biodistribution of the drug are investigated in absorption, 
distribution, metabolism and excretion (ADME) studies. Toxicological drug 
effects are usually explored preclinically through carcinogenicity, teratogenicity 
and toxicity studies and the aim of these investigations is to select molecules 
with the lowest probability of being associated with adverse events. Following 
the submission of data from preclinical studies, a successful investigational new 
drug (IND) application to the FDA allows drugs to enter the clinical phases of 
investigation.  
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In Phase I clinical trials, the emphasis is on testing the safety of novel chemicals 
in humans before Phase II trials explore the efficacy of compounds for a specific 
condition. Once these aspects of the drug have been examined, a larger 
population of patients is included in Phase III studies so that the effects of the 
drug on a wider, more varied set of patients can be investigated and more 
information can be gained which may contribute to advertising or product 
labelling. In these studies, the assessment of any other risk factors such as age, 
gender or environment may also be undertaken. In some cases, a further Phase 
(IV) may be included voluntarily following FDA approval, or at the request of the 
FDA, in which post-marketing trials are conducted in order to provide additional 
data on the drug on an even larger cohort of patients. This process ensures that 
reasonable steps are taken by drug developers to ensure the safety of 
patients25-32.  
 
1.2 Adverse drug reactions 
ADRs are those that may require intervention or an interruption in treatment in 
order to ensure the safety of the test species under investigation, and are the 
most common reason for drug attrition during the drug development process. 
Despite most clinical trials being completed without major findings, due to the 
comprehensive portfolio of preclinical work performed before drugs are tested in 
man, the focus understandably tends to be on the low incidence of ADRs 
occurring in clinical studies or when drugs are released into the general 
population. This is demonstrated in the high profile case of Rofecoxib (a non-
steroidal anti-inflammatory drug (NSAID), approved in 1999 as Vioxx® for the 
treatment of pain), which was withdrawn from the market in 2004 after being 
associated with an increased risk of myocardial infarction33-36. A similar story is 
true of the lipid-lowering compound cerivastatin (an HMG CoA reductase 
inhibitor (statin)), which was withdrawn from the market in 2001 following a 
number of fatal events associated with skeletal muscle toxicity in patients 
exposed to the drug. Although the effects were proven not to be specific to this 
class of drugs, there were considerable consequences on the reputation and 
profits of the manufacturer. There were also knock-on effects on patient 
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compliance with this class of compound, due to the fear of possible harmful 
effects associated with long-term medication37,38.  
 
Despite the rare situations where preclinical safety testing of a novel compound 
has failed to predict adverse effects observed post-marketing, there are many 
successes. In fact, statins and NSAIDs are generally considered to have a good 
safety profile, as indicated by the number of drugs in these classes that are 
currently prescribed clinically for the treatment of obesity or inflammation, 
respectively. Current strategies for dealing with possible adverse effects include 
the close monitoring of the status of skeletal muscle (for patients on lipid-
lowering drugs) or for gastrointestinal effects sometimes associated with 
NSAIDs. Additionally, improvements in product labelling are sometimes 
requested in order to guard against complications that may arise from the drug 
being administered to more susceptible sections of the population. Improved 
methods of monitoring adverse events, combined with an improved 
understanding of the mechanisms behind them, would allow investigators to 
monitor the effects of new molecules better during drug development39-44.  
 
ADRs are manifested in a number of ways and the manner in which preclinical 
safety assessment departments are organised within pharmaceutical 
companies reflects this. Reproductive toxicology studies, for example, examine 
whether drug treatment to a pregnant mother could result in birth defects, 
malformations or even the death of an embryo. The need for such routine 
testing was established following the tragedy of Thalidomide which was 
marketed in 1957 as an anti-emetic but withdrawn from the market 4 years later 
after it was associated with severe birth defects in newborns45. Another 
important part of safety assessment is the screening for damage to 
deoxyribonucleic acid (DNA) which can result in a genetic mutation or, in some 
cases, uncontrolled cell replication and subsequent carcinogenesis. The 
potential of compounds to cause mutations in DNA is usually screened using 
tests such as the Ames test or the comet assay46-49. 
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1.2.1 Target organ toxicity 
ADRs are often considered in terms of their target or off-target effects. So called 
“recurrent toxicity” issues are those that are characteristic of certain classes or 
types of compounds and that may occur in studies involving these compounds. 
Although the effects seen with some of these compounds may not be totally 
unexpected, in most cases, the exact mechanism by which toxicity is caused 
may be unknown or may be complicated. This leaves chemists to either attempt 
to design out unwanted features of a molecule, whilst retaining its efficacy, or to 
consider using lower doses of the compound for an alternative indication.  
 
The direct effect on a specific susceptible organ may also be due to several 
other factors, including the position of the organ. This is true of the gastro-
intestinal tract with which a drug may have an increased amount of contact, 
when taken orally50,51. Other drugs may have a chemical structure that is 
associated with a particular toxicity and this is demonstrated in the case of 
cationic amphiphilic drugs (CADs) with which an abnormal accumulation of 
phospholipids can occur within cells of the target organ. Due to the high levels 
of phospholipids contained within surfactant in the lungs, this is often a target 
organ (in the form of lung-congestion), as seen with amiodarone (an anti-
arrhythmic CAD-like drug for the treatment of irregular heart beat)52-54. The liver 
is often a site for toxic effects due to its detoxification role, and hepatotoxicity is 
most commonly the complication associated with drug attrition55-57. 
 
1.2.2 Skeletal muscle toxicity  
Skeletal muscle disorders can occur due to a wide range of factors including the 
misuse of muscles, congenital disease, inflammatory, metabolic or endocrine 
disorders. Symptoms vary with the degree of myopathy ranging from mild 
muscle pain (myalgia), cramp or weakness to much more serious effects, such 
as rhabdomyolysis. This serious, and sometimes fatal condition, is 
characterised by the breakdown of skeletal muscle tissue and the release of 
proteins found in high concentration in skeletal muscle (such as myoglobin) into 
the circulation. These proteins migrate to the kidney where they can result in 
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renal failure due to the harmful effects of these molecules to structures in the 
kidney. Once detected, there are numerous procedures for the treatment of 
skeletal muscle related disorders, such as resting the affected muscle groups, 
more contemporary treatments such as intramuscular stimulation or even 
surgery58-62.  
 
As well as the causes of myopathy already described, myopathy can also be 
drug-induced and usually results in an interruption of the nervous stimuli or a 
direct effect on the muscle fibre such as trauma or ischemia, which results in 
necrosis or apoptosis and subsequent cell death. Drug-induced myopathies are 
perhaps one of the more preventable types of skeletal muscle injury and are a 
concern to pharmaceutical companies, researchers and medical professionals 
endeavouring to understand the underlying causes of these effects, which are 
most frequently associated with drugs in the lipid-lowering class of compounds.  
 
When used carefully, lipid-lowering drugs can significantly reduce the risk of 
myocardial infarction due to reduced levels of circulating lipids, altered 
thrombogenesis and beneficial effects on inflammatory responses. The effects 
of these compounds are mainly considered to be beneficial but there are some 
concerns regarding incidences of skeletal muscle toxicity seen in clinical studies 
involving some compounds in this class. Although the clinical incidence of 
myopathy is relatively low, the increasing number of patients being treated 
chronically for hypercholesterolemia with drugs such as the aforementioned 
statins and peroxisome proliferator-activated receptor (PPAR) agonists mean 
that the associated myopathy is a cause for concern. Even more worrying is the 
fact that combination therapy is common with such compounds and often leads 
to an increased risk of myopathy and a dose-related increase in the incidence of 
the more serious effects on skeletal muscle already described63-65.  
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PPAR agonists are a large class of nuclear receptor proteins that act as 
transcription factors to modulate the expression of genes involved in lipid 
metabolism via the activation of specific receptors. These receptors (α, δ and γ) 
have different roles in the regulation of pathways of mammalian metabolism 
which include fatty acid oxidation and lipogenesis. The diverse physiological 
functions of these receptors are based partly on their different tissue 
distribution. PPAR-α is highly expressed in liver, heart, intestine and proximal 
tubule cells of the kidney, PPAR-δ is expressed ubiquitously (but most 
abundantly in skeletal muscle) and PPAR-γ is expressed predominantly in 
adipose tissue and in the immune system. PPAR-α promotes fatty acid 
oxidation under conditions of lipid catabolism such as fasting, while PPAR-γ 
promotes lipogenesis in adipose tissue. Less is known about the function of 
PPAR-δ, although this receptor is believed to alter the circulating lipid profile, 
lipid handling in the macrophages and skeletal muscle metabolism66-69.  
 
Peroxisome proliferators have been shown to cause an increase in the number 
and size of peroxisomes in the liver, kidney and heart in rodents and are 
believed to induce hepatocarcinogenesis in these species following long-term 
exposure, although there is less evidence for this clinically. As muscle is a 
major site for PPAR expression (especially PPAR-δ), another concern with this 
class of compounds is skeletal muscle toxicity seen with these compounds and 
a concerted effort is being made to understand the nature of the skeletal muscle 
changes associated with PPAR agonists. The fact that a significant amount of 
research is directed towards the use of these compounds as high-affinity 
specific PPAR receptor agonists for the treatment of hyperglycaemia, 
hyperlipidaemia and other metabolic diseases suggests that it is important to 
understand whether the muscle fibre degeneration associated with these 
compounds is due to altered lipid utilisation, muscle type switching or direct 
toxicity70-78.  
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Statins inhibit the action of 3-hydroxy-3-methylglutamyl-coenzyme-A (HMG 
CoA) reductase during a rate-limiting step in cholesterol biosynthesis. As a 
result, circulating cholesterol levels are decreased leading to an improved 
circulating lipid profile in patients. The resulting improvement in the prognosis of 
patients with regards to reduced risk of coronary heart disease and stroke is, 
however, overshadowed by the risk of muscle disorders and much work tends 
to be focused on monitoring the adverse effects of treatment rather than the 
beneficial effects79-85.  
 
Phenylenediamines, such as 2,3,5,6 tetramethyl-p-phenylenediamine (TMPD; 
also known as Würster’s blue), are a class of compounds that specifically 
induce skeletal muscle toxicity through the generation of unusually unstable 
radical cations (Wϋrster salts), superoxide and hydroxyl radicals, and hydrogen 
peroxide. Free radicals, such as those described, are normally prevented from 
doing damage by an endogenous antioxidant system (which includes 
glutathione, glutathione reductase and superoxide dismutase). Cytotoxicity 
usually occurs as a result of glutathione depletion and the formation of mixed 
disulphides, eventually causing damage to cells through oxidative stress due to 
the rate of consumption of these protective molecules exceeding their 
synthesis. TMPD has been used in toxicology experiments in vivo and in vitro 
as an experimental myotoxin due to the predictable and specific nature of the 
toxicity induced in skeletal muscle86-90. 
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1.2.3 Assessment of myopathy 
Besides the direct visualisation of cells or tissue by light or electron microscopy, 
there are few reliable methods of assessing skeletal muscle toxicity in vivo 
(Figure 1). Many routinely used markers for the assessment of skeletal muscle 
toxicity are not ideally suited for use in a clinical setting because they are 
usually non-specific to the site of injury, insensitive to small changes in the 
status of skeletal muscle or their measurement requires a relatively invasive 
sample collection procedure. The fact that such measurements have limited 
value in the assessment of the early stages of myopathy presents a problem for 
researchers evaluating the safety of NCEs. The safety of patients involved in 
clinical trials is of paramount importance and, as such, more useful biomarkers 
are required that may provide additional information on the mechanisms by 
which myotoxicity is caused.  
 
Figure 1: A haematoxylin and eosin stained section of skeletal muscle 
The effects of drug-treatment are commonly assessed in toxicology experiments by 
histopathological examination of tissue sections. A transverse section of skeletal 
muscle tissue taken from the upper hind limb of a female rat treated with 40μmol/kg 
TMPD for 7 days is shown. Treatment with the experimental myotoxin caused single 
cell necrosis in affected animals (necrotic fibres indicated by the arrows). Magnification 
x40. 
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Effects on skeletal muscle are routinely evaluated in toxicology studies by 
measuring the circulating levels of enzymes known to be in high concentration 
in skeletal muscle tissue, such as aspartate aminotransferase (AST), creatine 
kinase (CK), lactate dehydrogenase (LDH) and aldolase (ALD). AST is a mainly 
mitochondrial enzyme, although it is also found in the cytosol of cells. Its wide 
distribution in various organs (especially the heart) means that the origins of an 
increase in AST usually have to be confirmed using other biochemical markers. 
LDH is an enzyme found in a variety of tissues, including liver, heart and 
skeletal muscle. The enzyme is tetrameric and is composed of four subunits of 
two molecules. Various combinations of these molecules result in 5 different 
isoenzymes (LDH1-LDH5), and LDH5 is the isoenzyme found in the highest 
concentrations in skeletal muscle. ALD is a cytosolic enzyme that is found at 
particularly high levels in skeletal muscle tissue and released into the circulation 
following injury to skeletal muscle. However, like the other markers discussed, it 
is not specific to skeletal muscle, and is also present in other tissues, such as 
kidney, liver and intestine91-93.  
 
CK is the most commonly used, and perhaps most useful, routinely used 
marker of muscle injury and is a dimeric enzyme made up of two subunits (M 
and B). The three isoforms; CK-MB, CK-BB and CK-MM are in highest 
concentration in cardiac muscle, brain and skeletal muscle, respectively92,93. 
The measurement of CK in toxicology studies can be problematic because it 
has a short half-life in the circulation and is believed to degrade rapidly in the 
medium when enzyme leakage from cells is measured during in vitro 
experiments. In addition, this marker lacks specificity for skeletal muscle unless 
the specific isoenzymes previously mentioned are measured88. More recently, 
reportedly more specific markers of skeletal muscle toxicity such as 
parvalbumin, skeletal troponin I (sTnI), myosin light chain 3 (Myl3) and fatty acid 
binding protein 3 (FABP3) have been proposed, but many of these are yet to be 
validated and established as useful biomarkers of myopathy. Issues such as the 
sensitivity and specificity of these markers to low levels of injury to skeletal 
muscle have yet to be fully assessed91,94-100. 
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1.2.4 Models used in toxicology 
Preclinical animal studies are a legal requirement in order to demonstrate the 
safety and efficacy of new compounds prior to testing in man. However, there is 
a desire to replace current methods with more humane methods (where 
possible), to refine the methods used in order to minimise the suffering of study 
animals and also to reduce the number of animals used in studies (also known 
as the 3Rs). The aim is to find alternatives to using animals where possible and, 
whilst it is generally accepted that they cannot completely negate the 
requirement for animal testing in drug development, ex vivo or in vitro models 
are often utilised in an attempt to model certain aspects of toxicology seen in 
vivo101-106. The rat L6 skeletal muscle cell line (originally isolated from primary 
cultures of Rattus norvegicus thigh muscle) is often used in vitro to model the 
effects of compounds on skeletal muscle tissue107-112. 
 
Myoblasts are immature, undifferentiated cells that retain the ability in vitro to 
divide and differentiate into more specialised skeletal muscle cells. 
Differentiation into skeletal muscle cells (myogenesis) is regulated by a family of 
myogenic regulatory factors (MRFs) that activate the expression of specific 
skeletal muscle genes. Transcription factors such as MyoD and Myf5 are 
expressed early in development before myogenin stimulates the fusion of 
myoblasts into myotubes. MRF4 is highly expressed in myofibres when cells 
withdraw from the cell cycle. The conversion of myoblasts to myotubes 
correlates with the in vivo situation when repair follows damage to skeletal 
muscle tissue. Satellite cells normally remain quiescent amid other cells, but 
play a role in repair by proliferating and fusing together during the differentiation 
process to form multinucleated myotubes, thus replacing or repairing tissue lost 
through disease or injury (Figure 2) 113-117. 
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Rat L6 myoblasts myotubes Myofibre  
Figure 2: The differentiation of myoblasts into myotubes 
Rat L6 myoblasts retain the ability to proliferate in vitro and can be differentiated into 
myotubes when cell culture conditions are modified. Differentiation of mononuclear 
myoblasts into myotubes is confirmed by the elongation of the cells due to the fusion of 
two or more myoblasts into one multinucleated cell. This in vitro system correlates with 
in vivo muscle, in that satellite cells are normally present in a quiescent state, but are 
activated when damage is done to skeletal muscle tissue. The subsequent proliferation 
of myoblasts and their fusion into myotubes facilitates the repair of damaged skeletal 
muscle tissue. 
 
1.3 Tools used in biomarker discovery 
Current guidelines for safety testing involve the use of well-established 
disciplines such as histopathology and clinical chemistry which, although 
generally considered fit for purpose, sometimes lack the predictivity and 
sensitivity required for the safety assessment of NCEs118-121. Biological samples 
such as urine, blood or more complex tissues can be analysed using relatively 
novel techniques compared to those applied routinely in safety assessment 
screening. The data obtained can then be interpreted using a variety of 
statistical methods in order to correlate the condition of a particular patient with 
specific changes or with a pattern of changes.  
 
The need to find better ways to monitor or assess drug effects, and therefore 
streamline drug development and reduce the rate of attrition of much needed 
drug therapies, has been recognised by the FDA in their Critical Path Initiative. 
This initiative recognises the slowdown in the registration of new drugs, and the 
case has been made for R&D companies to invest in and utilise new 
technologies and biomarkers when testing the safety and efficacy of new 
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compounds. At the forefront of the technologies employed in biomarker 
discovery are genomics, metabolic profiling and proteomics; broadly classified 
as toxicogenomics122-124.  
 
Biomarker discovery can be broadly classified into two main areas, “closed” or 
“open” profiling. Measurements can be performed in a directed or closed 
manner in which known molecules are specifically measured in order to 
correlate the levels of a particular parameter or set of endpoints with a clinical 
observation or range of observations. This approach is often applied when there 
is some prior knowledge of the effects or targets of the compound. In addition, 
there are usually some measures already available with which decisions on the 
prognosis of a patient or the direction of drug development can be correlated 
with.  
 
An open-screening approach involves the comparison of a population of 
unaffected or control subjects or cells with an identical population that have 
been treated with relevant doses or concentrations of a test compound. 
Molecules or patterns of molecules that may be indicative of an effect resulting 
from the administration of the compound can then be discovered. Differences 
observed in the levels of putative biomarkers between the different populations 
that correlate well with treatment are likely to be related to treatment. Following 
validation, these biomarkers may prove useful in preclinical studies and may 
also translate to the clinic125-127.  
 
Efforts are currently being made to improve the tools or markers used in safety 
assessment so that they are not simply descriptive of the effects of drugs, but 
are able to reliably, and reproducibly, predict these effects. Biomarkers should 
be specific to the target, sensitive to low levels of injury and should also reflect 
reversibility when a drug has been removed and where recovery is evident. 
Biomarkers should also be easily measured and, preferably, quantifiable in 
samples that do not require invasive sampling of the patient. A rapid change in 
its circulatory levels after an adverse effect and a long half-life in the circulation 
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are also advantageous so that the window of opportunity in which it can be 
measured is sufficiently long to prevent important changes being missed. The 
bridging of preclinical biomarkers to clinical studies is also a desirable feature 
so that the effects of new compounds in the clinic can be reliably predicted in 
preclinical studies128,129.  
 
Biomarkers can also be classified into several types. For example, biomarkers 
of toxicity can be used to indicate an existing or potential effect of a drug, whilst 
disease biomarkers are reflective of the presence or absence of disease. 
Mechanistic biomarkers provide information on the way in which the effect of an 
external stimulus may have arisen. A biomarker can be any one of these types 
or a combination of more than one type but, ultimately, surrogate endpoints are 
desirable that, as previously stated, can act as a substitute for a clinical 
endpoint130,131. 
 
1.3.1 Metabolic profiling 
Metabolic profiling studies examine changes in the expression of small 
molecules (typically <1000Da) in response to stimuli such as drugs, disease or 
the environment. It is one of a number of technical or disciplinary approaches to 
the discovery of biomarkers and, in its application, nuclear magnetic resonance 
(NMR) spectroscopy is often supplemented by liquid chromatography-mass 
spectrometry (LC-MS). NMR or LC-MS spectra are usually considered in 
combination with genomic and proteomic data in order to fully understand the 
changes observed and discover metabolite profiles that may be characteristic of 
perturbations to normal biochemical pathways. In toxicology studies, data 
generated following the analysis of samples from control and treated subjects is 
compared in order to discover differentially expressed metabolites that may be 
indicative of a drug effect132-138. 
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Duchenne muscular dystrophy (DMD) is caused by a mutation in the gene that 
codes for dystrophin, which results in an inability to express the dystrophin 
protein. This condition is characterised by muscle degeneration and 
subsequently a reduced life expectancy. Diagnosis of this congenital condition 
can be performed in prenatal tests or by examining DNA but it is usually 
conducted by taking a muscle biopsy and performing specific 
immunohistochemical staining for dystrophin. Specific profiles for DMD have 
been revealed in dystrophic cardiac muscle, skeletal muscle, cerebral cortex 
and cerebellum by Griffin et al139 using NMR profiling. Previous to this study, 
taurine had also been proposed as a biomarker of DMD by McIntosh et al140 
and these studies demonstrate the utility of metabolic profiling as a tool for 
biomarker discovery.  
 
Metabolic profiling is often conducted using urine samples due to the value of 
this sample as a repository for metabolites, and the non-invasive collection of 
urine samples for metabolic profiling studies is a feature of this discipline. A 
large amount of useful data is usually obtained from these studies and it 
provides an extensive picture of the effects of drugs on an organism. However, 
the equipment used for these investigations is extremely expensive and 
requires extensive laboratory resources. As with most biomarker discovery 
tools, skilled scientists are required to operate the equipment and also to 
analyse the complex data produced141,142. 
 
1.3.2 Transcriptomics 
Genes are often differentially expressed in response to different stimuli and 
transcriptomic profiling is the study of changes in relative messenger 
ribonucleic acid (mRNA) levels in response to these stimuli. Such changes can 
be linked to a possible outcome of drug treatment. The work of Hirata et al143 
demonstrates the value of this approach to biomarker discovery and, in this 
particular study, osteopontin was proposed as a biomarker of muscle 
regeneration in mice following cardiotoxin treatment.  
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Transcriptomic profiling is a sensitive technique that is capable of detecting 
early changes that may have been missed using other techniques. This 
discipline is perhaps more suited to the discovery of mechanistic biomarkers as 
changes seen tend to reflect the response of the organism to the stimulus 
rather than the ultimate effect. This can be a problem though as specific 
changes in mRNA expression may not be translated into the functional protein 
product partly due to the possibility of alternative splicing of genes or post-
translational modifications to proteins. In addition, the technique is often 
conducted using expensive DNA microarrays (e.g. Affymetrix® GeneChip 
microarrays or Illumina  BeadChip™ arrays) or quantitative polymerase chain 
reaction (Q-PCR) reagents, and this can be restrictive when conducting large 
studies144-148.  
 
1.4 Proteomics 
Proteomics is a powerful analytical tool that can be used to measure and 
characterise proteins in a wide variety of biological samples. It can be used to 
elucidate mechanisms of toxicity and to discover novel and, hopefully, predictive 
markers of disease, toxicity or efficacy149,150. Biomarkers discovered using 
proteomics are more likely to be useful in their application due to the fact that 
the functional protein product is measured directly and not usually subject to 
any structural modifications that may occur when, for instance, genes are 
translated145,151-153. Alternative splicing of genes, post-translational modifications 
or protein degradation can occur during the complex processing of genes to 
active proteins. Therefore measuring the functional protein reduces the 
possibility of these events affecting the predictive value of markers154-158. 
Proteomics has been successfully used for biomarker discovery in several 
disease and toxicity studies investigating different forms of cancer159-167, 
hepatotoxicity168-173, pulmonary hypertension174-176, myocardial infarction177, 
nephrotoxicity178-181 and skeletal muscle toxicity95,182-184.  
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Protein profiling experiments usually consist of two main steps; protein 
separation followed by identification. The separation is necessary to allow the 
visualisation of proteins within a complex mixture as individual constituents. The 
identification can be performed by simply obtaining a mass:charge (m/z) ratio or 
can be more complicated, involving discovering the identity of interesting 
proteins using MS and database searching. These steps are sometimes 
followed by confirming the response of proteins using an antibody-based method 
which may be able to measure proteins more specifically185-187.  
 
Top-down proteomics investigations typically examine intact proteins without 
the need to generate peptides enzymatically (or chemically) prior to MS 
analysis. The term middle-up has also been used to describe the analysis of 
long peptides. Gel-based techniques (e.g. one-dimensional or two-dimensional 
electrophoresis) or MS-based techniques such as matrix-assisted laser 
desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS) can be 
used for differential protein expression investigations in these studies. 
Sometimes, proteins are then separated or isolated and peptides generated 
using enzymes in order to facilitate the identification of proteins. The top-down 
approach benefits from there being a greater likelihood of examining a large 
proportion of the sequence of molecules. Also, post-translational modifications 
are more easily detected in this way (Figure 3)188-190. 
 
Using a bottom-up proteomic approach, a complex mixture of proteins in a 
biological sample is subjected to enzymatic digestion in order to generate 
peptides. The resulting peptides can then be separated using techniques such 
as LC prior to MS analysis. By comparing the intensity of the peptides in 
samples from control and treated subjects or by examining the ratio of tags or 
labels incorporated into the peptides, protein biomarkers can then be 
discovered. Proteins can also be identified using tandem MS (MS/MS) analysis 
of the peptides, combined with database searching. The main advantage of this 
method is that peptides are easier to detect than proteins, being smaller in size 
and therefore within the upper mass limit of most high resolution mass 
spectrometers (Figure 3)191,192.  
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Figure 3: Strategies for MS-based protein biomarker discovery 
The top-down approach to proteomic investigations is typically used to study the 
differential expression of intact proteins using techniques such as electrophoresis or 
MALDI-TOF-MS. The identification of the molecules can subsequently be performed 
(following the generation of peptides by enzymatic digestion) using MS in combination 
with database searching. Sometimes specific tags are used to relatively quantify 
peptides or proteins. More novel proteomic techniques, such as surface-enhanced 
laser desorption/ionization-TOF-MS (SELDI-TOF-MS), allow the separation and 
characterisation of proteins prior to MS analysis. The bottom-up approach involves the 
analysis of proteolytic peptide mixtures, which can be separated and characterised 
using MS for the discovery of protein biomarkers during differential peptide or protein 
analysis. 
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1.4.1 Enzymatic digestion of proteins 
Protein identification has traditionally been performed using techniques such as 
N-terminal sequencing (Edman sequencing), immunoblotting or even by 
comparing the electrophoretic migration of unknown and known proteins 
(standards)193,194. As previously discussed, the proteolytic cleavage of proteins 
at specific amino acid residues combined with MS is another option. Protein 
databases containing information on the theoretical masses of peptides 
generated from proteins can then be interrogated using the peptide masses 
determined experimentally in order to identify the proteins of interest. Only a few 
peptides are required for the identification of proteins, but it is easier to identify 
larger proteins as they are likely to generate more peptides following digestion, 
therefore increasing the likelihood  of detecting peptides195-197. 
 
Enzymes, by their nature, are very specific in their interactions, and 
endoproteases such as trypsin and chymotrypsin break specific peptides bonds 
within proteins prior to MS analysis. For example, trypsin hydrolyses the C-
terminal of peptides to arginine or lysine residues (unless they are followed by 
proline) whilst the specificity of chymotrypsin is broader and occurs at the C-
terminal to phenylalanine, tryptophan or tyrosine residues (again, unless 
followed by proline).  
 
In order to digest proteins (after a gel destaining step, if an in-gel digestion is 
performed), they are usually denatured using reagents such as urea or sodium 
dodecyl sulphate (SDS), sometimes with a reducing agent such as dithiothreitol. 
This procedure causes the proteins to unwind and disrupt the disulphide 
linkages therefore allowing the protease to access the unfolded protein. After 
denaturing, the sample is incubated with an enzyme such as trypsin for a few 
hours or overnight at 37°C so that proteolytic cleavage of the proteins can occur 
(the time of incubation depending on the resistance of the proteins to cleavage). 
As cysteine can be readily reduced or oxidised, the alkylation of the resulting 
thiol groups using iodoacetamide is usually performed in order to transform the 
cysteine groups to a more stable form (S-carboxyamidomethylcysteine). When 
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proteins are separated by electrophoresis prior to trypsin digestion, the 
reduction and alkylation steps previously described can be performed prior to 
the proteins being denatured in the SDS contained within the gels194,198-201. 
 
Trypsin tends to be the enzyme of choice due to its predictable and specific 
action, the simplicity of the digestion procedure and the fact that its use usually 
results in peptides that are of a suitable size to be analysed by MS. It is also 
readily available, cheap, available as a pure preparation (without contamination 
by chymotrypsin) and also available in a form that is less prone to the autolytic 
action of the enzyme on itself202-205.  
 
1.4.2 Protein or peptide separation 
Protein or peptide separation is a critical stage in protein expression studies. 
Techniques such as two-dimensional polyacrylamide gel electrophoresis (2DE) 
are frequently used to separate proteins206,207. This method is theoretically 
capable of separating thousands of different proteins from individual samples. 
In its application, a complex protein mixture is loaded onto an immobilised pH 
gradient (IPG) strip before a voltage is applied. The proteins migrate through 
the gel until they reach their isoelectric point (the point at which their charge is 
the same as the surrounding pH) due to the pH gradient from the top to the 
bottom of the IPG strip.  
 
The strip is then applied to a polyacrylamide gel that provides a supporting 
medium through which the proteins can migrate. The strong negative charge 
inherent with SDS within the gel effectively makes all the proteins the same 
charge and facilitates the migration of the proteins towards the anode when a 
voltage is applied across the gel. Protein separation occurs according to size as 
smaller proteins move faster through the gel than larger ones. Following 
separation, proteins can then be visualised by staining using Coomasie Blue, 
silver or SYPRO® ruby staining (depending on the sensitivity of detection 
required).  
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Although it can be time-consuming and resource demanding, if it is not 
automated, 2DE is a reliable and data-rich method. A gel-based approach to the 
separation of proteins is useful in biomarker discovery, as it is not biased 
towards a particular class of molecules on the basis on their physiochemical 
properties. However, this method of separation can sometimes fail to reveal, 
very low molecular weight (Mw) proteins, low abundance proteins or proteins 
that do not stain well. Hydrophobic or very basic proteins are also sometimes 
difficult to visualise in these gels208-210. Sometimes, one-dimensional gel 
electrophoresis (1DE) is used as an alternative separation step and is simpler 
and quicker to conduct although the separation of proteins is not as extensive 
as 2DE. It can, however, sometimes reveal proteins that are not shown by 
2DE211.  
 
In-gel methods of digesting proteins have made it easier to first separate 
proteins using electrophoresis so that peptides generated from different 
sections of the gel can be introduced into the mass spectrometer in stages 
using LC. This, in turn, allows a more complete analysis of all the peptides 
generated from the sample(s) and the presence of SDS in the gels means that 
proteins are already denatured prior to trypsin digestion. 
 
Generated peptides are subsequently separated by LC and the individual 
peptides are then analysed by MS. During LC, a liquid mobile phase is passed 
over a stationary phase in the form of a column composed of chromatographic 
packing (e.g. C18 for reverse-phase separations or porous beads used for ion-
exclusion chromatography). Interactions between the molecular constituents of 
the samples and the stationary phase are determined by their physicochemical 
properties and this determines their retention times and therefore the time at 
which they are eluted from the column. LC is very amenable to automation and 
therefore it is frequently used in combination with other techniques such as 
MS212,213.  
 
 43
1.4.3 Mass spectrometry 
MS is used to obtain m/z information on peptides, proteins or other molecules 
of interest and can be conducted in a number of ways, usually classified based 
on the ionisation and mass analysis methods employed. The principles behind 
MS ionisation remain the same though and samples are usually introduced via 
an inlet and ionised in the source. Mass analysis of the resulting ions then 
occurs and the quantity of the ions detected is recorded before analysis is 
performed on the collected data (Figure 4). The most popular methods for 
ionisation of molecules involve the use of MALDI or electrospray ionisation 
(ESI) time of flight (TOF) MS (or methods analogous to these).  
Mass analyser
(quadrupole, time of flight,
ion-trap)
Ion source
(electrospray, MALDI, 
SELDI)
Inlet
(direct probe,  liquid 
chromatography)
Detector
Data analysis
 
Figure 4: Schematic of the basic components of a mass spectrometer 
Samples are introduced into the mass spectrometer via an inlet. MS analysis requires 
the introduction of charged and dried molecules into the mass analyser using either a 
direct probe or LC. Commonly utilised ionisation methods include electrospray 
ionisation or matrix-assisted laser-desorption/ionization. Analytes can then be 
characterised in terms of their m/z in the mass analyser using techniques such as time 
of flight or ion trap MS. Data produced can then be analysed using a number of data-
handling tools and statistical methods. 
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1.4.3.1 Matrix-assisted laser desorption/ionization 
Prior to mass analysis, ions must be produced and there are various methods 
of ionising molecules for this purpose. MALDI is a common method for ionising 
proteins and is the method of choice for large biomolecules, as other ionisation 
techniques are less suitable for this purpose. In MALDI, the sample is mixed 
with an energy-absorbing molecule (also known as the matrix) which is usually 
a weak acid, capable of donating one or more protons to the sample molecules 
(e.g. sinapinic acid or α-cyano-4-hydroxycinnamic acid (CHCA)). The resulting 
crystalline protein-matrix complex is then irradiated by a 337nm nitrogen laser 
during MS analysis. The matrix is vapourised by the laser and also imparts 
laser energy to the molecules in the complex whilst also protecting the analytes 
from any potentially harmful effects of the laser. This process facilitates the 
desorption and ionisation of molecules from the surface of the MALDI target 
prior to ions entering the mass analyser section of the mass spectrometer 
(Figure 5). 
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Figure 5: Matrix-assisted laser desorption/ionization 
During the process of MALDI, sample is applied to the target on the sample stage and 
mixed with an energy-absorbing molecule (matrix). The matrix (usually a weak acid) 
co-crystallises with the molecules within the sample to form a crystalline complex and 
donates protons to the molecules within the sample. Upon irradiation with a 337nm 
nitrogen laser, molecules are ionised and a voltage is applied to the sample stage, 
forcing the ions away from the sample stage and into the mass analyser section of the 
mass spectrometer. 
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MALDI is commonly used for analysing proteins although, in its application, 
issues with reproducibility can arise. When matrix is applied manually to the 
MALDI target, it can sometimes be applied unevenly. This, combined with the 
fact that the laser usually only irradiates a part of the MALDI target in a single 
sweep or scan, and that there can be pulse to pulse variation in the laser, can 
contribute variations in the signal and this can affect the overall reproducibility 
of spectra. As a result, multiple scans are necessary and an average of the 
multiple scans is then taken in order to allow an accurate representation of the 
whole target area. Despite this, the technique has the advantage of requiring 
only a small amount of protein in the analysis. It is also amenable to the 
analysis of large molecules with a theoretical upper range of approximately 
400kDa depending on the mass analyser used and is relatively straightforward 
in its application214-216.  
 
1.4.3.2 Electrospray ionisation 
ESI is another soft ionisation method and it produces intact charged and dried 
analytes, which then have the capacity to travel or “fly” in the vacuum of the 
mass analyser. During ESI, the application of a high voltage between the 
microcapillary and the MS inlet allows sample to be introduced into the mass 
spectrometer as a fine spray via the microcapillary. The voltage applied results 
in the formation of an aerosol containing charged droplets and ions of the same 
polarity (depending on whether the mass spectrometer is run in positive or 
negative mode) are drawn out towards the counter electrode along the 
capillary. When the excess charge at the tip of the capillary overcomes surface 
tension, a droplet is formed which travels through the first vacuum stage of the 
mass spectrometer. The use of an inert heated drying gas (e.g. nitrogen) in this 
region aids the evaporation of solvent from the droplets during this journey and 
the droplet size is reduced resulting in the formation of a multiply charged, 
desolvated ions217-220. 
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The formation of ions occurs via evaporation of the volatile buffers and solvents 
used or via fission caused by electric repulsion between like charges of the 
analytes. More specifically, the ion evaporation model (IEM) and the charged 
residue model (CRM) have been proposed as the mechanisms by which the 
formation of charged molecules takes place. In the IEM, it is proposed that, as 
the droplet shrinks, the analyte achieves sufficient energy to transfer into its 
gaseous phase. Alternatively, the CRM suggests that all the solvent evaporates 
leaving a bare gas phase ion which can then be analysed in the mass analyser 
section of the mass spectrometer221,222.  
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Figure 6: Electrospray ionisation 
During ESI, sample is introduced to the mass spectrometer via a microcapillary. The 
application of a potential difference results in charged ions that are drawn along the 
capillary towards a counter electrode in the volatile effluent. The use of a heated drying 
gas (e.g. nitrogen) facilitates the desolvation of the ions during the production of 
multiply charged ions. 
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1.4.3.3 Time of flight mass analysis 
The simplest form of mass analysis is conducted is a TOF mass analyser. 
Molecules are ionised at the source before an accelerating potential is applied 
to the sample target and facilitates the travel of the charged ions towards the 
detector. The flight of the ions takes place in a field free region (vacuum) and 
the time taken for ions to reach the detector in the TOF tube is directly 
proportional to their mass and charge (Figure 7). Small ions reach the detector 
more quickly than larger ones and this travel time is also dependent on the 
charge of the molecules. This information allows the construction of a mass 
spectrum using the m/z ratio plotted against the intensity of each ion detected. 
Sample 
target
Laser
Acceleration
region
Detector
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Ion flight path in field free region
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Figure 7: Time of flight mass spectrometry 
A TOF mass spectrometer is shown with a MALDI source. Ions are produced from the 
sample target and accelerated into the mass analyser when a potential difference is 
applied in this region. Ions then travel through the vacuum in the TOF tube towards the 
detector, which records the time of arrival and the relative quantity of the ions. The time 
taken for the ions to reach the detector is proportional to the mass (m) and charge (z) 
of the ions and this is represented in a mass spectrum, which shows m/z on the x-axis 
and relative ion intensity of the y-axis. The incorporation of a reflectron in some 
instruments increases the path length for the ions and thus improves the resolution of 
ions from each other although it can lead to a loss in sensitivity, as more ions can be 
lost during the extended time of flight. 
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The TOF tube is commonly combined with a quadrupole in which the radio 
frequency (rf) and direct current (dc) voltages can be modified. In this way, ions 
are transported through an electric field generated by four metal rods and these 
rods can either allow all ions to pass through in full scan mode or can be 
modified in selected ion monitoring (SIM) mode in order to stabilise the path of 
the ions passing through the rods whilst destabilising unwanted ions. Ions with 
an unstable trajectory remain undetected as they are discarded before they 
reach the detector. Ions with a stable path through the rods, are detected and 
quantified (Figure 8).   
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Figure 8: The path of ions through a quadrupole 
Following the production of ions in the source, they are transported into the mass 
spectrometer through the source slit. The quadrupole rods can be adjusted to allow all 
ions to pass through to the detector. Alternatively, their radio frequency and direct 
current voltages can be adjusted such that the passage of certain molecules is 
favoured and they have a stable path through the quadrupole and towards the detector. 
Other ions travel through with an unstable trajectory and are discarded before they 
reach the detector.  
 
Whereas, the techniques described can provide m/z information on molecules 
of interest, they are unable to provide structural information, as they are soft 
ionisation techniques that are incapable of breaking up molecules. This is 
usually performed post-source in a collision cell where ions can be collided with 
inert gases such as nitrogen, argon or helium during MS/MS analysis (termed 
collision-induced dissociation (CID)). When ions are collided in this way, their 
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kinetic energy is internalised and contributes to the production of ion fragments, 
which can then be measured precisely in the mass analyser (Figure 9). Peptide 
cleavage usually occurs along the backbone of peptides and the fragment ion 
type produced following the cleavage of peptides can be described more 
specifically. If it occurs at the peptide amide bond and the amino terminal 
retains the charge of the ion they are termed b ions whilst, if the charge is 
retained at the carboxy terminal, they are termed y ions223-226. 
 
Multiple reaction monitoring (MRM) is usually performed using triple-quadrupole 
instruments (QQQ). In such instruments, two quadrupoles and a collision cell 
are combined in series (quadrupole-collision cell-quadrupole). The first 
quadrupole scans for a specific parent ion, which is then fragmented by CID in 
the collision cell before the specific fragments are detected and quantified in the 
final quadrupole. 
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Figure 9: Hybrid quadrupole-time of flight mass spectrometer 
The hybrid mass spectrometer consists of a source (usually electrospray) in which 
molecules are ionised prior to entering the mass spectrometer. After entry into the 
mass spectrometer, they are focused by lenses to pass through the quadrupole mass 
filter where specific molecules can be directed towards the collision cell. In this area, 
molecules are fragmented by CID and the resulting fragments produced are then 
pushed into the time of flight tube where their m/z can be accurately determined. 
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1.4.3.4 Ion trap mass analysis 
Ion trap instruments operate differently to other mass spectrometers in that ions 
can be formed directly in the trap as well as being characterised within the 
same area. Two endcap electrodes (at the entrance and exit) and two ring 
electrodes provide rf and dc oscillations in order to create electric fields. Once 
ions are trapped within the electric field, they can be selected and scanned 
individually from the trap for mass analysis. Alternatively, they can be excited 
by the application of a potential difference whilst, at the same time, an inert gas 
is introduced into the trap. The subsequent collision of the ions with the collision 
gas results in fragmentation of the ion (in MS/MS mode) and this can be 
repeated several times (MSn)227,228. 
 
The low mass range and the slow scanning speed of the ion trap have been 
identified as being disadvantages of this type of mass spectrometer. Also, there 
may be a bias towards multiply charged ions that have more kinetic energy and 
therefore more chance of colliding with the inert gases within the collision cell. 
This can also be considered an advantage as it effectively extends the mass 
range (m/z) of peptides that can be detected. The ability to perform different 
forms of MS in the same analyser, combined with the improved sensitivity over 
other instruments, is also an advantage. 
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Figure 10: Schematic of an ion trap 
In an ion trap mass spectrometer, ions are retained within the trap formed by the rf and 
dc voltage applied to the endcap electrodes and the ring electrodes. Ions can then be 
sequentially selected from the trap and detected. In MS/MS mode, a small amount of 
energy can also be applied to ions in order to excite them before being dissociating 
using an inert gas within the trap by collision-induced dissociation. In this way, 
structural information on analytes of interest can be obtained. 
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1.4.4 Surface-enhanced laser desorption/ionization 
The demand for high-throughput proteomics has meant that more novel and 
perhaps less resource-demanding technologies for screening proteins based 
around MALDI, such as SELDI-TOF-MS, have been developed. In the case of 
SELDI-TOF-MS, proteins are first captured using classical chromatographic 
chemistries on the active areas of ProteinChip® arrays. A range of ProteinChip® 
arrays are available, each designed to selectively retain or enrich specific 
subsets of proteins or peptides from complex biological samples, based on the 
physicochemical properties of the proteins within the sample, and also 
dependent on the assay conditions specified by the user. The technique 
reduces the sample preparation steps prior to MS analysis and also allows the 
removal of salts and other reagents that can interfere with the process of 
ionisation229-233.  
 
ProteinChips such as CM10 (weak cation exchange), Q10 (strong anion 
exchange), H50 (hydrophobic) or immobilised metal affinity capture (IMAC 30) 
arrays are commonly used for differential protein expression mapping 
experiments. Using these arrays, the subset of proteins retained on the array 
surface can be enriched by altering assay conditions such as the pH, the salt 
concentration or buffers used for binding or washing the arrays during the 
protein capture process. After subsets of proteins are separated from the more 
complex mixture of proteins in the sample, matrix is applied to enable the 
desorption and ionisation of proteins from the ProteinChip® surface for 
measurement by TOF-MS, as described for MALDI (Figure 11).  
 
SELDI has been applied to a wide variety of sample types in differential protein 
expression mapping experiments. In such experiments, researchers have 
aimed to accurately predict or describe toxicological events using either a single 
protein biomarker or a panel of biomarkers. The potential of SELDI has been 
demonstrated in the identification of biomarkers in disease or toxicity areas 
such as ovarian cancer163,234, prostate cancer165, breast cancer161,235,236, 
nephritis237, pulmonary hypertension174 and myopathy95,238. 
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Figure 11: Schematic of SELDI-TOF-MS 
The system incorporates a TOF tube in which molecules which are ionised and 
desorbed from the ProteinChip® by a laser (λ=337nm) travel towards the detector. The 
time taken for the molecules to reach the detector is dependent on their size and 
charge. Smaller molecules reach the detector more quickly than larger proteins and 
this information is used to construct a mass spectrum displaying m/z on the x-axis and 
relative ion intensity on the y-axis is produced. The system is similar to MALDI-TOF-
MS except that the chemically modified surfaces of the target allow the enrichment and 
subsequent analysis of specific subsets of molecules prior to MS analysis239. 
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1.4.5 Quantitative proteomics 
A number of MS-based methods have been applied to the relative quantification 
of different analytes for the purpose of differential protein or peptide expression. 
These can either make use of specific labels incorporated into the molecules or 
can be label-free. 
 
1.4.5.1 Absolute or relative quantitation 
The use of a chemically labelled isotope-coded affinity tag (ICAT) allows 
samples to be differentially labelled with two forms of ICAT reagent. Prior to 
analysis, samples are tagged with either a light ICAT reagent (typically a biotin 
affinity group with a linker that is labelled with hydrogen) or a heavy ICAT 
reagent (typically a biotin affinity group with a linker that is labelled with 
deuterium). Following purification of the peptides, the resulting differences in the 
relative amounts of specific peptides (generated after enzyme digestion) can 
then be exploited for differential protein expression mapping using MS240,241.  
 
Isobaric tag for relative and absolute quantitation (ITRAQ) is another MS based 
technique used for quantitative protein expression profiling. The N-terminus of 
peptides generated by enzymatic digestion of proteins are labelled using 
chemical tags, before comparing the levels of group-specific tags in control and 
treated or diseased samples by LC-MS/MS. Following the identification and 
relative quantitation of the different peptides using their fragmentation patterns, 
differential peptide-expression can be performed, since fragmentation of the 
chemical tags also results in the formation of reporter ions that can be used to 
provide information on the relative concentrations of the peptides242-245.  
 
In the case of stable isotope labelling with amino acids in cell culture (SILAC), 
cells grown in culture are provided with normal amino acids or amino acids 
labelled with non-radioactive heavy isotopes (grouped according to treatment). 
Differences between labelled and non-labelled proteins can be determined by 
MS, and therefore, changes in the levels of proteins within each sample (and 
most likely due to treatment) can be distinguished246-248. 
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Using standards, absolute quantitation can be achieved using these methods. 
In addition, these methods offer high sensitivity, high protein coverage, and are 
amenable to high-throughput proteomic analysis. However, they suffer from the 
requirement for the expensive tags used which are usually patented and only 
available commercially249,250,251. 
 
1.4.5.2 Multidimensional protein identification technology 
In shotgun experiments, whole samples are subjected to enzymatic digestion in 
order to generate peptides. Changes in the entire peptide profile are then 
examined by MS in the search for treatment related changes in protein 
expression. Multidimensional protein identification technology (MudPIT) utilises 
a similar whole protein digestion methodology. In this case, the protein sample 
is digested and the constituent peptides are separated using two on-column LC 
steps and peptides are scanned in the mass spectrometer as they leave the 
second column. Peptides with a known m/z can then be identified by MS/MS 
and database searching. A cation exchange column is usually used followed by 
a reversed-phase column and the use of two columns allows a greater amount 
of separation to be achieved than using one column252-255. 
 
The major advantage of this technique is that it is sensitive to low abundance 
proteins, mainly due to the use of sensitive MS equipment (e.g. ion trap). 
However, it is sometimes difficult to resolve the nature of interesting proteins as 
the analysis is not conducted using intact proteins. For this reason, it is 
sometimes preferable to separate the proteins prior to the application of this 
technique213,256-262. 
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1.4.5.3 GeLC-MS 
Sometimes proteins within the samples are separated using 1DE, before 
dividing the gel into an appropriate number of sections. This results in the 
separation of individual samples from each other and also divides each sample 
into several different Mw regions, which can then processed separately. 
Peptides from individual sections of the gel are then generated by enzymatic 
digestion and the specific masses of the generated peptides can then be used 
to identify the proteins using LC-MS and protein database searching. Using this 
GeLC-MS approach, differential peptide analysis and protein identification is 
performed simultaneously254,263,264.  
 
Both MudPIT and GeLC-MS can collectively be considered as label-free 
quantitative proteomics (LFQP) when used without labels or tags and have 
proved useful in the discovery of biomarkers of lung cancer265, ovarian 
cancer266 and breast cancer236. The combination of LC with MS is favourable in 
that it is amenable to automation and, therefore, ideal as a method of 
introducing samples into the mass spectrometer. When a vast number of ions 
are detected, limitations on the sampling time or in the ability of the detector to 
record information can lead to ion-suppression whereby the ionisation or 
detection of molecules is adversely affected by other constituents that co-elute 
with the molecules of interest. The phased introduction of peptides into the 
mass spectrometer reduces the number of co-eluting peptides and therefore 
increases the proportion of the proteome that can potentially be examined from 
samples.  
 
However, a disadvantage of this approach is that small proteins do not usually 
generate a sufficient number of peptides to facilitate a confident identification of 
the proteins. Also, the relative quantitation of peptides relies on a high degree of 
accuracy when preparing samples. For example, sample loading must be equal 
when 1DE is performed and gels must also be cut precisely so that accurate 
comparisons can be made between different regions of the gels186,267,268. 
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1.5 Summary 
In this study, a variety of proteomic techniques were used to detect, measure 
and characterise protein expression changes in cultured skeletal muscle cells 
following the exposure of the cells to compounds shown in vivo to have 
myotoxic potential. SELDI-TOF-MS was used alongside LFQP due to the 
documented success of these techniques in the searching for protein 
biomarkers of toxicity, combined with their potential to discover biomarkers of 
myopathy in myoblasts and myotubes treated with low concentrations of the test 
compounds. 
 
1.6 Hypothesis 
“Proteomic profiling can be used to identify alterations in protein expression that 
are predictive of compound-induced skeletal muscle toxicity using an in vitro cell 
culture system.” 
 
1.7 Project aims 
• To compare protein expression in control and treated rat L6 myoblasts and 
myotubes.  
• To identify changes in the protein expression profiles, and in the levels of 
specific protein ions, resulting from the administration of potentially myotoxic 
compounds. 
• To purify and identify potential biomarkers discovered to be useful in an in 
vitro rat skeletal muscle cell system. 
•  
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Chapter 2 
2. Materials and methods 
 
Materials 
Rat L6 myoblasts were obtained (cryopreserved) from American Type Cell 
culture (Virginia, USA). Heat-inactivated horse serum was obtained from 
Invitrogen Ltd. (Paisley, UK). 4-[2-(3-Fluoro-4-trifluoromethyl-phenyl)-4-
methyl-thiazol-5-ylmethylsulfanyl]-2-methyl-phenoxy}-acetic acid (GWδ), 
which is a highly selective PPAR-δ agonist, was kindly supplied by 
GlaxoSmithKline R&D, Stevenage, UK. 
 
Alanine aminotransferase (ALT), AST, CK and LDH kits were obtained from 
Bayer (Newbury, UK). The ALD kit used in these investigations was supplied 
by Randox laboratories (County Antrim, UK). sTnI, FABP3, parvalbumin-α 
and Myl3 measurement kits were obtained from Meso Scale Discovery 
(Maryland, USA). 
 
NP20 (normal phase), H50, CM10, IMAC 30 ProteinChip® arrays and 
sinapinic acid energy-absorbing molecule (EAM) were purchased from 
Ciphergen Biosciences (Fremont, USA). 
 
Precast NuPage® 10% bis(2-hydroxyethyl)-imino-tris(hydroxymethyl)-
methane (Bis-Tris) gels, SeeBlue® Plus 2 pre-stained Mw marker, 2-(N-
morpholino)ethane sulphonic acid SDS running buffer, lithium dodecyl 
sulphate (LDS) sample buffer and NuPage antioxidant were obtained from 
Invitrogen Ltd. Instant Blue™ was obtained from Novexin Ltd. (Cambridge, 
UK). Sequencing grade modified porcine trypsin was obtained from 
Promega, UK. HPLC grade acetonitrile, formic acid and methanol were 
supplied by VWR international Ltd., (Lutterworth, UK). Zorbax 300-SB-C18 
Chapter 2: Materials and methods 
 58
traps (5 x 0.3mm2) were obtained from Agilent Scientific (Wokingham, UK) 
and C18 PepMap columns (75μM internal diameter, 15cm length) were 
obtained from LC Packings, (Cumberly, UK). 
 
For immunoblotting, polyclonal Rho GDP dissociation inhibitor (GDI) alpha 
(Rho GDI) and myosin light chain polypeptide 2 (Myl2) primary antibodies, 
anti-rabbit immunoglobulin G (IgG), horseradish peroxidase linked secondary 
antibody and biotinylated protein ladder were obtained from New England 
Biolabs (Cambridge, UK). Invitrolon polyvinylidene fluoride (PVDF) 
membranes, thin filter blotting paper and thick blotting paper were obtained 
from Invitrogen. Kodak D19 developing solution and unifix fixing solution 
were obtained from Agar Scientific (Stansted, UK) and hyperfilm ECL 18x24 
was obtained from Amersham Pharmacia (Chalfont St Giles, UK).   
 
Dulbecco’s modified Eagle’s medium (DMEM), 2,3,5,6 tetramethyl-p-
phenylene diamine (TMPD), dimethyl sulfoxide (DMSO), 
penicillin/streptomycin, horse serum, foetal bovine serum (FBS), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), trifluoroacetic 
acid (TFA), iodoacetamide, ammonium bicarbonate, acetic acid, Triton® X-
100, transfer buffer, Tween® and all other reagents were obtained from 
Sigma-Aldrich Co. Ltd. (Poole, UK).  
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Methods 
2.1 Cell culture and treatment 
Skeletal muscle growth medium (SKGM) was prepared by supplementing 
DMEM with 10% FBS, 2mM glutamine, penicillin (100 u/ml penicillin G 
sodium) and streptomycin (100μg/ml streptomycin sulphate). Skeletal muscle 
differentiation medium (SKDM) was prepared by supplementing DMEM with 
2% heat-inactivated horse serum, 2mM glutamine and penicillin and 
streptomycin.  
 
Prior to seeding, a vial of rat L6 myoblasts containing 1x106 cells was 
removed from storage in the vapour phase of liquid nitrogen (-150°C). The 
vial was then allowed to stand at room temperature (RT) for 1min before 
placing the vial (without total submersion) in a water bath at 37°C, until 
partially thawed. The contents of the vial were then slowly transferred to a 
sterile centrifuge tube containing pre-warmed SKGM. The cell density of 
myoblasts was then adjusted to 1x104 cells/ml by the addition of an 
appropriate amount of SKGM. This mixture was then transferred into a 
suitable number of collagen-coated flasks or plates and allowed to proliferate 
by incubating the cells at 37°C in a humidified atmosphere of 5% CO2 and 
95% air.  
 
Myoblasts were maintained as an adherent culture and growth medium was 
replenished every 3-4 days until at least 80% confluence was achieved. Cells 
were then sub-cultured at a ratio of 1:3-1:5 as the myoblastic, proliferative 
properties of cells diminish if the cells are allowed to become over-crowded. 
SKGM was aspirated from the flask before rinsing the cells with Ca2+ and 
Mg2+ free Dulbecco’s phosphate buffered saline (D-PBS). Trypsin/EDTA 
(0.25%) was then added to the flask(s), which were then incubated for at 
least 5min at 37°C to detach cells from the surface of the growth vessel. The 
added trypsin was subsequently inactivated by adding a small amount of 
SKGM (containing serum) to the flask. After counting the cells using a 
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haemocytometer, cells were subcultured into the cell culture vessels until 
sufficient numbers of cells were available for experiments. For experiments 
using myotubes, myoblasts were differentiated by replacing SKGM with 
SKDM, following a wash with D-PBS. Medium was replaced every 3-4 days 
until a sufficient proportion (approximately 80%) of the cell population could 
be distinguished as myotubes, as observed by LM (usually 10-14 days). 
Differentiation into myotubes was apparent by an attenuation of the 
proliferative properties of the cells, along with clear morphological changes 
such as the increased presence of multinucleated cells (myotubes).  
 
When cells were treated, a stock solution of the test compound was prepared 
in neat DMSO before preparing the highest concentration by diluting the 
stock solution in each experiment. Cells were then treated with a range of 
concentrations of the test compounds for a period of 24h.  
 
2.2 Cell morphology  
Cells were examined by transmission electron microscopy (EM) and also by 
light microscopy (LM) to check cells for signs of drug-induced damage. 
These results were compared with other measures of cytotoxicity such as 
total intracellular protein and MTT reduction (described in the following 
sections). 
 
Experiments were terminated by aspirating growth or differentiation medium 
from cells and then washing the cells twice with D-PBS. To prepare cells for 
EM, cells were washed twice (using Ca2+ and Mg2+ free D-PBS) to remove 
any residual cells or growth medium. Cells were then fixed in 4% 
formaldehyde/1% glutaraldehyde (v/v) for at least 1h and then centrifuged 
into a pellet at 14000 x g for 1min for short-term storage prior to analysis. 
 
Cells were processed for EM examinations by washing them five times in a 
pH 7.4 sodium phosphate buffer before being fixed in 1% buffered osmium 
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tetroxide for 1h and processed into Agar 100 resin. Ultra-thin sections (60-
90nm) were then prepared, stained with 5% uranyl acetate (v/v) and 2.5% 
lead citrate (v/v) for 1h and then examined using a Hitachi H7500 
transmission electron microscope, operated at 60-80kV. Representative 
digital images were captured using the AMT Advantage Camera System 
(v5.42.515).  
 
EM examinations were qualitative assessments of general morphological 
features and cells were screened for any ultrastructural abnormalities likely 
to be indicative of an adverse effect of drug-treatment. The operation of the 
electron microscope during EM examinations was kindly performed by Paul 
McGill (Pathology, GlaxoSmithKline R&D, Ware, UK). 
 
2.3 Total intracellular protein 
Samples were prepared for the measurement of total intracellular protein by 
washing the cells as previously described for cell morphology examinations. 
Protein extraction buffer (containing 9M urea, 2% CHAPS and 1% DTT) was 
then added to each well before the cell culture plate was incubated on a 
horizontal shaker for at least 30min at 2-8°C. Cell lysates were then stored at 
-80°C until analysis.  
 
Total intracellular protein was then assessed using the bicinchoninic acid 
(BCA) protein assay according to the manufacturer’s instructions269. Results 
obtained were compared to the absorbances obtained at 595nm following 
the analysis of samples from a standard curve (bovine serum albumin) on 
the same plate. 
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2.4 MTT reduction 
Samples for the MTT reduction assay were analysed directly in separate 
plates as the MTT assay eventually results in damage to the cells under 
investigation.  
 
Two hours before the end of each 24h experiment, 200µl of 5mg/ml MTT 
reagent was added to 2ml of growth or differentiation medium in each well of 
a 24-well cell culture plate before incubating the plate at 37°C, 5% CO2 and 
95% humidity for a further 2h. During this period, MTT reagent was taken up 
and reduced by the mitochondria of viable cells to form an insoluble 
formazan product. This accumulated within the cell, as it was unable to pass 
through the plasma membrane. The growth medium was then removed from 
the wells of the plate and the remaining formazan product was solubilised by 
adding 2ml of isopropanol to each well and incubating for 30min. The relative 
absorbance of the cell lysates was then compared at 550nm270.  
2.5 Biochemical analyses 
Growth or differentiation medium was prepared for the evaluation of enzyme 
leakage by collecting the medium from the cell culture plates and centrifuging 
it at 3000 x g for 5min to ensure that samples were not contaminated with 
cells. The supernatant was then collected for analysis.  
 
Cell lysates were prepared for biochemical analysis by initially washing the 
remaining cells free of growth or differentiation medium (as described 
previously for total intracellular protein and EM measurements). Cells were 
then lysed by adding 0.1% Triton® X-100 (v/v) and the plate incubated for 
30min at 2-8°C with agitation in order to release the intracellular contents of 
the cells. The lysates were then stored at -80°C until analysis.  
 
The Advia 1650 (Bayer, Newbury, UK)  is a discrete automated chemistry 
analyser capable of running a wide variety of spectrophotometric assays in 
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serum, urine and in vitro samples and was used to analyse the levels of the 
leaked and intracellular levels of ALT, AST, CK, LDH and ALD.  
 
Leaked and intracellular levels of sTnI, FABP3, parvalbumin-α and Myl3 
were also assessed. These assays were performed using Meso Scale 
Discovery technology, which uses MultiArray™ plates in combination with 
electrochemiluminescence detection. Proprietary antibodies are attached to 
the surface of the wells of MultiArray™ plates and are able to capture 
specific analytes of interest. The use of a non-radioactive light emitting tag 
on the antibodies facilitates the quantitation of markers of interest at 620nm 
upon electrical stimulation of the target. The wells of the plates also 
incorporate carbon electrodes which enhance the electrochemiluminescence 
signal when stimulated97,271,272.  
 
The operation of the Advia 1650 clinical chemistry analyser for the 
measurement of ALT, AST, CK, LDH, ALD was kindly conducted by Aubrey 
Swain (Clinical Pathology, GlaxoSmithKline R&D, Welwyn, UK) and the 
operation of the Meso Scale Discovery MultiArray™ plate reader was 
performed by Ian Roman (Clinical Pathology, GlaxoSmithKline R&D, 
Welwyn, UK). 
 
2.5.1 Alanine aminotransferase 
The kit for the measurement of ALT contains two reagents and, during the 
analysis, 20μl of sample is initially added to 80μl of a first reagent (containing 
L-alanine). The measurement of ALT involves a coupled reaction which is 
initiated by the addition of 16μl of a second reagent (containing α-
oxoglutarate) and ALT within the sample catalyses the conversion of L-
alanine and 2-oxoglutarate to pyruvic acid which in turn is involved in the 
oxidation of NADH to NAD+. The rate of the resulting absorbance decrease is 
monitored at 340nm over 5min and is directly proportional to the activity of 
ALT in the sample. The method is validated by the manufacturer as being 
linear between 0-1100U/L273-275. 
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α-ketoglutarate + L-alanine L-glutamate + Pyruvate 
ALT
LDH
Pyruvate + NADH + H+ Lactate + NAD+  
2.5.2 Aspartate aminotransferase 
The sample volumes and assay conditions for this assay are as described for 
ALT except that the first reagent contains L-aspartate instead of L-alanine. In 
the first reaction, AST catalyses the reaction between α-ketoglutarate and L-
aspartate and L-glutamate and oxaloacetate are formed. In the second 
reaction, malate dehydrogenase (MDH) catalyses the oxidation of NADH to 
NAD+ and the rate of the resulting decrease in the absorbance of the 
reaction mixture (monitored at 340nm) is directly proportional to the AST 
activity in the sample. The linear range of the assay is between 0-
1000U/L275,276. 
α-ketoglutarate + L-aspartate L-glutamate + Oxaloacetate 
AST
MDH
Oxaloacetate + NADH + H+ Malate + NAD+  
2.5.3 Creatine kinase 
In this assay, 80μl of the reagent (containing creatine phosphate, adenosine 
diphosphate (ADP), NADP and glucose) is reacted with 8μl of sample and 
incubated for 5min. The CK-catalysed reaction between creatine phosphate 
and ADP results in the formation of creatine and adenosine triphosphate 
(ATP). The ATP derived is, in turn, reacted with glucose and CK activity is 
determined by measuring the rate of the increase in the absorbance at 
340nm when NADP+ is reduced to NADPH as a result of this reaction277,278.  
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ATP + glucose ADP + glucose-6-phosphate
D-glucose-6-phosphate + NADP+ 6-Phosphogluconate + NADPH + H+
Creatine phosphate + ADP Creatine + ATP 
CK
Hexokinase
Glucose-6-phosphate dehydrogenase
 
2.5.4 Lactate dehydrogenase 
LDH activity is determined by exploiting the LDH-catalysed reduction of 
pyruvate to lactate. In the assay, 14μl of sample is reacted with 80μl of the 
working reagent (containing pyruvate and NADH) and the rate of the 
decrease in the absorbance at 340nm resulting from the oxidation of NADH 
to NAD+ is directly proportional to the activity of LDH279. 
LDH
Pyruvate + NADH + H+ Lactate + NAD+  
2.5.5 Aldolase 
In measuring ALD, 20μl sample is initially incubated with 250μl of a reagent 
containing fructose-1,6-diphosphate which is converted into glyceraldehyde-
3-phosphate (GAP) and dihydroxyacetone phosphate (DAP) in the presence 
of ALD. Triosphosphate isomerase (TIM) is added along with 
glycerolphosphate dehydrogenase (GDH) and NADH (in 6μl of a second 
reagent) and this converts DAP to glycerol-1-phosphate. The simultaneous 
oxidation of NADH to NAD+ is used to assess the levels of ALD by 
monitoring the decrease in absorbance at 340nm280,281. 
GAP DAP
DAP + NADH + H+       Glycerol-1-phosphate + NAD+
Fructose-1,6-diphosphate GAP + DAP 
ALD
TIM
GDH
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2.5.6 Meso Scale discovery markers 
In measuring the levels of  sTnI, Myl3, FABP3 and parvalbumin-α, 25μl of 
assay diluent was initially added to the assay plates and incubated for 30min 
at RT prior to the addition of 25μl of the sample or calibration standard. This 
was followed by a 2h incubation at RT before washing each array with 0.1% 
PBS-tween. The relevant specific detection antibody (25μl) was then added 
to each well of the plate before another 2h incubation at RT, which was then 
followed by another 0.1% PBS-tween wash of the plate. Read buffer (150μl) 
was then added before measuring the absorbance of each plate at 620nm. 
 
2.6 SELDI-TOF-MS analysis 
2.6.1 ProteinChip® preparation 
Samples were analysed by SELDI-TOF-MS on NP20, H50, CM10 and IMAC 
30 ProteinChip® arrays in order to determine the protein expression profiles 
of skeletal muscle cells under different assay conditions (Figure 12).  
Active spotProteinChip® array Hydrophobic coating
 
Figure 12: A SELDI-TOF-MS ProteinChip® array 
Samples were applied to the active spot of the ProteinChip® array and incubated for 
a short period. This facilitated the interaction between proteins within the sample 
and the chemistry on the ProteinChip® surface (based on their physicochemical 
characteristics). Non-specifically bound proteins were washed away before 
specifically retained proteins were co-crystallised with a solution of EAM prior to MS 
analysis. 
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H50 ProteinChip® arrays were prepared for SELDI-TOF-MS analysis by 
washing each array in 50% acetonitrile:water (v/v) for 5min in centrifuge 
tubes (on a roller-mixer). The arrays were then allowed to air-dry for at least 
30min before use. IMAC 30 ProteinChips were supplied in a metal-free form 
and these were prepared for use by adding 150μl of 100mM copper sulphate 
(loading buffer) to each active spot of the array and incubating it with 
horizontal shaking for 10min. Loading buffer was then removed before 
washing the ProteinChips for 1min with deionised water to remove excess 
buffer. Other ProteinChip® arrays did not require the same preparation steps 
prior to SELDI-TOF-MS analysis. 
 
All ProteinChip® arrays were then prepared for sample addition by placing 
them into a bioprocessor assembly, which allows a sample volume of up to 
300μl to be applied to each spot of the array. The binding buffer (150μl in 
each well) was then added and the bioprocessor was incubated on a 
horizontal shaker for 5min, before again removing the buffer. This wash was 
repeated once more before samples were diluted at least 10-fold in the 
binding buffer and 1µg total protein of the cell lysates was applied, in 
duplicate, to each spot of the ProteinChip® array. After a 60min incubation 
period, samples were removed from the arrays and non-specific binding of 
proteins was reduced by performing three 5min washes of the array surface 
using 150μl of the washing buffer in each well. This was followed by a short 
(1min) wash using deionised water to remove any excess buffer that might 
interfere with MS analysis (Table 1). 
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Table 1: Binding and washing buffers used for ProteinChip® 
preparation 
Binding and washing buffers used during SELDI-TOF-MS analysis of control and 
treated skeletal muscle cells are shown for each array. Buffers also contained 0.1% 
Triton® X-100 to reduce non-specific interactions between proteins in the sample 
and the ProteinChip® surface.  
 
ProteinChip® 
array
Assay 
conditions Binding/washing buffer
NP20 H20 H20
H50 10% acetonitrile 10% acetonitrile, 0.1% TFA
CM10 pH 4 100mM sodium acetate, pH 4
CM10 pH 6 100mM sodium acetate, pH 6
CM10 pH 8 100mM sodium acetate, pH 8
IMAC 30 Copper 100mM sodium acetate, pH 4
 
2.6.2 ProteinChip® mass spectrometry 
Prior to MS analysis, ProteinChip® arrays were allowed to air-dry before the 
addition of 0.5μl of EAM (saturated sinapinic acid solution in 50% 
acetonitrile:water (v/v) containing 0.5% TFA) to each spot of the array. 
Another 0.5μl of EAM was applied to each spot of the array at least 5min 
after the first application before allowing the arrays to air-dry again. The 
arrays were then inserted into the Ciphergen ProteinChip® Biology System 
IIc (PBS IIc) for MS analysis. ProteinChips were analysed according to an 
automatic data collection protocol. The ProteinChip® reader was focused on 
a mass of 12kDa, optimised from 2-20kDa, set to a high mass of 100kDa. 
Transients were averaged over 50% of the target area in a linear sweep (with 
the mass deflector set at 1.5kDa) to generate each spectrum. 
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2.6.3 SELDI-TOF-MS data pre-processing and analysis 
Spectra collated following the MS analysis of ProteinChip® arrays were 
normalised by total ion current (TIC) to ensure that minor irregularities in the 
ionisation of protein ions (resulting from inconsistencies in procedures such 
as the addition of the EAM) could be accounted for post-analysis. TIC 
normalisation ensures that the area under the curve for all spectra is 
constant for all spectra obtained. 
 
Spectra were also externally calibrated for mass accuracy using a protein 
standard mixture containing bovine insulin (5733.6 Da) and equine 
myoglobin (16951.5 Da). This ensured that the Biomarker Wizard (BMW) 
software supplied by Ciphergen was able to correctly identify SELDI-TOF-
MS protein ions with the same m/z (within the specified tolerance of 0.3%) as 
a cluster whose levels could then be compared to each other in subsequent 
statistical analyses (Figure 13). The use of the BMW software uses an ion 
detection algorithm which identifies peaks in each spectrum based on the 
signal to noise ratio (S/N) and the local valley depth of SELDI-TOF-MS 
protein ions. This includes an initial first pass peak detection, followed by a 
more sensitive, directed, second pass detection. The appearance of an ion is 
then considered in all spectra generated from different samples within a 
defined experiment, and clusters of corresponding ions that occur in spectra 
produced from different samples are identified and compared. The relative 
ion intensity of a particular ion or set of ions is then reported for all the 
spectra as an average m/z value for the cluster of corresponding ions from 
the various spectra analysed (Figure 13).  
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Figure 13: Cluster generation using the Biomarker Wizard in Ciphergen 
Peaks software 
Skeletal muscle cells were grown and treated with TMPD or GWδ (section 2.1). Cell 
homogenates were analysed using SELDI-TOF-MS (section 2.6) before peak 
detection was performed. A representative diagram is shown to demonstrate cluster 
generation in 6 SELDI-TOF-MS spectra using the BMW. The use of the BMW 
allows a consistent set (or cluster) of protein ions to be selected in experiments 
(based on user defined settings) so that the levels of a protein ion at the same m/z 
can be compared across selected spectra. In this example, the height of the missing 
peak in cluster 3 (spectrum 6) is reported at the average m/z of the other peaks in 
the cluster. 
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The BMW was set so that ions were initially detected if they had a S/N ratio 
of at least 5 and the second pass was set at a S/N of 2 (Figure 14). This was 
performed so that the effect of chemical noise from the EAM or electrical 
noise from the internal machinery of the mass spectrometer was minimised 
in the spectra. Ions were clustered with a mass tolerance of 0.3% between a 
mass range of 2.5 and 20kDa, as the detection of ions below this range 
tends to be of limited use due to the influence of ions arising from the use of 
sinapinic acid as an EAM. In addition, the limited numbers of ions usually 
detected above this range tend to be broad and have low S/N ratios 
compared to other ions. In spectra where an ion within a cluster was missing, 
an estimated ion intensity was reported. This can cause problems with 
statistical analysis of the data as this sometimes leads to the inclusion of 
peaks that have a relative ion intensity that is, in reality, below the sensitivity 
of the instrument. In order to address this, ions with a relative ion intensity of 
less than 0.5 (the average noise level calculated for spectra generated in 
these experiments) were reported as 0.5 (Figure 15). 
 
Figure 14: Biomarker Wizard detection settings 
Skeletal muscle cell homogenates were analysed using SELDI-TOF-MS and protein 
ions were detected in the resulting spectra. The BMW detects peaks in two phases. 
The initial phase determined peaks with a S/N ratio of 5, while the second pass 
detected smaller peaks at those peak locations using greater sensitivity (lower S/N 
of 2). Peaks were recognised as a cluster if the difference was within 0.3% of the 
average m/z. 
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Figure 15: Noise calculation in Ciphergen Peaks software 
An example of the noise calculation is shown above with the dotted line 
representing the noise setting for this SELDI-TOF-MS spectrum. Ions below this 
level (as shown in the magnified region in the red circle) were entered as a relative 
ion intensity of 0.5. This was the average noise setting at the maximum ion height 
for the spectra in this experiment and this defined the limit of sensitivity for the 
measurements. 
 
2.6.4 SELDI-TOF-MS statistical analysis 
Average values for all protein ions within SELDI-TOF-MS spectra were 
calculated for the replicates of each sample. A statistical analysis was then 
performed in order to identify ions whose relative levels were significantly 
different between treatment groups (Student’s t-test, p<0.05). This procedure 
was performed in repeat experiments in order to focus on changes that were 
consistent in the repeat experiments of a training dataset. A third repeat 
experiment functioned as a test-dataset in which changes observed in the 
training dataset were validated. 
 
Statistical analysis was performed using Microsoft Excel (Microsoft 
Corporation, Washington, USA), Statistica 8.0 (Statsoft Inc, Oklahoma, 
USA), GraphPad Prism® (GraphPad software, California, USA) and SIMCA-
P+ v11.5 (Umetrics, Umeå, Sweden). Database searching for the 
identification of responsive protein ions was performed using tools (e.g. 
TagIdent) which were available via the Expert Protein Analysis System 
(ExPASy) web-based server (www.expasy.org). 
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2.7 Label-free quantitative proteomics  
LFQP differential protein expression profiling experiments were conducted 
using a combination of 1DE and LC-MS/MS. Skeletal muscle cells treated 
with the same concentrations of TMPD and GWδ as used in SELDI-TOF-MS 
protein-profiling investigations (25 and 50μM, respectively) were analysed 
using this approach. Samples were prefractionated by 1DE in order to 
reduce their complexity before subjecting individual gel fractions to 
enzymatic digestion and measuring the relative expression of the generated 
peptides using LC-MS/MS.  
 
2.7.1 One-dimensional sodium dodecyl sulphate polyacrylamide gel-
electrophoresis 
Samples were prepared by denaturing 5μg total protein in lithium dodecyl 
sulphate (LDS) buffer and then reducing the sample in 5mM dithiothreitol, at 
70°C for 10min. Samples were then cooled to RT for 10min before alkylating 
with 50mM iodoacetamide for 20min. Proteins in the samples were then 
separated by 1DE using 10% Bis-Tris gels. Following electrophoresis, gels 
were stained with Instant Blue™ for 15min before rinsing off excess stain with 
deionised water. Gels were then examined so that differences in the intensity 
of protein bands likely to have resulted from drug treatment (as indicated by 
their consistency within the control or treated groups) could be identified.  
 
2.7.2 In-gel protein digestion 
Samples were prepared for LC-MS/MS analysis by cutting the gels 
longitudinally into individual lanes for the different samples (6 control and 6 
TMPD-treated samples) and also transversely into 11 Mw regions (Figure 
16). Stain was then removed from the stained gel pieces by incubating each 
gel piece in 1ml 100mM ammonium bicarbonate in 50% acetonitrile until the 
gel pieces were transparent (the solution being replenished as necessary to 
achieve this). Individual gel pieces were then washed in deionised water 
before dehydrating in acetonitrile for at least 30min. Following this, 
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acetonitrile was removed before drying the gel pieces in a vacuum 
centrifuge. In-gel protein digestion was then performed by the addition of 
300μl of 50mM ammonium bicarbonate containing 1ng/μl porcine trypsin and 
incubating the sample at 37°C for at least 16h. After this incubation period, 
peptides were extracted by the addition of 300µl 0.1% formic acid in 2% 
acetonitrile:water [v/v] and mixed for 30min. An aliquot of this sample (400μl) 
was removed, freeze-dried and stored until MS analysis.  
 
2.7.3 LC-MS/MS analysis 
The lyophilised sample was reconstituted in 60μl of water containing 0.1% 
TFA immediately prior to mass spectrometric analysis. Peptides were applied 
(in a 10μl injection) onto a Zorbax 300-SB-C18 trap (5 x 0.3mm2) and 
separated by nano-LC using 75μm internal diameter, 15cm C18 Pepmap 
columns. A flow rate of 250nl/min was used over a linear gradient of 0-45% 
acetonitrile containing 0.1% formic acid (v/v) for 70min. Two traps and 
columns were run in parallel in order to increase sample throughput although 
the run order was adjusted such that samples for comparison to each other 
were analysed on the same traps and columns. After LC analysis, eluted 
peptides were introduced by electro-nanospray into an LTQ linear ion trap 
mass spectrometer for peptide measurement and identification using the 
settings detailed in Table 2. 
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c) d)
 
 
Figure 16: Sectioning of one-dimensional electrophoresis gels 
Skeletal muscle cells were cultured before they were treated with TMPD for 24h 
(section 2.1). Proteins within the samples were separated using 1-dimensional 
electrophoresis (section 2.7.1) before the gels were (a) divided longitudinally into 
lanes to separate individual samples and (b) transversely into Mw regions (c) guided 
by Mw markers in order to fractionate the gels prior to subjecting individual excised 
sections (d) to proteolytic digestion using porcine trypsin. 
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Table 2: Ion trap mass spectrometer settings used for the analysis of 
skeletal muscle cells 
Skeletal muscle cells were cultured and treated with TMPD (section 2.1). An LTQ 
ion trap mass spectrometer was used to analyse the peptides generated following 
1DE analysis of skeletal muscle cells (section 2.7.1) using the settings described 
below. 
Ion source Nanospray ionisation
Capillary temperature (°C) 180
Source voltage (kV) 1.4
Capillary voltage (V) 3
Data acquisition time (min) 70
Optimised m/z range 400.0-1600.0
Data dependent settings
          Minimum signal required 1000
          MS isolation width (Da) 2
          MS normalised collision energy 35
          Activation Q (v) 0.25
          Activation time (ms) 30
 
Please note: 
a) A small capillary voltage applied adds a small amount of internal energy, which can assist in the 
fragmentation of ions within the trap. 
b) Minimum signal required refers to the minimum intensity of ions selected for MS/MS. 
c) MS isolation width is the error permitted for the selection of ions from the trap. 
d) A normalised collision energy accounts for the fact that ions at a higher m/z range require more collision 
energy for fragmentation. This relationship between the m/z and the fragmentation is linear and 
predictable and is corrected for by this normalisation. 
e) The activation Q is the radio frequency used during ion fragmentation. 
 
2.7.4 LS-MS/MS data analysis 
Bioworks Browser v3.2 (Thermo Fisher Scientific, Massachusetts, USA) was 
used in combination with SEQUEST to search for protein identification 
matches within a rat database of proteins and contaminants (Rattus 
norvegicus RefSeq obtained from the NCBI ftp site, updated on 06/02/2008) 
which contains 36612 entries282. Searches were made for all tryptic peptides 
(assuming that the enzyme cleaved at both ends and also allowing for up to 
two missed cleavages). Cysteine residues were treated as a fixed 
modification (carboxyamidomethylation) and no variations in the other 
residues were considered. The mass tolerance for the precursor and 
fragment ions was set at 2.0 and 1.0 atomic mass units (amu), respectively 
and chromatography data was limited to between 15 and 45min, as data 
outside these times only contained a minimal number of peptides.  
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Using Bioworks Browser, unified search results file (srf) files were generated 
for all of the proteins measured and used to examine and compare normal 
protein expression in myoblasts and myotubes. This data was also examined 
to investigate changes in protein expression that may have been induced by 
drug administration on a global level using all the proteins expressed in the 
skeletal muscle cells. 
 
For a more focused differential peptide expression analysis, data was 
imported into Decyder™ MS software version 2.0 (GE Healthcare, Chalfont 
St. Giles, UK) where peptide ions were detected using the settings described 
in Table 3. Base ion chromatograms were time-aligned in the PepMatch 
portion of the Decyder™ MS software (so that chromatography retention 
times were consistent between different LC runs) before peptide matching 
was performed using the settings also shown in Table 3. 
 
Table 3: Detection settings used in Decyder™ MS software 
Peptides were detected in the PepDetect module of Decyder™ MS software using 
the settings shown so that an optimal S/N was achieved. Subsequent peptide 
matching between chromatographic runs was performed using the PepMatch 
module of the Decyder™ MS software during differential peptide expression 
analysis. 
Detection settings
Crop retention time 15-45
Typical peak width (min) 0.8
LC peak shape tolerance (%) 20
m/z shift tolerance (amu) 0.6
m/s shape tolerance (%) 5
Remove peptides below S/N 1.1
Remove peptides of unspecified charge below S/N 1.1
Include charge states 1-3
Matching settings
Tolerance for retention time matching (min) 0.5
Tolerance for m/z matching (Da) 0.5  
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Following the detection and matching of peptides, the levels of each peptide 
detected were then assessed and compared between control (n=6) and 
TMPD-treated (n=6) samples. The aim was to identify proteins that showed 
consistent and reproducible differences in their levels in response to 
treatment with TMPD (Student’s t-test; p<0.05).  
 
Proteins were only considered as putative biomarkers if all the peptides 
contributing to its identification showed a consistent response to treatment 
(i.e. in their relative levels in samples and also in terms of being increased or 
decreased). Whilst a peptide may have been detected at sufficient levels to 
contribute to the identification of a protein, it was recognised that it might not 
necessarily be above the limit of quantitation. As such, peptides were only 
used for the quantitation of proteins if they were detected in at least half of 
the samples included (6/12) to ensure that unreliable data was not used for 
quantitation. The cross-correlation (Xcorr) value obtained from SEQUEST 
gives an indication of how close the peptide fragment mass spectrum 
obtained matches the theoretical spectrum predicted for that peptide and a 
score of >2 usually indicates a good match283-285. In considering proteins as 
possible biomarkers, the Xcorr value was also taken into account, as was the 
correlation between the Mw region of the 1D-gel in which it was found and 
the calculated Mw. 
Chapter 2: Materials and methods 
 79
Retention time (min)
m
/z
Control Treated
Peptide detection
Differential peptide analysis
Control Treated
(a) (b)
(c)
(d)
Retention time (min)
m
/z
K.LKGADPEDVITGAFK.V  
Figure 17: Schematic of quantitative Decyder™ MS differential peptide 
analysis 
(a) All the peptides detected were initially represented in a gel-view plot where the 
intensity of individual spots represented the levels at which individual peptides were 
detected. (b) Peptides were then detected using user-defined settings (Table 3). 
Blue boxes represent peptides selected for comparison and brown crosses show 
where MS/MS data was available for the identification of peptides. (c) The intensity 
of selected peptides could then be compared to determine differences in peptide 
expression between control and treated samples. (d) The peptides could also be 
visualised using a 3D plot. One of the peptides used in the quantitation of myosin 
light chain 2 in myotubes is shown here. 
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2.7.5 Immunoblotting 
Compound-induced changes in the expression of some of the protein 
biomarkers discovered by LC-MS/MS analysis were confirmed by Western 
blotting. Cell lysates were analysed by 1DE (10μg total protein per 
sample/lane; all other procedures and conditions as described in section 
2.7.1). Samples were analysed along with prestained Mw markers and a 
biotinylated protein ladder in order to accurately estimate protein Mw and the 
transfer of proteins to the PVDF membrane.  
 
Prior to the transfer of proteins from the gel to the PVDF membrane, thick 
blotting paper was immersed until saturated in transfer buffer. A 0.45μM 
(pore size) PVDF membrane was then fully immersed in methanol for 1min 
followed by another 1min immersion in deionised water, before a final 5min 
immersion in transfer buffer. Thin filter paper was also immersed in transfer 
buffer prior to preparing a sandwich of thick blotting paper/thin filter 
paper/PVDF membrane/gel/thin filter paper/thick blotting paper with the 
PVDF membrane nearest the positive electrode onto the positive electrode of 
a semi-dry blotter (Figure 18). Excess air was then removed from the blot by 
rolling with a test tube before placing the negative electrode on top of the 
sandwich and allowing the transfer of proteins to the membrane by running 
the semi-dry blotter at 120mA for 1h. 
+
-
+
-
Gel
PVDF membrane
Thin filter paper
Thick blotting paper
 
Figure 18: Set up of PVDF membrane/gel sandwich for protein transfer 
Following 1DE, gels were set up for the transfer of separated proteins to a PVDF 
membrane. Thick blotting paper and filter paper were also incorporated into a 
sandwich in between the negative and positive electrode of a semi-dry blotter before 
transferring proteins from the gel to the PVDF membrane by applying a charge of 
120mA for 1 hour. 
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Non-specific binding sites were blocked by incubating the PVDF membrane 
with blocking solution (5% BSA [w/v] in 0.1% PBS/Tween) for 1h at RT with 
agitation. The membrane was then washed using 0.1% PBS/Tween (3 x 
5min washes). The primary antibodies were then diluted appropriately 
(1:1000 for RhoGDI and 1:500 for Myl2 in blocking solution) and the 
membrane incubated in the antibody solution at RT with agitation (1h for 
RhoGDI and 4h for Myl2). Following this, the membrane was washed again 
(3x5min with 0.1% PBS/Tween) before incubating in a solution containing the  
horseradish peroxidase (HRP)-linked secondary antibody and antibiotin HRP 
(at 1:2000 and 1:1000 dilution, respectively). Final washes in (3 x 5min) in 
0.1% PBS/Tween were then performed prior to antibody detection. 
 
In order to detect bound proteins, the PVDF membrane was incubated (with 
agitation) with freshly prepared Lumiglo® peroxidase chemiluminescence 
substrate solution for 1min before draining any excess reagent from the 
membrane and placing it inside a plastic transparent wallet within a 
developing cassette. Under red light conditions, hyperfilm was exposed to 
the membrane for an appropriate exposure time such that films were not 
over or under exposed (approximately 15s). The film was subsequently 
developed by immersing the film in developer solution for 5min, followed by a 
short 30s wash in tap water. This was then followed by a 5min incubation in 
fixing solution followed by a 1min wash in tap water. Films were then air-
dried before examining the expression of specifically bound proteins. 
Quantitative assessments of the levels of the proteins measured specifically 
by immunoblotting were made using ImageJ picture processing and analysis 
software available from http://rsbweb.nih.gov/ij/. 
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Chapter 3 
3. Results 
 
The value of an in vitro system for assessing the myotoxic potential of novel 
compounds was investigated using cultured rat L6 myoblasts and myotubes 
differentiated from myoblasts. The effectiveness of different strategies for 
testing the effects of test compounds on skeletal muscle was examined and 
treatment-induced changes in the levels of proteins expressed in skeletal 
muscle cells were assessed in order to identify possible biomarkers of 
myopathy. 
 
3.1 Establishment of the cell culture system 
After seeding, myoblasts remained in the medium as unattached, spherical cells 
in suspension within the growth medium (Figure 19a). After this, cells gradually 
attached to the surface of collagen-coated cell culture plates and non-attached 
cells were removed when the medium was replenished after 2h (Figure 19b). 
Over the next 22h, cells increased to 10-15% coverage of the cell culture plate 
(Figure 19c). When observed at 24h, myoblasts were spindle-shaped and were 
also shown (by EM) to be present as individual cells with a single nucleus 
(Figure 19d). They also displayed features of an immature, undifferentiated cell 
such as an abundance of ribosomes attached to rough endoplasmic reticulum 
(RER). There were also very few mitochondria and a euchromatic (often folded) 
nucleus containing a prominent nucleolus and many free (unattached) 
ribosomes present within the cell, indicative of an actively proliferating cell 
involved in protein synthesis (Figure 19e).  
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Figure 19: Establishment of the rat L6 myblast cell culture system 
Rat L6 myoblasts were resuscitated before a) seeding the cells as a suspension culture 
(section 2.1). Cultures were then prepared for morphological examinations and cell 
morphology was examined using LM and EM (section 2.2). b) During a 2h period, the 
majority of myoblasts attached to the surface of collagen-coated plates, appearing as 
individual spindle-shaped cells. c) Over the next 24h, cells gradually increased to 10-
15% plate coverage due to proliferation. d) Myoblasts were characterised by a 
euchromatic nucleus containing a prominent nucleolus (∗) and many ribosomes, but 
few other organelles within the cytoplasm. These cells also interdigitated with adjacent 
cells without fusing to each other. e) As shown in the area defined by the dashed box in 
(d), the cytoplasm of myoblasts also contained an abundance of ribosomes, few 
mitochondria (arrows) and profiles of RER dilated with medium electron dense 
material. (Magnification shown). 
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After 10 days, successful myotube formation was evidenced as approximately 
80% of the cells present showed features typical of mature differentiated 
skeletal muscle cells (Figure 20a). LM revealed the presence of elongated 
myotubes and these were shown (when examined by EM) to be multinucleated, 
having been formed by the fusion of two or more myoblasts (Figure 20b). The 
differentiation of myoblasts into myotubes was further confirmed by the 
presence of myofilaments, although they were disorganised in their orientation 
(Figure 20c). Within cultures of myotubes, a proportion of cells (approximately 
5-10%) were present whose appearance was more typical of the myoblasts 
shown in Figure 19.  
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Figure 20: Morphology of rat L6 myotubes treated with vehicle control alone 
Myoblasts were initially cultured and then differentiated into myotubes over the course of 10-14 days (section 2.1). Cells were then 
prepared for EM examinations (section 2.2) and (a) myotubes were distinguished by the presence of elongated cells, which were formed 
by the fusion of myoblasts. b) The multinucleate nature of myotubes was apparent in this portion of the myotube and (c) the differentiated 
status of the cell was further confirmed by an abundance of myofilaments characteristic of skeletal muscle, as indicated by the arrows in 
the area defined by the dashed box in (b). (magnification shown). 
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Intracellular levels of ALD, ALT, AST, CK, LDH, sTnI, Myl3, FABP3 and 
parvalbumin-α were compared between myoblasts and myotubes in order to 
examine the influence of successfully myotube formation on their levels. 
Significant changes in the intracellular concentrations of ALD, ALT, AST, CK, 
LDH and sTnI were observed between myoblasts and myotubes (Student’s t-
test, p<0.05). ALD and AST were increased 2-fold whilst ALT was increased 3-
fold. These changes were accompanied by a 1.4-fold reduction in LDH. The 
most marked changes were in CK and sTnI, which were, increased 12 and 11-
fold, respectively, in myotubes when compared to myoblasts. Increases in the 
levels of these proteins were due to myoblasts maturing into adult skeletal 
muscle cells (Figure 21).  
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Figure 21: Baseline biochemical levels in skeletal muscle cells 
Skeletal muscle cells were cultured (section 2.1) and sampled for biochemical analysis 
(section 2.5). The myotube/myoblast ratio was calculated as the fold-change of 
individual myotube cultures (n=3) compared to the mean of myoblast cultures (n=3). 
Significant increases in the intracellular levels of ALD, ALT, AST, CK and sTnI were 
observed when myotubes were compared to myoblasts (Student’s t-test, p<0.05). The 
dotted line represents the level at which there was no difference in the intracellular 
levels of the proteins (myotube/myoblast ratio=1). The changes in the levels were due 
to the maturation of myoblasts into myotubes and the largest increases were seen in 
CK and sTnI (12 and 11-fold, respectively). Where visible, error bars show standard 
error of the mean (SEM) and significant changes are denoted by *p<0.05, **p<0.01. 
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Myoblasts were grown after being resuscitated from storage at -150°C in the 
vapour phase of liquid nitrogen and displayed features characteristic of an 
actively proliferating skeletal muscle cell. Following differentiation, these cells 
showed very different morphological characteristics that were more typical of 
skeletal muscle tissue in vivo. In addition, the intracellular levels of the 
biochemical parameters measured were compared and the maturation of the 
myoblasts into myotubes was corroborated by significant increases in the 
intracellular concentrations of ALD, ALT, AST, CK and sTnI. These 
observations confirmed that cell culture conditions could be modified so that 
cells were encouraged to fuse together during differentiation and form mature 
myotubes. 
3.2 Effect of the test compounds on skeletal muscle cells 
The effects of treating skeletal muscle cells for 24h with of a range of 
concentrations (up to 100μM) of an experimental myotoxin (TMPD) or a 
potentially myotoxic drug (GWδ) were investigated by examining changes in the 
morphology of cells. Changes in the intracellular protein content were also 
examined along with changes in the ability of cells to reduce a tetrazolium salt 
to a formazan dye (MTT assay). 
 
3.2.1 Effect of test compounds on myoblasts 
Myoblasts treated with ≤25μM TMPD were indistinguishable from those treated 
with vehicle alone in terms of size, shape and general appearance. Cell death 
following treatment with 50 and 100μM TMPD was apparent by a reduction in 
the number of intact cells due to a loss of cell-membrane integrity (Figure 22). 
At these concentrations of TMPD, a small proportion of the myoblasts were 
necrotic or unusually dense, degenerate cells that, on occasions, had ridge-like 
folds of the membrane. Some myoblasts showed additional degenerative 
ultrastructural changes such as swollen mitochondria with disrupted cristae, 
increased numbers of neutral lipid droplets or evidence of cytoplasmic 
vacuolation (Figure 23).  
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Figure 22: Effect of a range of concentrations of TMPD on rat L6 myoblasts following 24 hours of TMPD treatment. 
Myoblasts were cultured before being treated with the test compound (section 2.1). Morphological examinations (section 2.2) showed the 
typical spindle-shaped appearance of rat L6 myoblasts. The number of intact cells was also reduced to approximately 50% and 20% when 
cells were treated with 50 and 100μM TMPD, respectively. (Magnification x200). 
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Figure 23: Degenerative ultrastructural changes in myoblasts caused by 
TMPD treatment. 
Myoblasts were cultured before they were treated with TMPD (section 2.1) and 
prepared for EM examination (section 2.2). a) Myoblasts treated with ≥ 50μM TMPD 
contained vacuoles of variable size (one indicated by the arrow), a number of lipid 
droplets (L) and slightly swollen mitochondria (M) with disorganised cristae. These 
features were not observed in cells treated with vehicle alone. b) Interdigitations of 
individual myoblasts with neighbouring cells were absent, whilst single nuclei contained 
marginated chromatin and a fragmented nucleolus. Several swollen, degenerate 
mitochondria and some lipid droplets were also present in the cytoplasm of affected 
cells. (Magnification shown). 
 
Total intracellular protein content was used as a measure of cell viability, as 
total protein levels decrease when cell death occurs and cells are detached 
from the surface of the cell culture plate and subsequently removed when 
growth medium is replenished. TMPD had no significant effect on the total 
intracellular protein content of myoblast cultures treated with ≤25μM TMPD 
(Student’s t-test, p<0.05) and significant reductions were only observed when 
myoblasts were treated with 50 and 100μM TMPD (Figure 24a). The effect of 
GWδ on myoblasts was also investigated and a change in total intracellular 
protein content was only observed in myoblasts treated with 100μM GWδ  
(Figure 24b). 
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MTT reduction was used to assess the ability of the mitochondria of healthy 
cells to reduce a yellow tetrazolium salt (MTT) to an insoluble purple formazan 
dye, which is assumed to be proportional to the number of viable cells 
remaining in the cell culture. Significant changes in the ability of myoblasts 
treated with >25μM TMPD to reduce MTT confirmed that TMPD was cytotoxic 
at 50 and 100μM (Figure 24a). GWδ was not toxic to myoblasts at 
concentrations of ≤50μM and the toxic effect of this compound at 100μM was 
confirmed by a significant change in MTT reduction (Figure 24b).  
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Figure 24: Effect of a range of concentrations of TMPD and GWδ on 
myoblasts 
Myoblasts were cultured and treated with TMPD or GWδ (section 2.1). a) Intracellular 
protein content was assessed (section 2.3) and was decreased significantly in 
myoblasts treated with 50 and 100μM TMPD (n=8 controls and 8 treated) and (b) in 
myoblasts treated with 100μM GWδ (Student’s t-test, p<0.05). This was supported by 
significant reductions in MTT reduction (performed as described in section 2.4) at the 
same concentrations of both test compounds. Increases in intracellular protein content 
and MTT reduction may reflect an increase in cell proliferation at low concentrations of 
the test compounds. Significant changes compared to controls are denoted by *p<0.05, 
**p<0.01, ***p<0.001. Due to small variance, errors bars are not always visible on 
these graphs. Error bars show ± SEM. 
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Reductions in the intracellular levels of protein, the ability of myoblasts to 
reduce MTT and changes in the morphology of myoblasts at concentrations of 
50 and 100μM together demonstrated that TMPD was cytotoxic to myoblasts at 
these concentrations. Similar changes in total intracellular protein, MTT 
reduction and cell morphology were indicative of the toxic effect of GWδ at a 
higher concentration of 100μM.  
 
3.2.2 Effect on test compounds myotubes 
Myotubes treated with 6.25, 12.5 and 25μM TMPD were identical in appearance 
to cells treated with vehicle alone. Cytotoxicity was only evident in cells treated 
with 50 and 100μM TMPD and was demonstrated by similar degenerative 
ultrastructural changes to those described for myoblasts treated with the same 
concentrations of TMPD. At these concentrations of TMPD, necrotic cells and 
ridge-like folds in the plasma membrane were observed. It was also noted that, 
of the viable cells remaining, a higher proportion contained a single nucleus, as 
was the case with myoblasts (Figure 25). This indicated that a higher proportion 
(approximately 15%) of myoblasts either failed to differentiate into myotubes or 
may have been dedifferentiated into myoblasts. These changes were 
accompanied by a decrease in the number of intact cells when viewed by LM 
(Figure 26). 
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Figure 25: Degenerative ultrastructural changes in myotubes  
Myotubes were differentiated from cultured myoblasts (section 2.1). Cells were then 
prepared and examined qualitatively by EM (section 2.2). a) Of the viable cells 
remaining, myotubes treated with ≥50μM TMPD had an elongated shape typical of 
myotubes, although some of the cells (approximately 15%) contained a single nucleus 
within the cell and, in this way, resembled myoblasts (Figure 19). b) In the area defined 
by the dotted box in (a) there were many vacuoles of variable size (derived from 
swollen rough endoplasmic reticulum (arrows)) and some lipid droplets (L). Some 
areas of disrupted myofilaments (*) that were contained within the cytoplasm of 
affected myotubes are also shown. These degenerative changes were absent from 
myotubes treated with vehicle control alone. 
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Figure 26: Effect of a range of concentrations of TMPD on rat L6 myoblasts following 24 hours of TMPD treatment. 
Myotubes were differentiated from myoblasts before treating them with a range of concentrations of TMPD (section 2.1). Myotubes were 
then examined by light microscopy (section 2.2) and, in contrast to myoblasts, they were elongated due to the fusion of multiple myoblasts 
during cell differentiation. The number of intact cells was reduced to approximately 80% and 30% plate coverage when cells were treated 
with 50 and 100μM TMPD, respectively, due to drug-induced reductions in cell viability. (Magnification x200). 
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The effect of TMPD on myotubes was also assessed by measuring total 
intracellular protein content. Significant reductions in the intracellular levels of 
protein at concentrations of 50 and 100μM demonstrated that TMPD was 
cytotoxic to myotubes at these concentrations (Student’s t-test, p<0.05) (Figure 
27a). The effects of GWδ were also assessed by measuring intracellular protein 
content, and this compound was toxic to myotubes at a concentration of 100μM 
(Figure 27b). 
 
Significant decreases in the ability of myotubes to reduce MTT again confirmed 
that TMPD was cytotoxic at 50μM and 100μM (Figure 27a). Similar changes in 
MTT reduction were again indicative of the toxic effect of GWδ at a higher 
concentration of 100μM (Figure 27b), as it was for myoblasts. 
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Figure 27: Effect of a range of concentrations of TMPD and GWδ on 
myotubes  
Myotubes were differentiated from cultured myoblasts and treated with TMPD or GWδ 
(section 2.1). a) Intracellular protein content was assessed (section 2.3) and was 
measured at significantly lower levels in myotubes  treated with 50 and 100μM TMPD 
(n=8 controls and 8 treated) or (b) 100μM GWδ. TMPD and GWδ were toxic to 
myotubes at the same concentrations observed for myoblasts as demonstrated by 
significant decreases in MTT reduction at the same concentrations of the test 
compounds (Student’s t-test, ≤0.05). Significant changes compared to controls are 
denoted by *p<0.05, **p<0.01 or ***p<0.001. Error bars show SEM although, due to 
small variance, they are not always visible on these graphs. 
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These results demonstrated that the in vitro system established using 
myoblasts (section 3.1) was sensitive to treatment with either an experimental 
myotoxin (TMPD) or a potentially myotoxic drug (GWδ). Furthermore, the 
assessment of cell morphology, total intracellular protein content and MTT 
reduction showed that TMPD and GWδ realised their myotoxic potential at 
concentrations of 50 and 100μM, respectively. One of the aims of this work was 
to discover changes in the levels of proteins that were likely to be predictive of 
drug effects rather than descriptive. As such, it was decided to focus further 
biomarker discovery investigations on changes observed in skeletal muscle 
cells treated with concentrations of the test compounds that were not overtly 
cytotoxic (≤25μM TMPD and ≤50μM GWδ). 
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3.3 Measurement of candidate biomarkers to discover protein 
biomarkers of myopathy 
These investigations were conducted in order to determine whether a selection 
of candidate biomarkers could detect drug-induced changes in the function of 
skeletal muscle cells at lower concentrations of the test compounds than the 
methods already described (total intracellular protein content, MTT reduction 
and cell morphology). These markers were a combination of established 
markers commonly used for the assessment of skeletal muscle toxicity in vivo 
(CK, LDH, ALT, AST, ALD)91,92 and markers that have more recently been 
proposed as biomarkers of myopathy (sTnI, Myl3, FABP3 and parvalbumin-
α)95,286,287. 
 
3.3.1 Effect of drug treatment on the leakage of candidate markers 
Circulatory levels of markers known to be in high concentration in skeletal 
muscle are commonly used to determine the status of the tissue in clinical 
studies or toxicology experiments. Therefore, the effect of a range of 
concentrations of TMPD (up to 100μM) on the levels of the aforementioned 
candidate markers in medium taken from treated cells was investigated.  
 
In medium taken from myoblasts, the only marker that demonstrated a dose-
related increase in its levels was AST which was significantly increased at 50 
and 100μM TMPD (Student’s t-test, p<0.05). sTnI and parvalbumin-α were not 
detected in the medium taken from myoblasts (Figure 28). 
 
In myotubes, both AST and sTnI were significantly increased in the medium 
from cells treated with 50 and 100μM TMPD. In addition, CK and FABP3 were 
also increased in myotubes treated with 100μM TMPD. Myl3 and parvalbumin-α 
were not detected in the medium taken from myotubes (Figure 29). 
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Figure 28: TMPD-induced changes in leakage into myoblast conditioned 
medium 
Myoblasts were grown and treated with up to 100μM TMPD (section 2.1) before 
measuring the levels of ALD, ALT, AST, CK, LDH, sTnI, Myl3, FABP3 and 
parvalbumin-α leaked into the medium (section 2.5). Significant dose-related increases 
in the levels of AST leaked into the medium were observed in cells treated with 50 and 
100μM TMPD, although cell death was already evident in cells treated with this 
concentration (section 3.2). sTnI and parvalbumin-α were not detected in the medium 
taken from myoblasts. Error bars show SEM deviation (where visible) and significant 
changes are denoted by *p<0.05 (Student’s t-test).  
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Figure 29: TMPD-induced changes in leakage into myotube conditioned 
medium 
Myotubes were differentiated from myoblasts and treated with up to 100μM TMPD 
(section 2.1) before measuring the levels of candidate biomarkers leaked into the 
medium (section 2.5). Significant increases in the leakage of AST and sTnI were 
observed in cells treated with 50 and 100μM. These changes were accompanied by 
increases in CK and FABP3 in medium taken from cells treated with 100μM TMPD. 
Myl3 and parvalbumin-α were not detected in the medium taken from myotubes. Error 
bars show SEM deviation and significant changes are denoted by *p<0.05, **p<0.01, 
***p<0.001 (Student’s t-test).  
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Leaked levels of AST (and sTnI in the case of myotubes) proved to be most 
sensitive for detecting drug-induced changes in skeletal muscle cells. 
Treatment-related increases in the leaked levels of these markers were 
observed when cells were treated with 50 or 100μM TMPD, although these 
changes were seen at concentrations already shown to be cytotoxic to 
myoblasts and myotubes (section 3.2). There were also increases in the levels 
of CK and FABP3 in myotubes at the highest concentration of TMPD tested 
(100μM). Overall, there was no additional value in measuring the leakage of 
candidate markers in the medium compared to examining changes in cell 
morphology or measuring intracellular protein content or MTT reduction. 
 
3.3.2 Drug-induced changes in the intracellular levels of candidate 
markers 
The effect of a range of concentrations of TMPD (up to 100μM) on the 
intracellular levels of ALD, ALT, AST, CK, LDH, sTnI, Myl3, FABP3 and 
parvalbumin-α was also assessed.  
 
Reductions in the levels of ALT, AST, CK, LDH and sTnI related to the cytotoxic 
effect of the test compound were only observed when myoblasts were treated 
with 100μM TMPD (Student’s t-test, p<0.05) (Figure 30).  
 
The levels of AST and LDH were decreased in myotubes treated with 100μM 
TMPD. The most responsive markers to the treatment of myotubes with TMPD 
were ALD and CK, which were reduced following treatment with ≥12.5μM 
TMPD (Figure 31). 
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Figure 30: TMPD-induced changes in intracellular enzymes in myoblasts 
Myoblasts were grown and treated with up to 100μM TMPD (section 2.1) before the 
intracellular levels of ALD, ALT, AST, CK, LDH, sTnI, Myl3, FABP3 and parvalbumin-α 
were assessed (section 2.5). Significant reductions in the levels of ALT, AST, CK, LDH 
and sTnI were only observed in cells treated with 100μM TMPD. These changes were 
related to the toxic effects of drug-treatment. Error bars show SEM (where visible) and 
significant changes are denoted by *p<0.05, **p<0.01, ***p<0.001 (Student’s t-test).  
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Figure 31: TMPD-induced changes in intracellular enzymes in myotubes 
Myotubes were obtained by differentiating myoblasts and these cells were treated with 
up to 100μM TMPD (section 2.1). Intracellular enzyme levels were assessed (section 
2.5) and significant dose-related reductions in the intracellular levels of AST and LDH 
were only observed in cells treated with 100μM TMPD (Student’s t-test, p<0.05). ALD 
and CK were more sensitive to treatment and were reduced following treatment with 
lower concentrations of TMPD (≥12.5μM TMPD). Error bars show SEM deviation and 
significant changes are denoted by *p<0.05, **p<0.01, ***p<0.001.  
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In the assessment of the intracellular levels of the candidate biomarkers 
measured, ALD and CK were the most responsive markers to the effects of 
TMPD in myotubes and were decreased when cells were treated with ≥12.5μM 
TMPD. These markers were responsive at lower concentrations of the test 
compound than intracellular protein content, MTT reduction and cell morphology 
assessments (section 3.2) and could serve as sensitive biomarkers of myopathy 
in vitro.  
 
3.4 Differential protein expression profiling using SELDI-TOF-MS 
Results described in section 3.2 demonstrated that TMPD was cytotoxic at a 
concentration of 50μM in both myoblasts and myotubes and that GWδ was toxic 
to both cell types at a concentration of 100μM. SELDI-TOF-MS protein profiling 
was subsequently used in an attempt to discover protein ions whose levels 
changed when skeletal muscle cells were treated with the test compounds. 
Concentrations of the test compounds were used that were not overtly cytotoxic 
with a view to discovering putative biomarkers of myopathy in myoblasts and 
myotubes.  
 
A number of different ProteinChip® arrays and assay conditions were used in 
order to enrich specific subsets of proteins on the array surfaces, based on their 
physicochemical characteristics (Figure 32). By using a number of different 
surfaces and assay conditions, an investigation of a greater proportion of the 
proteome was possible than might have been achieved using a more limited set 
of assay conditions. 
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Figure 32: Representative SELDI-TOF-MS spectra of skeletal muscle cells from different ProteinChip® arrays 
Myoblasts and myotubes were cultured (section 2.1) and prepared for SELDI-TOF-MS analysis as described in section 2.6. Spectra 
generated following SELDI-TOF-MS analysis of the cell homogenates on normal phase (NP20), hydrophobic (H50), weak cation 
exchange (CM10) and immobilised metal affinity capture (IMAC 30) loaded with copper are shown. Protein expression analysis was 
conducted on a variety of ProteinChip® array surfaces (and using different assay conditions) in order to modify the proteins retained from 
the samples on each array. The m/z is shown on the x-axis and the relative ion intensity on the y-axis. 
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3.4.1 Optimisation of SELDI-TOF-MS protein ion detection settings 
Prior to differential protein expression analysis, consideration was given to 
suitable BMW settings for detecting clusters of protein ions (as described in 
section 2.6.3). The aim was to achieve BMW settings such that a maximal 
number of protein ions could be detected with the minimal inclusion of electrical 
noise from the mass spectrometer or chemical noise from reagents used during 
ProteinChip® array preparation288-290. 
 
Using SELDI-TOF-MS data generated following the analysis of myoblasts on 
NP20 ProteinChip® arrays (n=6 control, 6 TMPD-treated analysed in duplicate; 
total 24 spectra), BMW settings were adjusted so that ions were detected using 
a range of S/N settings between 10 and 1 during the first phase of cluster 
generation (Figure 14). This range was selected as a S/N setting of 1 tends to 
include many ions (possibly including noise), whilst a setting of 10 may exclude 
some useful ions due to its high stringency. The S/N setting in the second pass 
had no significant effect on the number of ions detected as this phase simply 
supplements the first phase of detection. Therefore, a default setting of 2 was 
used for this phase of detection. 
 
A suitable S/N setting of 5 was selected for the BMW based on the deduction 
that the large drop in the number of ions detected from 814 (at a BMW S/N 
setting of 1) to 54 ions (when the setting was at 5) was due to the exclusion of 
noise (Figure 33). An example of the ions detected in myoblasts is shown in 
Figure 34. 
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Myoblasts were cultured and treated with the TMPD or GWδ (section 2.1) before 
analysing cell homogenates using SELDI-TOF-MS (section 2.6). In order to determine 
suitable BMW detection settings, they were adjusted so that the S/N of ions included in 
clusters ranged from 1-10. A S/N setting of 5 was used for the BMW in subsequent 
experiments, as a setting of 10 was too stringent, leading to the exclusion of a high 
proportion of ions whilst a setting of 1 resulted in the inclusion of 814 ions, which 
incorporated spectral noise. S/N = signal to noise ratio. 
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Figure 34: Peaks detected in SELDI-TOF-MS spectra using selected 
Biomarker Wizard detection settings  
Myoblasts were cultured and treated with the test compounds (section 2.1) before 
analysing cell homogenates by SELDI-TOF-MS (section 2.6). Suitable detection 
settings (S/N of ions detected = 5 in the first pass detection) for the BMW were  
obtained as shown in Figure 33 and 54 ions detected on NP20 ProteinChip® arrays in 
this experiment are highlighted (L). 
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3.4.2 Discovery of protein profiles that discriminate between control and 
treated muscle cells 
SELDI-TOF-MS analysis of 6 control and 6 treated samples on NP20, H50, 
CM10 (at pH 4, 6 and 8) and IMAC 30 ProteinChip® arrays was considered as a 
“SELDI-TOF-MS experiment run” during these investigations. For each SELDI-
TOF-MS experiment run, a different culture of skeletal muscle cells was 
resuscitated from storage and treated with the test compounds (as described in 
section 2.1). Cell homogenates were then analysed on NP20, H50, CM10 (at 
pH 4, 6 and 8) and IMAC 30 ProteinChip® arrays, as described in section 2.6 to 
form the dataset for a SELDI-TOF-MS experiment run. 
 
Principal component analysis (PCA) of data generated in an initial SELDI-TOF-
MS experiment run established that the treatment of myoblasts with TMPD 
(Figure 35a) and GWδ (Figure 35b) resulted in changes in the levels of some 
protein ions as indicated by the separation between control and treated 
myoblasts in the scores plots. Furthermore, these changes were observed in 
myoblasts treated with concentrations of the test compounds at which no 
adverse effects of treatment were detected by examining cell morphology or by 
using measures such as MTT reduction or total intracellular protein content.  
 
PCA of data generated following the SELDI-TOF-MS analysis of myotubes was 
also conducted in order to determine whether there were any changes in the 
protein ion profiles of TMPD or GWδ-treated myotubes. For both TMPD and 
GWδ-treated myotubes, there was natural separation (in PC2) between control 
and treated samples. This demonstrated that, as with myoblasts, treating cells 
with the test compounds resulted in changes to the protein ion profiles in 
myotubes (Figure 36). 
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Figure 35: Principal components analysis comparing control and treated 
myoblasts following SELDI-TOF-MS analysis 
Myoblasts were cultured (section 2.1) and data generated following SELDI-TOF-MS 
analysis of the cell lysates (section 2.6) was evaluated using PCA (including all 592 
ions detected in the analysis). a) Separation between control and TMPD-treated 
myoblasts is shown in the scores plot and the variation describing the separation due 
to TMPD treatment in myoblasts (22%) is mainly in principal component 2 (PC2). b) 
GWδ-treatment also resulted in differences between the protein ion profiles of control 
and treated myoblasts, which was accounted for mainly in PC1 (17% of the variation).  
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Figure 36: Principal components analysis comparing control and treated 
myotubes following SELDI-TOF-MS analysis 
Cultured myotubes were collected (section 2.1) and data generated following SELDI-
TOF-MS analysis (section 2.6) was evaluated using PCA (including all 331 ions 
detected in the analysis). a) Separation between control and TMPD-treated myotubes 
is shown in the scores plot and the variation describing the separation due to TMPD 
treatment in myotubes (18%) is mainly in principal component 2 (PC2). b) GWδ-
treatment also resulted in differences between the protein ion profiles of control and 
treated myotubes, which was accounted for mainly in PC2 (15% of the variation). 
These results demonstrated that the treatment of myotubes with TMPD and GWδ 
resulted in changes to the protein ion profiles. 
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PCA was unsupervised and was performed in order to determine whether there 
was any natural separation between control and treated skeletal muscle cells. 
The natural separation between control and treated skeletal muscle cells shown 
by PCA served as evidence that treating the cells with TMPD or GWδ resulted 
in changes to the protein expression profile in the cells. Partial least squares 
discriminant analysis (PLS-DA) was subsequently conducted and this 
supervised method of data analysis was performed in an attempt to determine 
the protein ions responsible for the separation between control and treated 
myoblasts previously shown by PCA. This analysis, however, resulted in the 
identification of over 85 protein ions (out of a total of 592 ions) in TMPD-treated 
myoblasts that had a variable importance of projection (VIP) coefficient >1 
(Figure 37a and b). The VIP coefficient is a measure that summarises the 
importance of each variable in the model. A VIP coefficient of >1 suggests that 
an ion was an important variable in describing the separation between control 
and treated samples291,292. Myoblasts treated with GWδ had over 95 ions that 
had VIP coefficients >1 and that were therefore important in discriminating 
between control and treated samples (Figure 37c and d).  
 
As with myoblasts, PLS-DA was conducted in order to determine the main ions 
that were changed in response to treatment with the test compounds. Again, 
this was difficult to determine using this method, mainly due to the high number 
of ions (331) included in the analysis. Although the scores plot showed clear 
separation between control and TMPD-treated myotubes (Figure 38a and b), 
there were 87 ions that had a VIP coefficient of >1. In GWδ-treated myotubes, 
there was again clear separation between control and treated cells but the 97 
ions with VIP coefficients of >1 again made it difficult to determine the most 
important ions (Figure 38c and d). 
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Figure 37: Partial least squares discriminant analysis (PLS-DA) comparing 
control and treated myoblasts 
Cultured control and treated myoblasts (section 2.1) were collected and spectra 
generated following SELDI-TOF-MS analysis (section 2.6) were evaluated using PLS-
DA. a) Separation between control and TMPD-treated myoblasts is shown in the 
scores plot following the supervised analysis. b) The loadings plot is shown for 
illustrative purposes and 85 ions had a VIP coefficient of >1 which suggests that the 
variables were important in the model. c) Separation between control and GWδ-treated 
myoblasts is shown in the scores plot. b) Again, the loadings plot is shown for 
illustrative purposes and, in this case, 95 ions had a VIP coefficient of >1. This data 
demonstrated the difficulty in discovering the most influential ions when all 592 peaks 
detected on ProteinChip® arrays were included in the analysis.  
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Figure 38: Partial least squares discriminant analysis (PLS-DA) comparing 
control and treated myotubes 
Cultured control and treated myotubes (section 2.1) were collected and spectra 
generated following SELDI-TOF-MS analysis (section 2.6) were evaluated using PLS-
DA. a) Separation between control and TMPD-treated myotubes is shown in the scores 
plot following the supervised analysis. b) The loadings plot is shown for illustrative 
purposes only and 87 ions had a VIP coefficient of >1 which suggests that the 
variables were important in the model. c) Separation between control and GWδ-treated 
myotubes is shown in the scores plot. b) Again, the loadings plot is shown for 
illustrative purposes and, in this case, 97 ions had a VIP coefficient of >1. When all 331 
peaks detected on ProteinChip® arrays were included in the analysis, it was difficult to 
determine the most influential ions.  
Chapter 3: Results 
 112
These results demonstrated that the treatment of myoblasts and myotubes with 
TMPD or GWδ resulted in changes in their pattern of protein expression. This 
was demonstrated by PCA of data generated following the SELDI-TOF-MS 
analysis of skeletal muscle cells on a variety of ProteinChip® arrays. Although 
PLS-DA showed clear separation between control and treated samples, it was 
not an appropriate method for determining the main ions that changed in 
response to treatment, due to the high number of variables entered into the 
analyses. The loadings plots generated resulted in the discovery of a high 
number of ions that could be considered as important in the models and the 
inclusion of all the ions detected may have lead to the inclusion of some 
unsuitable protein ions. Because of this, it was decided to focus on the levels of 
specific ions and determine whether individual ions where responsive to 
treatment using a univariate approach, rather than the multivariate one 
described here. 
 
3.4.3 Selection of TMPD or GWδ responsive protein ions in skeletal 
muscle cells 
Changes in the expression of specific protein ions were examined in order to 
determine whether their levels were changed significantly in response to 
treatment with either TMPD or GWδ (Student’s t-test, p<0.05). SELDI-TOF-MS 
data from the same SELDI-TOF-MS experiment run described in section 3.4.2 
was examined and consideration was also given to the possibility of false 
discoveries, where a number of false positives may have occurred by chance. 
In order to address this, a correction for multiple testing was applied in the form 
of a Benjamini-Hochberg false discovery rate (BH-FDR)293. Another commonly 
used method for correcting for an expected number of false discoveries was 
also applied in the form of a Bonferroni correction294. Ions that were changed in 
response to treatment here were validated in an independent repeat SELDI-
TOF-MS experiment run. 
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When changes in the levels of protein ions in myoblasts were examined, these 
methods resulted in the exclusion of a large proportion of the responsive protein 
ions initially discovered. Despite this, 3 protein ions (1 ion at m/z 5743 on CM10 
arrays at pH 8 and 2 ions at m/z 8557 and 9389 on IMAC arrays) were 
significantly changed in response to TMPD treatment following correction with 
the milder form of correction (BH-FDR). The ion at m/z 8557 was also included 
as being responsive to TMPD treatment following the application of the 
Bonferroni correction (Table 4). None of the ions were included when GWδ 
treatment was considered. However, in the repeat SELDI-TOF-MS experiment 
run (No. 2), only the levels of the ion at m/z 5743 were significantly altered in 
response to TMPD treatment although this same ion was ultimately excluded by 
both the BH-FDR and Bonferroni corrections. 
 
Table 4: Number of responsive proteins ion discovered in myoblasts  
Myoblasts were cultured and treated with TMPD or GWδ for 24h (section 2.1) prior to 
SELDI-TOF-MS analysis (section 2.6). The number of proteins ions whose levels were 
significantly altered in response to treatment is shown along with the number of 
responsive proteins ions discovered after correction for the BH-FDR or using a 
Bonferroni correction (Students t-test, p<0.05). The number of selected protein ions 
was vastly reduced when the corrections for multiple testing were applied suggesting 
that these corrections may have been too harsh in this case. Use of the BH-FDR 
correction resulted in the inclusion of 3 ions at m/z 5743, 8557 and 9389 for TMPD-
treated myoblasts whilst a Bonferroni correction resulted in the inclusion of just 1 ion at 
m/z 8557. 
TMPD GWδ TMPD GWδ TMPD GWδ
NP20 10 8 0 0 0 0 54
H50 9 6 0 0 0 0 109
CM10 (pH 4) 15 11 0 0 0 0 112
CM10 (pH6) 17 14 0 0 0 0 107
CM10 (pH8) 18 19 1 0 0 0 106
IMAC 30 11 13 2 0 1 0 103
ProteinChip 
array
Number of responsive protein ions
Number of 
ions detectedNo correction BH-FDR Bonferroni
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When changes in the levels of protein ions measured in myotubes were 
examined following correction for multiple testing, a higher number of protein 
ions remained than was observed in myoblasts. As with myoblasts, the BH-FDR 
correction resulted in the inclusion of a higher number of ions than the 
Bonferroni correction (Table 5). 
 
Table 5: Number of responsive proteins ion discovered in myotubes 
Myotubes were cultured and treated with TMPD or GWδ for 24h (section 2.1) before 
SELDI-TOF-MS analysis was conducted (section 2.6). The number of responsive 
protein ions is shown before and after correction for multiple testing using the BH-FDR 
or using the Bonferroni correction. In most cases, the number of responsive protein 
ions was vastly reduced as these correction methods apply a threshold to the p value 
obtained. 
TMPD GWδ TMPD GWδ TMPD GWδ
NP20 4 5 2 2 2 1 24
H50 29 8 15 12 3 2 77
CM10 (pH 4) 1 1 1 1 1 1 50
CM10 (pH 6) 8 6 1 0 1 0 61
CM10 (pH 8) 18 17 1 1 1 1 66
IMAC 30 30 25 21 19 2 2 53
ProteinChip 
array
Number of responsive protein ions Number of 
ions 
detected
No correction BH-FDR Bonferroni
 
More protein ions were included after the corrections for multiple testing were 
applied than there were with myoblasts. Following a BH-FDR correction in the 
initial SELDI-TOF-MS experiment run (No. 1), a total of 41 ions were shown as 
being responsive to treatment with TMPD in myotubes (35 ions for GWδ). When 
the Bonferroni correction was applied to the same data, the number of 
responsive ions was reduced to only 10 ions (7 for GWδ). Of these, only the 
levels of ions at m/z 5298 (on CM10 arrays at pH 4) and 6588 (on NP20 arrays) 
were still changed significantly in the repeat SELDI-TOF-MS experiment run 
experiment (No. 2). However, the ion at m/z 6588 was excluded by the 
Bonferroni correction in all cases despite that its levels were significantly 
changed in response to treatment (Student’s t-test, p<0.05). 
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The BH-FDR and the Bonferroni correction are sometimes considered to be 
severe methods for accounting for false discovery and this appeared to be the 
case for myoblasts295. Only 1 ion at m/z 5743 resulted that was changed in 
response to the treatment of myoblasts with TMPD in an initial SELDI-TOF-MS 
experiment run (No. 1). However, even this ion was eventually excluded after 
the correction thresholds were applied in an independent SELDI-TOF-MS 
experiment run (No. 2).  
 
When SELDI-TOF-MS data from myotubes was examined, a higher number of 
protein ions were included after the correction thresholds were applied in the 
initial SELDI-TOF-MS experiment run (No. 1) than there were for myoblasts. 
However, a high number of those ions were not included when tested in an 
independent repeat SELDI-TOF-MS experiment run. Despite this, an ion at m/z 
5298 was still included.  
 
The risks associated with accepting the changes from a single experiment were 
also recognised during these investigations and it was therefore decided to 
address the possibility of false discovery by repeating experiments and looking 
for consistent changes in the levels of protein ions in different, independent 
SELDI-TOF-MS experiment runs. 
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3.4.4 Reproducibility of SELDI-TOF-MS protein ions in muscle cells 
Prior to differential protein expression experiments, an investigation into SELDI-
TOF-MS reproducibility was conducted. Data from two repeat SELDI-TOF-MS 
experiment runs (No.s 1 and 2) were considered as a training dataset whilst the 
findings from these experiments were validated in a third independent SELDI-
TOF-MS experiment run (test dataset, No. 3). An investigation into the 
variability of the ions detected using the biomarker settings described in section 
2.6.3 was conducted in order to gain an appreciation for the intra and inter-
experimental variability of the SELDI-TOF-MS data generated on CM10 
ProteinChip® arrays (at pH 4) in the training dataset (SELDI-TOF-MS 
experiment run (No.3).  
 
In myoblasts, the average coefficient of variation in the levels of the 112 protein 
ions detected was 27% in the first SELDI-TOF-MS experiment run. In the repeat 
SELDI-TOF-MS experiment run of the training dataset, the coefficient of 
variation was 25%. The levels of 12 of the 112 protein ions measured by 
SELDI-TOF-MS were significantly different between the two repeat experiments 
(Student’s t-test, p<0.05) (Figure 39). In myotubes, the average CV% for the 50 
ions measured in the first experiment run was 24% and was 17% in the second 
experiment run. The levels of 4 of the 50 ions measured were significantly 
different between repeat experiment runs (Figure 40).  
 
These results demonstrated that whilst some of the ions detected by SELDI-
TOF-MS demonstrated a degree of intra and inter-experimental variability, the 
majority of the ions were reproducible within acceptable limits as determined by 
their CV% and significance testing between the repeat experiments. Also the 
reproducibility appears to be comparable with that obtained by other SELDI-
TOF-MS users296-298. The source of the variation may be difficult to pinpoint 
without additional investigations but these results highlighted the need to 
examine changes observed within experiment runs before examining changes 
across different repeat SELDI-TOF-MS experiment runs. 
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Figure 39: Intra and inter-experiment reproducibility of SELDI-TOF-MS protein ions in myoblasts 
Myoblasts were cultured (section 2.1) and untreated myoblasts were analysed using SELDI-TOF-MS on CM10 ProteinChip® arrays (pH 
4). The CV% for all of the ions detected is shown and the red line is set at 30% which is the approximate CV% commonly observed in 
SELDI-TOF-MS experiments by other users. The levels of the ions detected were compared between 2 repeat SELDI-TOF-MS 
experiment runs in order to evaluate inter-experiment reproducibility. The filled bars (12/112) represent the ions whose levels varied 
significantly between the 2 repeat experiments and significant changes are denoted by *p<0.05, **p<0.01, p<0.001(Student’s t-test). Error 
bars represent SEM where visible. 
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Figure 39 continued 
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Figure 40: Intra and inter-experimental reproducibility of SELDI-TOF-MS protein ions in myotubes 
Myotubes were cultured (section 2.1) and untreated myotubes were analysed using SELDI-TOF-MS on CM10 ProteinChip® arrays (pH 4). 
The CV% for all of the ions detected is shown and the red line is set at 30% which is the approximate CV% commonly observed in SELDI-
TOF-MS experiments by other users. The levels of the ions detected were compared between 2 repeat SELDI-TOF-MS experiments in 
order to evaluate inter-experiment reproducibility. The filled bars (4/50) represent the ions whose levels varied significantly between the 2 
repeat experiments and significant changes are denoted by *p<0.05, **p<0.01 (Student’s t-test). Error bars represent SEM where visible. 
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Figure 40 continued 
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3.4.5 Validation of TMPD and GWδ responsive protein ions in skeletal 
muscle cells 
Differential protein expression was investigated further in the two repeat SELDI-
TOF-MS experiment runs of the training dataset (No.s 1 and 2). In order to 
ensure that the same ions were compared between the different defined 
experiments, SELDI-TOF-MS data from both experiment series was combined 
before clusters of protein ions were detected using the BMW (as described in 
section 2.6.3). Differentially expressed ions were considered for further 
statistical analyses if the ion was consistently expressed at significantly different 
levels between control and treated samples in both repeat experiment runs of 
the training dataset (Student’s t-test, p<0.05). This consideration for the 
consistency of the response of individual protein ions effectively reduced the p 
value for selected protein ions to less than 0.0025 (i.e. p=0.052). 
 
A total of 592 protein ions were detected in myoblasts on 6 different types of 
ProteinChip® array using the BMW settings described in section 2.6.3. The 
treatment of myoblasts with 25μM TMPD resulted in a consistent increase in the 
levels of 3 protein ions at m/z 5743, 6910 and 7177 along with a decrease in the 
levels of 7 ions at m/z, 6306, 6420, 9097, 9113, 9123, 9137 and 9161 in the two 
repeat experiments of the training dataset. These changes were detected on a 
combination of NP20 and CM10 (pH 4 and 6) ProteinChip® arrays (Table 6 and 
Figure 41a).  
 
Treating myoblasts with 50μM GWδ resulted in a significant increase in the 
levels of 6 ions at m/z 4910, 4913, 5655, 7177, 7222 and 13814. These 
changes were accompanied by a decrease in the levels of 7 protein ions at m/z, 
6306, 6420, 9097, 9113, 9123, 9137 and 11708. The changes associated with 
GWδ treatment were detected on a combination of NP20, H50 and CM10 (pH4, 
6 and 8) ProteinChip® arrays. Also, the levels of the ions at m/z 6306, 6420, 
7177, 9097, 9113, 9123 and 9137 were changed in response to treatment with 
both TMPD and GWδ (Table 6 and Figure 41b). 
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Table 6: Summary of protein expression changes in myoblasts 
Myoblasts were cultured, treated with the test compounds (section 2.1) and analysed 
using SELDI-TOF-MS (section 2.6). The total number of protein ions detected (section 
2.6.3) on each type of ProteinChip® array and in 2 repeat SELDI-TOF-MS experiments 
that formed the training dataset is shown. Cell homogenates from control myoblasts 
were compared with TMPD or GWδ-treated samples. Spectra from both experiments 
were combined before ion detection was performed simultaneously for both 
experiments in order to ensure the generation of consistent clusters of protein ions 
using the BMW. The number of ions that were responsive to treatment in each of the 
repeat experiments and those that were consistently responsive to treatment are 
shown (Student’s t-test, p<0.05).  
TMPD GWδ TMPD GWδ TMPD GWδ
NP20 10 8 29 26 7 6 54
H50 9 6 52 47 0 1 109
CM10 (pH 4) 15 11 32 30 1 1 112
CM10 (pH6) 17 14 35 29 2 4 107
CM10 (pH8) 18 19 21 22 0 1 106
IMAC 30 11 13 2 2 0 0 103
ProteinChip 
array Experiment 1 Experiment 2 Combined
Number of responsive protein ions Total number 
of ions 
detected
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Figure 41: Responsive SELDI-TOF-MS protein ions in myoblasts  
Rat L6 myoblasts were cultured and treated with 25μM TMPD or 50μM GWδ for 24h 
(section 2.1). Samples were then analysed on NP20, CM10 (at pH 4, 6 and 8) and 
IMAC 30 ProteinChip® arrays (section 2.6). Protein ions whose levels were consistently 
changed in response to treatment with a) TMPD or b) GWδ in two repeat SELDI-TOF-
MS experiment runs are shown by solid bars (Student’s t-test, p<0.05). Ions whose 
levels changed in response to treatment with TMPD are grouped on the left, those that 
changed following GWδ treatment are grouped in the middle section and those ions 
that changed following the treatment of myoblasts with both test compounds are 
grouped on the right. Error bars show ± SEM.  
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Proteins whose ion levels were consistently changed in myotubes in response 
to treatment with TMPD or GWδ were identified using a similar approach to that 
used for myoblasts. Again, SELDI-TOF-MS data generated in the 2 repeat 
SELDI-TOF-MS experiment runs of a training dataset was examined to discover 
protein ions whose levels were consistently changed in response to treatment 
(Student’s t-test, p<0.05).  
 
In myotubes, 331 protein ions were detected using the different ProteinChip® 
arrays and assay conditions previously described for myoblasts (section 2.6). 
The treatment of myotubes with 25µM TMPD resulted in a significant increase 
(in the training dataset) in the levels of 4 protein ions at m/z 3158, 3978, 5298, 
and 6305 along with a decrease in the levels of 6 ions at m/z 4815, 5579, 6312, 
6578, 6588 and 12357. These ions were detected on a combination of NP20, 
IMAC and CM10 (pH4 and 6) ProteinChip® arrays. Treating myoblasts with 
50μM GWδ resulted in an increase in the levels of 4 ions at m/z 3158, 5298, 
6305 and 9126 and a decrease in the levels of 3 ions at m/z 5753, 6588 and 
12357. The levels of the ions at m/z 3158, 5298, 6305, 6588 and 12357 were 
responsive to treatment with both test compounds (Table 7 and Figure 42). 
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Table 7: Summary of protein expression changes in myotubes 
Myotubes were grown (section 2.1) and analysed using SELDI-TOF-MS (section 2.6). 
Cell homogenates from control myotubes were compared with TMPD or GWδ-treated 
samples and the total number of protein ions detected (section 2.6.3) on each type of 
ProteinChip® array in the training dataset is shown. Spectra were combined and protein 
ions were detected simultaneously for both SELDI-TOF-MS experiments in order to 
ensure the generation of consistent clusters of protein ions using the BMW and those 
ions that were responsive in each of the repeat experiments are shown (Student’s t-
test, p<0.05).  
TMPD GWδ TMPD GWδ TMPD GWδ
NP20 4 5 9 8 3 4 24
H50 29 25 12 8 0 0 77
CM10 (pH 4) 1 1 4 7 1 1 50
CM10 (pH6) 8 6 16 10 2 2 61
CM10 (pH8) 18 17 11 9 1 0 66
IMAC 30 30 25 4 2 3 0 53
Total number 
of ions 
detected
ProteinChip 
array Experiment 1 Experiment 2 Combined
Number of responsive protein ions
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Figure 42: Responsive SELDI-TOF-MS protein ions in myotubes  
Rat L6 myotubes were differentiated from cultured myoblasts and treated with TMPD or 
GWδ for 24h (section 2.1). Samples were then analysed on NP20, CM10 (at pH 4, 6 
and 8) and IMAC 30 ProteinChip® arrays (section 2.6). Ions whose levels were 
consistently changed in response to treating myotubes with a) TMPD or b) GWδ are 
shown by solid bars (Student’s t-test, p<0.05). Ions whose levels were changed 
following treatment with TMPD are grouped on the left, those changed following GWδ 
treatment are grouped in the middle section and those ions that changed following 
treatment with both test compounds are grouped on the right. Error bars show ± SEM.  
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The levels of protein ions that were consistently responsive to treatment with 
the test compounds were examined in an independent repeat third SELDI-TOF-
MS experiment run (No. 3) in order to determine the most consistent of the 
changes observed in the training dataset. The levels of 7 out of the 10 protein 
ions originally found (at m/z 9161, 6306, 7177, 9097, 9113, 9123 and 9137) 
were significantly altered in response to the treatment of myoblasts with TMPD 
as they were in the two SELDI-TOF-MS experiment runs that formed the 
training dataset. However, the levels of the other 3 ions originally tested were 
not significantly changed in the test dataset (Figure 43). This included an ion at 
m/z 5743, which had also been selected as being responsive to treatment with 
TMPD after the BH-FDR and Bonferroni corrections, but was excluded by the 
corrections in the repeat SELDI-TOF-MS experiment run No. 2 (section 3.4.2). 
A similar story was true for myoblasts treated with GWδ in that ions at m/z 6306, 
7177, 9097, 9113, 9123, 9137 and 9161 were significantly changed in response 
to treatment, as they were in the training dataset but the levels 7 of the 13 ions 
examined were not changed in the test dataset (Figure 44). Representative 
SELDI-TOF-MS putative biomarkers in myoblasts are shown in Figure 45. 
 
Protein ions in myotubes whose levels were consistently changed treated with 
TMPD or GWδ were also examined in the myotubes test dataset to see whether 
they were still responsive in the independent test dataset. The levels of 3 
protein ions at m/z 4815, 3185 and 5298 were changed significantly in response 
to treatment with TMPD although the levels of 7 other ions tested were not 
changed significantly when tested (Figure 46) (Student’s t-test, p>0.05). 
Amongst these, an ion at m/z 5298 was also selected in myotubes when the 
corrections for multiple testing were applied (BH-FDR and Bonferroni) and this 
may be a more robust marker than others found during these analyses. In the 
case of GWδ, the levels of the 7 ions tested were not significantly different to 
those in control myotubes (Figure 47). Representative SELDI-TOF-MS putative 
biomarkers in myotubes are shown in Figure 48. 
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Figure 43: Levels of TMPD-responsive protein ions in myoblasts 
Myoblasts were grown and treated with 25μM TMPD (section 2.1) before SELDI-TOF-
MS analysis on different ProteinChip® arrays (section 2.6). Proteins that were 
responsive to treatment in two repeat experiments of the training dataset were tested in 
an independent third dataset to examine their robustness as putative biomarkers of 
myopathy. All of the proteins examined showed similar responses to treatment with the 
test compound although significant differences were only observed in the levels of 
protein ions examined at m/z 6306, 7177, 9097, 9113, 9123, 9137 and 9161 (Student’s 
t-test, p<0.05). Where visible, bars show mean of the control or treated group and 
significant changes are denoted by **p<0.01. 
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Figure 44: Levels of GWδ-responsive protein ions in myoblasts  
Myoblasts were grown and treated (section 2.1) with 50μM GWδ prior to SELDI-TOF-
MS analysis (section 2.6). The levels of proteins that were responsive to treatment in 
the training dataset were examined in an independent test dataset. All protein ions 
examined showed similar responses to treatment with GWδ but significant differences 
were only observed in the levels of protein ions at m/z 6306, 7222, 9097, 9113, 9123 
and 9137 (Student’s t-test, p<0.05). Where visible, the bars show the mean of the 
control or treated group and significant changes are denoted by *p<0.05 and **p<0.01. 
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Figure 45: Representative SELDI-TOF-MS spectra showing putative biomarkers in TMPD or GWδ-treated myoblasts 
Rat L6 myoblasts were cultured and treated with 25μM TMPD or 50μM GWδ for 24h (section 2.1). SELDI-TOF-MS analysis  was 
conducted (section 2.6) and protein ions at m/z 6306, 7177, 7222, 9097, 9113, 9123, 9137 and 9161 (detected on NP20 and CM10 
ProteinChip® arrays) were consistently responsive to treatment with TMPD or GWδ in both the training and test datasets. The m/z is 
shown on the x-axis and the relative ion intensity is displayed on the y-axis. 
Chapter 3: Results 
 131
C
M
10
 p
H
8 
39
78
C
M
10
 p
H
6 
48
15
IM
AC
 5
57
9
IM
AC
 6
31
2
IM
AC
 6
57
8
C
M
10
 p
H
6 
31
58
C
M
10
 p
H
4 
52
98
N
P2
0 
63
05
N
P2
0 
65
88
N
P2
0 
12
35
7
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
R
el
at
iv
e 
io
n 
in
te
ns
ity
Control
Treated
TMPD responders Common responders
*
*
**
 
Figure 46: Levels of TMPD-responsive protein ions in myotubes  
Myotubes were cultured and treated (section 2.1) with 25μM TMPD prior to SELDI-TOF-
MS analysis (section 2.6). The levels of proteins that were responsive to treatment in the 
training dataset were examined in a test dataset. All protein ions examined showed similar 
responses to those observed in the training dataset but significant differences in their 
levels were only observed in ions at m/z 3158, 4815 and 5298 (Student’s t-test, p<0.05). 
Where visible, bars show the mean of the control or treated group and significant changes 
are denoted by *p<0.05 and **p<0.01. 
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Figure 47: Levels of GWδ-responsive protein ions in myotubes  
Myotubes were cultured and treated with 50μM GWδ (section 2.1) prior to SELDI-TOF-MS 
analysis (section 2.6). Proteins that were responsive to treatment in the training dataset 
were validated in the test dataset. All protein ions examined showed similar responses to 
treatment with GWδ but, in this case, none of the changes were statistically significant 
(Student’s t-test, p>0.05). Where visible, bars show the mean of the control or treated 
group. 
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Figure 48: Representative SELDI-TOF-MS spectra showing putative biomarkers of myopathy in myotubes 
Rat L6 myotubes were cultured and treated with TMPD or GWδ for 24h (section 2.1). SELDI-TOF-MS analysis was conducted (section 
2.6) and protein ions at m/z 3158, 4815 and 5298 (detected on CM10 ProteinChip® arrays) were consistently responsive to treatment 
with TMPD in repeat experiments. The m/z is displayed on the x-axis and the relative ion intensity is displayed on the y-axis. 
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A number of approaches to discovering the most robust markers of TMPD or 
GWδ treatment were attempted in these SELDI-TOF-MS investigations. The 
need for multiple approaches to the analysis of this data perhaps demonstrated 
the difficulty in determining the most useful protein ions. SELDI-TOF-MS was 
useful in discovering protein ions that were consistently responsive to the 
effects of treatment with the test compounds although the changes observed 
were relatively small changes and were difficult to distinguish amongst the 
background variation of their levels. When the levels of potentially useful protein 
ions were evaluated in the test dataset, they were either increased or 
decreased in response to treatment as previously observed some of the 
changes were not statistically significant when investigated in independent 
repeat SELDI-TOF-MS experiments. 
3.4.6 Selection of responsive protein ion combinations in skeletal muscle 
cells 
In the previous section, protein ions that were responsive to treatment with 
25μM TMPD or 50μM GWδ (Figure 41 and Figure 42) were discovered. 
However, not all of the protein ions suspected to be useful based on initial 
SELDI-TOF-MS experiments were verified successfully when examined in the 
test dataset. These ions still responded moderately to treatment and it was 
believed that, despite the changes in the levels of some of the protein ions 
being statistically insignificant (Student’s t-test, p>0.05), a combination of 
protein ions may have increased the ability to discriminate between control and 
treated cells when compared to the individual ions.   
 
In order to investigate the use of multiple protein ions, those ions whose levels 
were changed in response to TMPD or GWδ treatment in the 2 repeat SELDI-
TOF-MS experiment runs (No.s 1 and 2) were entered into a forward stepwise 
regression analysis (p to enter of 0.05, p to remove of 0.06). Those that were 
responsive to treatment with TMPD were used in the regression analysis for 
TMPD-treated cells and those ions whose levels were changed in response to 
GWδ treatment were used for GWδ-treated cells. Regression analysis was then 
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used in order to discover protein ions whose levels correlated well with 
treatment but that also contributed independently to the model (had a low 
covariance with each other). In a forward stepwise regression analysis, each 
variable is evaluated for its effectiveness in distinguishing between control and 
treated samples. If the variable assessed does not improve the model, it is 
removed and the utility of another variable is assessed in the next step of the 
analysis. This is continued until only variables that contribute significantly to the 
model remain299. This analysis was repeated using data from the test dataset 
(SELDI-TOF-MS experiment run No. 3) in order to validate findings from the 
training dataset (SELDI-TOF-MS experiment runs 1 and 2). 
 
When considering myoblasts, forward stepwise regression analysis of SELDI-
TOF-MS data from the training dataset resulted in the inclusion of 3 protein ions 
at m/z 5743, 6420 and 7177 in a model that described the differences between 
control myoblasts and those treated with TMPD. When regression analysis was 
repeated using data from the test dataset, the ions at m/z 6420 and 7177 were 
again selected as being useful when considered together. These same two 
protein ions were also selected by stepwise regression analysis when SELDI-
TOF-MS data from control and GWδ-treated myoblasts was examined (in both 
the training and test dataset) (Table 8). Therefore, in combination, these 2 
proteins ions were consistently useful in discriminating between control and 
treated myoblasts. 
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Table 8: Summary of forward stepwise regression of responsive protein 
ions in control and treated myoblasts 
Myoblasts were cultured and treated with TMPD or GWδ (section 2.1). Protein ions that 
were responsive to treatment were observed in spectra generated following SELDI-
TOF-MS analysis of cell homogenates (section 2.6) in 2 repeat experiments and a 
forward stepwise regression analysis of these ions was performed (p to enter of 0.05, p 
to remove of 0.06). A repeat regression analysis using SELDI-TOF-MS data from an 
independent test dataset allowed selected ions to be validated and ions at m/z 6420 
and 7177 were useful for characterising control and TMPD or GWδ-treated myoblasts.  
Training 
dataset Test dataset
p value p value
1 6420 NP20 0.002 <0.001
2 7177 CM10 (pH 6) 0.016 <0.001
3 5743 CM10 (pH 4) 0.041 0.72
1 7177 CM10 (pH 6) <0.001 0.001
2 6420 NP20 <0.001 <0.001
ProteinChip 
array
TMPD
GWδ
Test 
compound Step m/z
 
Correlation between the protein ions resulting from regression analysis was also 
considered in order to ensure that the ions selected contributed independently 
to the discrimination between control and treated myoblasts. The correlation 
coefficients for ions shown in Table 8 were examined and the variables at m/z 
6420 and 7177 had low correlation coefficients when compared to each other 
(between -0.3 and -0.1 for myoblasts treated with TMPD or <0.1 when GWδ-
treated myoblasts were considered). This suggested that these protein ions 
contributed independently to the model describing the differences between 
control and treated myoblasts300,301. 
Chapter 3: Results 
 137
Forward stepwise regression analysis was also applied to SELDI-TOF-MS data 
from the training dataset of myotubes and resulted in the inclusion of 5 protein 
ions at m/z 3158, 3978, 4815, 5298 and 6578 that correlated well with TMPD 
treatment. The ions at m/z 5298 and 4815 were consistently useful in the model 
when data from the test dataset was considered in a repeat regression analysis. 
However, when considering control and GWδ-treated myotubes, ions at m/z 
5298 and 6305 that were initially selected by regression analysis were not 
effective at discriminating between control and treated myotubes when tested 
using an independent dataset (Table 9). 
 
Table 9: Summary of forward stepwise regression of responsive protein 
ions in control and treated myotubes 
Myotubes were cultured and treated with TMPD or GWδ (section 2.1). Protein ions 
within the samples were observed in spectra following SELDI-TOF-MS analysis 
(section 2.6). A forward stepwise regression analysis of responsive protein ions from 
the training dataset determined the ions that contributed significantly to the 
discrimination between control and treated myotubes (Student’s t-test, p<0.05). A 
repeat regression analysis using SELDI-TOF-MS data from an independent test 
dataset allowed selected ions to be validated and ions at m/z 5298 and 4815 resulted 
from this analysis that were useful for TMPD-treated myotubes. 
Training 
dataset Test dataset
p value p value
1 5298 CM10 pH 4 <0.001 <0.001
2 4815 CM10 pH 6 <0.001 0.003
3 3978 CM10 pH 8 <0.001 0.649
4 3158 CM10 pH 6 <0.001 0.804
5 6578 IMAC 30 <0.001 0.995
1 5298 CM10 pH 4 <0.001 0.087
2 6305 NP20 0.020 0.072
Test 
compound Step m/z
ProteinChip 
array
GWδ
TMPD
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The correlation coefficients for protein ions selected by regression analysis and 
validated successfully in the test dataset were examined for ions (at m/z 5298 
and 4815) selected following the analysis of SELDI-TOF-MS data from control 
and TMPD or GWδ-treated myotubes. The correlation coefficients were low for 
these variables (r is between -0.3 and -0.1 for TMPD-treated cells or <0.1, when 
examining GWδ treatment) and this demonstrated that the ions selected 
contributed independently to the discrimination between control and TMPD-
treated myotubes.  
 
From the previous forward regression analysis, ions at m/z 6420 and 7177 were 
shown to contribute significantly and independently to the discrimination 
between control and TMPD or GWδ-treated myoblasts (Student’s t-test, 
p<0.05). When these ions were considered individually, they were unable to 
discriminate completely between control and treated myoblasts (Figure 43 and 
Figure 44). When these ions were considered together, their discriminatory 
power was greater and they were able to separate control and TMPD-treated 
(Figure 49a) or control and GWδ-treated myoblasts (Figure 49b) completely.  
 
When the ions at m/z 5298 and 4815 were examined individually their levels 
changed significantly in response to TMPD-treatment (Student’s t-test, p<0.05) 
(Figure 46). Complete separation between control and TMPD-treated myotubes 
was possible when they were used together although it was not possible when 
the ions were considered separately (Figure 50a). Ions at 6305 and 5298 were 
not changed significantly when examined individually in GWδ-treated myotubes 
in the test dataset (Figure 47). Even the combined power of these ions was not 
sufficient to discriminate completely between control and GWδ-treated 
myotubes although only 2/6 treated samples were classified incorrectly (Figure 
50b). 
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Figure 49: Two-dimensional scatterplots of TMPD and GWδ responsive 
protein ions selected by regression analysis in myoblasts 
Myoblasts were cultured and treated with TMPD or GWδ (section 2.1). Following 
SELDI-TOF-MS analysis (Section 2.6), protein ions at m/z 6420 and 7177 were 
selected by forward stepwise regression analysis for their combined ability to 
discriminate between a) control and TMPD-treated myoblasts and b) control and GWδ-
treated myoblasts. The broken line in the scatterplots shows the discrimination 
between control and treated myoblasts, based on the combined intensities of the ions 
shown. 
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Figure 50: Two-dimensional scatterplots of TMPD and GWδ responsive 
protein ions selected by regression analysis in myotubes 
Myotubes were cultured and treated with TMPD or GWδ (section 2.1). Following 
SELDI-TOF-MS analysis (Section 2.6), protein ions at m/z 5298 and 4815 were 
selected by forward stepwise regression analysis for their combined ability to 
discriminate between a) control and TMPD-treated myotubes. Ions at 6305 and 5298 
were tested for their combined power to discriminate between b) control and GWδ-
treated myotubes and they only misclassified 2/6 treated myotubes. The broken line in 
the scatterplots shows the discrimination between control and treated myotubes, based 
on the combined intensities of the ions shown. 
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These results demonstrated that whilst some of the protein ions selected by 
univariate analysis may not have been validated successfully in the test dataset, 
there was the possibility of combining protein ions in order to increase their 
discriminatory power. This was the case with TMPD and GWδ-treated 
myoblasts and also with TMPD-treated myotubes and complete separation 
between control and treated samples was possible using a combination of 
responsive protein ions even where it had previously not been possible with 
individual ions. Despite the increased power of protein ion combinations, 2/6 
GWδ-treated myotubes were still misclassified as control samples (false 
negatives).  
 
The levels of ions at m/z 6420 and 9137 that were seen to be useful in 
discriminating between control and treated myoblasts were assessed in cells 
treated with lower concentrations of the test compounds. However, neither the 
levels of the ion at m/z 6420 nor the ion at m/z 9137 were responsive to 
treatment with <25μM TMPD or <50μM GWδ (Figure 51).  
 
An ion at m/z 5298 was changed significantly when examined individually in the 
test dataset (Student’s t-test, p<0.05) and it was also selected by regression 
analysis. The levels of this ion in myotubes treated with lower concentrations of 
TMPD and GWδ than were used previously were also investigated but they 
were not changed in response to treatment with <25μM TMPD or <50μM GWδ  
(Figure 52). 
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Figure 51: Effect of TMPD or GWδ on rat L6 myoblasts 
Myoblasts were grown and tested with a range of concentrations of up to 25μM TMPD 
or up to 50μM GWδ (section 2.1) before SELDI-TOF-MS analysis of cell homogenates 
(section 2.6). Changes in the levels of putative protein ion biomarkers of myopathy at 
m/z 6420 and 9137 in myoblasts treated with lower concentrations of the test 
compounds than previously used were examined. These ions were not responsive to 
the treatment of myoblasts with <25μM TMPD or <50μM GWδ. VC = vehicle control. 
Error bars show ± SEM. Significant changes are denoted by *p <0.05, **p<0.01. 
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Figure 52: Effect of TMPD or GWδ on rat L6 myotubes 
Myotubes were differentiated from myoblasts and tested with a range of concentrations 
of up to 25μM TMPD or up to 50μM GWδ (section 2.1) prior to SELDI-TOF-MS analysis 
(section 2.6). Changes in the levels of a protein ion at m/z 5298 in myotubes treated 
with lower concentrations of the test compounds than previously used were examined. 
This ion was not responsive to the treatment of myotubes with <25μM TMPD or <50μM 
GWδ. VC = vehicle control. Error bars show ± SEM. Significant changes are denoted 
by **p<0.01. 
 
3.4.7 Identification of SELDI-TOF-MS putative biomarkers of myopathy 
Attempts were made to identify the protein ions discovered as putative 
biomarkers of myopathy in previous sections. The ExPASy server (provided by 
the Swiss institute of Bioinformatics and linked to the UniProt consortium 
knowledgebase) was interrogated using the Mw of putative biomarkers 
discovered by SELDI-TOF-MS. The charge (z) of the protein ions detected by 
SELDI-TOF-MS was taken as equal to one and the database was also 
interrogated with z equal to 1, 2 or 3 to account for multiply charged ions. 
Protein dimerisation was also accounted for and an error of 0.1% (the expected 
error for a SELDI-TOF-MS external calibration) in the interrogated mass was 
accounted for.  
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The masses of the ions discovered by SELDI-TOF-MS were also checked 
against those of proteins ions identified by LC-MS/MS (described in detail in 
section 3.5). The advantage of this method of verification was that the peptides 
and proteins included in the search were measured directly in this study and 
were not selected solely on the basis of a Mw match for the responsive ions 
discovered in myoblasts (Table 10-Table 12) or those discovered in myotubes 
(Table 13-Table 15). 
 
Table 10: Identification of SELDI-TOF-MS biomarkers of myopathy in 
myoblasts (TMPD responders) 
Myoblasts were cultured and treated with 25μM TMPD for 24h (section 2.1). Protein 
ions at m/z 5743, 6910 and 9181 were responsive to the treatment of myoblasts with 
TMPD when measured using SELDI-TOF-MS (section 2.6). Mw information available 
on the ExPASy database was interrogated using the TagIdent tool in order to discover 
possible matches for the ions detected on ProteinChip® arrays. LC-MS/MS data 
generated following the analysis of myoblasts cell homogenates was also interrogated 
via Bioworks Browser (section 3.5). Although several possible identifications were 
available for each of the ions when TagIdent was used, no possible identifications were 
provided from the LC-MS/MS data. 
TM
P
D
G
w
d
C
om
m
on
Protein Accession code Calculated Mw (Da) Charge (z)
Cytochrome c, somatic NP_036971 11474 1a
Vesicle-associated membrane protein 3 NP_476438 11480 1a
Vesicle-associated membrane protein 5 NP_446007 11495 1a
Octadecaneuropeptide NP_114054 1912 3
39S ribosomal protein L41, mitochondrial NP_001013444 13818 1a
Trefoil factor 1 NP_476470 6912 1
60S ribosomal protein L41 NP_620783 3456 2
Protein B-Myc NP_001013181 18317 1a
60S ribosomal protein L21 NP_445782 18335 1a
UDP-N-acetylglucosamine transferase subunit 
ALG13 homolog NP_001013973 18329 1
a
Corticotropin P01194 4582 2
TagIdent UniProtKB/Swiss-Prot search
Average 
relative level SEM
-0.7 0.04
0.26
0.09CM10 pH 6
CM10 pH 4
-
- -
-9
NP20 9
0.8
0.46910
5743
9161
SELDI-TOF-MS 
m/z (z=1)
ProteinChip® 
array
-
9 -
Responsive to 
treatment with
 
a) Charge (z) = 1 but the possibility of dimerisation was considered 
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Table 11: Identification of SELDI-TOF-MS putative biomarkers of myopathy in 
myoblasts (GWδ responders) 
Myoblasts were grown and treated with 50μM GWδ for 24h (section 2.1). The protein 
ions shown were responsive to treatment when measured using SELDI-TOF-MS 
(section 2.6). The TagIdent tool (available via the ExPASy server) was used to assign 
possible matches for the ions detected on ProteinChip® arrays. LC-MS/MS data was 
also cross-referenced via Bioworks Browser (section 3.5). No possible identifications 
were provided by TagIdent for the ions at m/z 4910 and 4913. Also, no identifications 
were provided by interrogating LC-MS/MS data. 
TM
P
D
G
w
d
C
om
m
on
Protein Accession code Calculated Mw (Da) Charge (z)
4910 CM10 pH 4 - 9 - 0.7 0.22 - - - -
4913 CM10 pH 8 - 9 - 0.6 0.17 - - - -
Ig lambda-2 chain C region P20767 11318 1a
Vesicle-associated membrane protein 8 NP_114015 11320 1a
7222 CM10 pH 6 - 9 - 0.4 0.04 Apelin-31 NP_113800 3607 2
Neighbor of COX4 NP_001012165 23406 1a
Coiled-coil domain-containing protein 153 NP_001013975 23407 1a
Membrane-associated progesterone receptor 
component 2 NP_001008375 23403 1
a
Regulator of G-protein signaling 18 NP_001040549 27645 1a
N-terminal acetyltransferase complex ARD1 
subunit homolog B NP_001019913 27623 1
a
Pyridoxal phosphate phosphatase 
PHOSPHO2 NP_001007643 27627 1
a
Monocyte to macrophage differentiation 
protein NP_001007674 27649 1
a
39S ribosomal protein L41, mitochondrial NP_001013444 13818 1
Trefoil factor 1 NP_476470 6912 2
TagIdent UniProtKB/Swiss-Prot search
SELDI-TOF-MS 
m/z (z=1)
ProteinChip® 
array
Responsive to 
treatment with
SEM
5655 CM10 pH 6 - 9
9
Average 
relative level
- - 0.180.6
- 0.05-0.6-911708
CM10 pH 613814
H50 
0.5 0.13-
 
a) Charge (z) = 1 but the possibility of dimerisation was considered 
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Table 12: Identification of SELDI-TOF-MS putative biomarkers of 
myopathy in myoblasts (common responders) 
Myoblasts were grown and treated with 25μM TMPD or 50μM GWδ (section 2.1). The 
protein ions shown were responsive to treatment with both compounds when measured 
using SELDI-TOF-MS (section 2.6). TagIdent was used to assign possible matches for 
the protein ions. The probability that the assignment of the ion at m/z 9123 as 40S 
ribosomal protein S21 (NP_112372) was correct was increased as it was identified 
directly in myoblasts using LC-MS/MS (section 3.5) and also showed a similar 
response to treatment with TMPD (relative level in TMPD-treated myoblasts = -0.3).  
TM
P
D
G
w
d
C
om
m
on
Protein Accession code Calculated Mw (Da) Charge (z)
Tubulin-specific chaperone A NP_001013263 12613 1a
Pituitary adenylate cyclase-activating 
polypeptide 27  NP_058685.1 3149 1
Somatostatin-28 NP_036791.1 3151 1
Nuclear transition protein 2 NP_058753.2 12849 1a
Cystatin-12 NP_714956.1 12829 1a
WAP four-disulfide core domain protein 12 NP_001008866.1 6425 1
Serine protease inhibitor Kazal-type 7 Q6IE51 6418 1
Melanotropin beta P01194 2141 3
Potassium voltage-gated channel subfamily E 
member 2 NP_598287.1 14357 1
a
Transmembrane protein 100 NP_001017479.1 14352 1a
Atriopeptin-2 NP_036744.1 2389 3
Melanin-concentrating hormone NP_036757.1 2389 3
Protein ARMET P0C5H9 18207 1a
Epithelial membrane protein 3 NP_110474 18198 1a
Secretin NP_073161 3028 3
TagIdent UniProtKB/Swiss-Prot search
SELDI-TOF-MS 
m/z (z=1)
ProteinChip® 
array
Responsive to 
treatment with
NP20 -
-
--
-
-
9
9097
-
NP20 - 9
0.080.5
-0.5 0.04
-0.6 0.04
Average 
relative level SEM
9
9
-0.7 0.03
CM10 pH 6
6306
6420
7177
NP20
 
a) Charge (z) = 1 but the possibility of dimerisation was considered  
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Table 12 continued 
TM
P
D
G
w
d
C
om
m
on
Protein Accession code Calculated Mw (Da) Charge (z)
Gremlin-1 NP_062155 18239 1a
Protein ARMET P0C5H9 18207 1a
Alpha-S2-casein-like B NP_775129 18244 1a
Small muscular protein NP_445847 9121 1
C-terminal peptide NP_036758 3041 3
Gremlin-1 NP_062155 18239 1a
Interleukin-18 NP_062038 18261 1a
Alpha-S2-casein-like B NP_775129 18244 1a
40S ribosomal protein S21 NP_112373 9127 1
Small muscular protein NP_445847 9121 1
C-terminal peptide NP_036758 3041 3
Protein max NP_071546 18272 1a
Interleukin-18 NP_062038 18261 1a
T-cell surface glycoprotein CD3 gamma chain NP_001071114 18285 1a
40S ribosomal protein S21 NP_112373 9127 1
QRF-amide NP_937843 4572 2
9
9
99123
9137 -
0.03-0.7-
Responsive to 
treatment with
-
0.03-0.7
NP20
NP20 - 0.03-0.7
-NP20
TagIdent UniProtKB/Swiss-Prot search
-
Average 
relative level SEM
SELDI-TOF-MS 
m/z (z=1)
ProteinChip® 
array
9113
 
a) Charge (z) = 1 but the possibility of dimerisation was considered  
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Table 13: Identification of SELDI-TOF-MS putative biomarkers of 
myopathy in myotubes (TMPD responders) 
Myotubes were differentiated from myoblasts and treated with 25μM TMPD for 24h 
(section 2.1). The protein ions shown were responsive to treatment when measured 
using SELDI-TOF-MS (section 2.6). Mw information available on the ExPASy server 
was interrogated using the TagIdent tool in order to discover possible matches for the 
ions detected on ProteinChip® arrays. LC-MS/MS data generated following 1DE 
analysis of myotubes was also interrogated via Bioworks Browser (section 3.5). No 
identification possibilities were available for ions at m/z 3978 or 4815 although the ion 
at m/z 6578 was a possible match with transcription elongation factor B (SIII), 
polypeptide 2 (NP_ 112391) which was detected and identified by LC-MS/MS. 
TM
P
D
G
w
d
C
om
m
on
Protein Accession code Calculated Mw (Da) Charge (Z)
3978 CM10 pH 8 9 - - 0.95 0.18 - - - -
4815 CM10 pH 6 9 - - -0.4 0.04 - - - -
5579 IMAC-30 9 - - -0.2 0.05 Beta-defensin 11 NP_001032594.1 5581 1
6312 IMAC-30 9 - - -0.3 0.04 Tubulin-specific chaperone A NP_001013263.1 12613 1a
Protein JTB NP_062086.1 13160 1a
Bone morphogenetic protein 4 NP_036959.2 13155 1a
6578 0.04-0.2--IMAC-30
Average 
relative level SEM
TagIdent UniProtKB/Swiss-Prot search
SELDI-TOF-MS 
m/z (z=1)
ProteinChip® 
array
Responsive to 
treatment with
9
 
a) Charge (z) = 1 but the possibility of dimerisation was considered  
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Table 14: Identification of SELDI-TOF-MS putative biomarkers of 
myopathy in myotubes (GWδ responders) 
Myotubes were cultured and treated with 50μM GWδ (section 2.1). The protein ions 
shown were responsive to treatment when measured using SELDI-TOF-MS (section 
2.6). TagIdent was used to assign possible matches for the protein ions based on Mw 
information (with a tolerance of 0.1%, which is typical of SELDI-TOF-MS mass 
accuracy). No identification possibilities were provided when LC-MS/MS data was 
interrogated. 
TM
P
D
G
w
d
C
om
m
on
Protein Accession code Calculated Mw (Da) Charge (Z)
60S acidic ribosomal protein P1 NP_001007605.1 11498 1a
Vesicle-associated membrane protein 5 NP_446007.1 11495 1a
Gremlin-1 NP_062155.1 18239 1a
Interleukin-18 NP_062038.1 18261 1a
Alpha-S2-casein-like B NP_775129.1 18244 1a
40S ribosomal protein S21 NP_112373.1 9127 1
Small muscular protein NP_445847.1 9121 1
C-terminal peptide NP_036758.1 3041 3
SELDI-TOF-MS 
m/z (z=1)
ProteinChip® 
array
Responsive to 
treatment with
-9126
5753 0.0799
-
9-
0.421.3
Average 
relative level SEM
9CM10 pH 6
TagIdent UniProtKB/Swiss-Prot search
-0.5NP20 -
 
 a) Charge (z) = 1 but the possibility of dimerisation was considered  
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Table 15: Identification of SELDI-TOF-MS putative biomarkers of 
myopathy in myotubes (common responders) 
Myotubes were differentiated from myoblasts and treated with 25μM TMPD or 50μM 
GWδ (section 2.1). The protein ions shown were responsive to treatment when 
measured using SELDI-TOF-MS (section 2.6) and TagIdent was used to assign 
possible matches based on Mw information. No identification possibilities were 
provided when LC-MS/MS data was interrogated. 
TM
P
D
G
w
d
C
om
m
on
Protein Accession code Calculated Mw (Da) Charge (Z)
 3158 CM10 pH 6 - - 9 1.3 0.23 - - - -
NADH-ubiquinone oxidoreductase NP_062096.1 10598 1
Endothelin-3 NP_001071118.1 2647 2
Tubulin-specific chaperone A NP_001013263.1 12613 1a
Pituitary adenylate cyclase-activating 
polypeptide 27 NP_058685.1 3149 2
Somatostatin-28 NP_036791.1 3151 2
Transcription elongation factor B polypeptide 2 NP_112391.1 13170 1a
Prolactin release-inhibiting factor 1 NP_036899.1 6585 1
Synaptogyrin-2 NP_446005.1 24711 1a
Regulator of G-protein signaling 19 NP_067693.1 24738 1a
Phosphatidylcholine transfer protein NP_058921.1 24734 1a
Neuron-specific vesicular protein calcyon NP_620270.1 24718 1a
60S ribosomal protein L10a NP_112327.1 24700 1a
Acyl-protein thioesterase 1 NP_037138.1 24709 1a
RPA-interacting protein NP_001028232.1 24710 1a
Sentrin-specific protease 8 NP_001012355.1 24728 1a
Transmembrane protein 204 NP_001009620.1 24701 1a
Follistatin-related protein 3 NP_446081.1 24719 1a
Fibroblast growth factor-binding protein 1 NP_072125.1 24696 1a
Macrophage migration inhibitory factor NP_112313.1 12346 1
Oligosaccharyl transferase subunit DAD1 NP_620265.1 12366 1
60S ribosomal protein L40 NP_113875.1 6182 2
SELDI-TOF-MS 
m/z (z=1)
ProteinChip® 
array
Responsive to 
treatment with
Average 
relative level SEM
- 9 0.080.8
0.01-0.49
0.35
9 0.07
1.3
-0.4
- 9
NP20
- -
--
NP20
NP20
-
-
12357
6588
6305
5298
TagIdent UniProtKB/Swiss-Prot search
CM10 pH 4
 
a) Charge (z) = 1 but the possibility of dimerisation was considered  
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The levels of several protein ions changed in response to the treatment of 
skeletal muscle cells with either TMPD or GWδ. Although the changes seen by 
SELDI-TOF-MS were useful in discriminating between control and treated cells, 
this technique does not routinely provide the identifications of the proteins 
measured on ProteinChip® arrays. The attempts made to conclusively identify 
the responsive protein ions based on Mw information and using the TagIdent 
tool available via the ExPASy server led to the inclusion of several possibilities. 
The interrogation of LC-MS/MS data generated following the analysis of skeletal 
muscle cells treated in the same way provided another possible means for 
verifying the identity of responsive proteins that had been measured in the 
samples. Furthermore, their response to treatment could be compared to that 
observed by SELDI-TOF-MS.  
 
For most cases, this method of discovering the identity of the protein ions 
discovered was not  useful, as the mass accuracy provided by SELDI-TOF-MS 
does not allow the options for the identity of the proteins to be narrowed down 
sufficiently to facilitate a conclusive identification of the proteins. The only 
possible exception was for an ion that was responsive to the treatment of 
myoblasts with TMPD and GWδ (at m/z 9123). The possibility that the identity of 
this ion was 40S ribosomal protein S21 (NP_112373) was increased as the 
protein was also measured by LS-MS/MS. Also comparing the response of the 
protein as measured by SELDI-TOF-MS and LC-MS/MS increased the 
likelihood of a correct identification although it is still not conclusive. Despite the 
lack of a definite identification, the changes observed using SELDI-TOF-MS 
could still be considered as part of an anonymous screening approach. An 
approach to biomarker discovery that would facilitate the simultaneous 
identification of the markers of interest alongside the quantitation would be 
advantageous. 
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3.5 Discovery of protein biomarkers of myopathy using label-
free quantitative proteomics 
An anonymous approach to the discovery of compound-induced changes in the 
levels of proteins in skeletal muscle cells was described in section 3.4. The 
identity of the ions was not readily available and the dynamic range of the 
observations was restricted to between 2 and 20kDa due to limitations in 
SELDI-TOF-MS. A label-free approach to the identification of biomarkers of 
compound effects was also attempted using skeletal muscle cells treated with a 
concentration of TMPD that was not seen to be overtly cytotoxic to skeletal 
muscle cells (25μM). 
 
Replicate cell lysate proteins were prefractionated by size using 1DE and the 
resultant polyacrylamide gel was sectioned before generating peptides through 
the enzymatic digestion of the proteins in each Mw section of the gel. The 
resulting peptide ions were then detected, quantified and identified using LC-
MS/MS before treatment-induced changes in the relative levels of some of the 
putative protein biomarkers were confirmed using immunoblotting. 
 
3.5.1 1D gel-electrophoresis of rat L6 muscle cells 
Samples were separated by 1DE along with Mw markers ranging from 3-
198kDa, and gels were divided into sections as described in section 2.7.1 
(Figure 53). The low Mw region (<3kDa) was excluded from further analyses as 
proteins in this region generated an insufficient number of peptides to facilitate a 
reliable identification (>2 peptides).  
 
There were no treatment-related changes in the intensities of the protein bands 
on 1D gels following the analysis of myoblasts (Figure 54) or myotubes (Figure 
55). Although this meant that clear changes in specific areas of the gel could 
not be focused on in future experiments, this method provided an effective way 
of separating proteins within the samples. 
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Figure 53: Fractionation of 1DE gels  
Skeletal muscle cells were cultured and treated with 25μM TMPD (section 2.1). 1DE 
was performed (section 2.7.1) and the resulting gels were cut transversely into 11 Mw 
regions and longitudinally into lanes in order to separate samples (along the dotted 
lines). In each gel, 6 control samples and 6 TMPD-treated samples were analysed, 
resulting in 132 individual sections in which in-gel protein digestion was subsequently 
performed using trypsin in order to generate peptides. M= Mw markers, C = control 
samples and T = TMPD-treated samples. 
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Figure 54: 1D gel of rat L6 myoblasts treated with vehicle control or 25µM 
TMPD 
Myoblasts were cultured and treated with 25μM TMPD (section 2.1). In each gel, 
proteins in 6 control samples (C) and 6 TMPD-treated samples (T) were separated 
(section 2.7.1) and the resulting gels were divided as shown in Figure 53. M= Mw 
markers, C = control samples and T = TMPD-treated samples. Mw markers are shown 
(M) and the positions where the gels were sliced are shown on the right.  
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Figure 55: 1D gel of rat L6 myotubes treated with vehicle control or 25µM 
TMPD 
Myotubes were differentiated from myoblasts and treated with 25μM TMPD (section 
2.1). Proteins in 6 control samples (C) and 6 TMPD-treated samples (T) were 
separated (section 2.7.1) and the resulting gels were divided as shown in Figure 53. 
M= Mw markers, C = control samples and T = TMPD-treated samples. Mw markers are 
shown (M) and the positions where the gels were sliced are shown on the right. 
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3.5.2 Liquid chromatography-tandem mass spectrometry analysis of rat 
muscle cell homogenates 
In the next stage of LFQP analysis, the peptides generated by enzymatic 
digestion of the 1D gel sections were detected, measured and identified 
simultaneously using a nano-LC system coupled with an LTQ-mass 
spectrometer for automated LC-MS/MS analysis (section 2.7.3). This was 
performed in order to ascertain whether treating cells with a low concentration 
of TMPD (25μM) resulted in any changes in the levels of the peptide ions 
measured in myoblasts and myotubes. 
 
The expression of peptides was initially examined using search results files (srf) 
generated using Bioworks Browser (as described in section 2.7.3). Proteins in 
each Mw region were identified by at least two unique peptides during their 
identification. In addition, the p value for the protein detected was <0.05 in order 
to ensure confidence in the protein identification and proteins and peptides that 
did not meet these criteria were excluded. In general, proteins were detected 
within the Mw region that correlated with their calculated m/z although some 
error was allowed for unexpected electrophoretic migration of proteins within the 
gel. All the proteins detected reliably in control and treated cells are considered 
here and the effects of treatment on the expression of proteins in considered in 
subsequent sections. The proteins detected and identified in myoblasts are 
detailed in Table 16. Proteins identified in myotubes are described in Table 17. 
 
In total 2100 peptides were detected and 1314 (63%) of these contributed to the 
identification of proteins in myoblasts. Out of the total number of peptides 
detected, 1664 (79%) of the total number of peptides detected contributed to 
the identification of proteins in myotubes. In myoblasts (and when considering 
both control and treated cells), a total of 217 proteins were identified ranging 
from 8249 to 918957 Da in size and 269 proteins were identified in myotubes 
(ranging from 5763 to 918957). Of these proteins, 155 were common to both 
myoblasts and myotubes (Figure 56).  
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Figure 56: Number of proteins identified in myoblasts and myotubes  
Myoblasts and myotubes were cultured (section 2.1) and the proteins in skeletal 
muscle cell homogenates were separated by 1DE (section 2.7.1). Peptides were 
generated from the different sections of the 1D gel by trypsin digestion and these were 
detected, measured and identified by LC-MS/MS (sections 2.7.2 and 2.7.3). A total of 
331 proteins were identified in myoblasts and myotubes. Of these proteins, 62 (19%) 
and 114 (34%) were unique to myoblasts and myotubes, respectively. 155 (47%) of the 
proteins identified were common to both the immature and differentiated form of the rat 
L6 skeletal muscle cells. In identifying these proteins, a total of 2100 peptides were 
measured (1314 in myoblasts and 1664 in myotubes). 
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Table 16: Proteins identified in rat L6 myoblasts 
Myoblasts were cultured (section 2.1) and cell homogenates were analysed by 1DE (section 2.7.1). Separated skeletal muscle cell samples were 
divided into Mw regions in the resulting gel and peptides were generated by trypsin digestion. Peptides detected, measured and identified by LC-
MS/MS are shown (section 2.7.3). Only proteins identified reliably by two or more peptides are included. 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
Number of gel 
sections 
detected in
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myoblasts
Detected in 
treated 
myoblasts
Also detected 
in myotubes
Mw range 6-14kDa
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit E
NP_536729.1 8249 1.1E-04 2 1 3-6 (1) 9 8 9
D-dopachrome tautomerase NP 077045.1 13125 1.9E-04 2 2 6-14 (2) 9 9 9
Heat shock 10 kDa protein 1 NP 037098.1 10869 7.4E-11 6 12 6-14 (12) 9 9 9
Prothymosin alpha NP 068508.1 12375 9.0E-10 3 2 14-17 (2) 8 9 9
Ribosomal protein S21 NP 112373.1 9122 9.2E-05 3 2 6-14 (2) 9 9 8
S100 calcium binding protein A10 NP 112376.1 11067 8.7E-05 2 1 6-14 (1) 9 8 8
S100 calcium binding protein A6 NP 445937.1 10028 6.4E-04 2 1 3-6 (1) 8 9 8
S100 calcium-binding protein A4 NP 036750.1 11769 3.5E-06 6 15 3-6 (3), 6-14 (12) 9 9 9
Thioredoxin NP 446252.1 11666 6.7E-08 5 12 6-14 (12) 9 9 9
Mw range 14-28kDa
Calmodulin 3 NP 036650.1 16827 6.8E-10 2 5 14-17 (5) 9 9 9
Cytochrome c oxidase, subunit Va NP 665726.1 16119 1.5E-05 2 2 6-14 (2) 8 9 8
Hemoglobin, epsilon 2 NP 001019976.1 16378 1.4E-04 2 1 75-98 (1) 8 9 8
Histone cluster 1, H2aa NP 068611.1 14275 1.1E-08 4 18 14-17 (6), 3-6 (2), 6-14 (10) 9 9 9
Lectin, galactoside-binding, soluble, 1 NP 063969.1 14847 1.5E-09 6 12 6-14 (12) 9 9 9
Profilin 1 NP 071956.2 14948 1.1E-09 5 5 6-14 (5) 9 9 9
Ribosomal protein S14 NP 073163.1 16249 7.5E-08 4 3 14-17 (3) 8 9 9
Ribosomal protein S19 NP 001032423.1 16076 6.6E-05 6 5 14-17 (5) 9 9 9
Superoxide dismutase 1, soluble NP 058746.1 15902 3.0E-09 4 4 14-17 (4) 9 9 9
Mw range 28-38kDa
Acidic (leucine-rich) nuclear phosphoprotein 32 family, 
member B
NP_571986.1 31042 5.4E-07 2 1 28-38 (1) 9 8 8
ADP-ribosylation factor 5 NP 077063.1 20517 2.5E-05 2 1 14-17 (1) 8 9 9
Aldo-keto reductase family 1, member B10 (aldose 
reductase)
NP_001013102.1 35976 5.5E-04 2 1 28-38 (1) 8 9 8
Aldo-keto reductase family 1, member B8 NP 775159.1 36168 7.7E-04 3 2 28-38 (2) 9 9 8
Aldo-keto reductase family 1, member C-like 2 NP 001008343.1 34478 1.2E-04 2 4 28-38 (4) 9 9 9
Annexin A4 NP 077069.3 35871 9.7E-05 4 2 28-38 (2) 8 9 9  
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Table 16 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
Number of gel 
sections 
detected in
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myoblasts
Detected in 
treated 
myoblasts
Also detected 
in myotubes
Mw range 28-38kDa continued
Annexin A5 NP 037264.1 35722 2.2E-09 13 12 28-38 (12) 9 9 9
Calcyclin binding protein NP 001004208.1 26525 5.7E-04 2 1 28-38 (1) 8 9 8
Calumenin isoform b NP 001029070.1 37124 6.3E-10 3 11 38-49 (11) 9 9 9
Chloride intracellular channel 1 NP 001002807.1 26964 6.6E-14 6 8 28-38 (8) 9 9 9
Chloride intracellular channel 4 (mitochondrial) NP 114006.1 28615 1.8E-09 3 3 28-38 (3) 9 9 9
Cofilin 1 NP 058843.1 18521 1.0E-06 3 5 17-28 (5) 9 9 9
Diaphorase (NADH/NADPH) NP 058696.2 30927 1.4E-10 9 12 28-38 (12) 9 9 9
F-actin capping protein beta subunit NP 001005903.1 30609 2.8E-05 2 1 28-38 (1) 8 9 9
Glutaredoxin 3 NP 116003.2 37825 3.4E-04 2 1 98-198 (1) 9 8 8
Glutathione S-transferase omega 1 NP 001007603.1 27665 1.4E-06 2 1 28-38 (1) 9 8 9
Guanine nucleotide binding protein, beta polypeptide 2-
like 1
NP_570090.1 35073 5.3E-09 4 8 28-38 (8) 9 9 9
Heterogeneous nuclear ribonucleoprotein A1 NP 058944.1 34191 1.2E-11 9 9 28-38 (5), 38-49 (4) 9 9 9
Heterogeneous nuclear ribonucleoprotein C (C1/C2) NP 001020804.1 32837 1.3E-04 3 2 38-49 (2) 9 8 8
Laminin receptor 1 NP 058834.1 32803 8.9E-15 8 20 28-38 (8), 38-49 (12) 9 9 9
L-lactate dehydrogenase B NP 036727.1 36589 5.7E-10 4 8 28-38 (8) 9 9 9
Malate dehydrogenase 1, NAD (soluble) NP 150238.1 36460 5.7E-09 5 6 28-38 (6) 9 9 9
Malate dehydrogenase, mitochondrial NP 112413.2 35661 4.9E-11 9 11 28-38 (11) 9 9 9
Myoglobin NP 067599.1 17146 4.1E-04 2 1 14-17 (1) 8 9 8
Non-metastatic cells 2, protein (NM23B) expressed in NP 114021.2 17272 6.6E-05 4 6 14-17 (6) 9 9 9
NudC domain containing 2 NP 001009621.1 17663 2.4E-05 2 1 14-17 (1) 8 9 8
PDZ and LIM domain 1 NP 059061.1 35503 6.9E-13 5 12 38-49 (12) 9 9 9
Peptidylprolyl isomerase A (cyclophilin A) NP 058797.1 17863 3.4E-10 7 11 14-17 (11) 9 9 9
Peptidylprolyl isomerase B NP 071981.1 22788 1.6E-09 2 3 14-17 (1), 17-28 (2) 9 9 9
Peroxiredoxin 1 NP 476455.1 22095 1.1E-05 4 12 14-17 (1), 17-28 (11) 9 9 9
Peroxiredoxin 2 NP 058865.1 21770 4.9E-05 4 9 14-17 (1), 17-28 (8) 9 9 9
Peroxiredoxin 4 NP 445964.1 30988 4.6E-04 2 2 17-28 (2) 8 9 9
Peroxiredoxin 5 precursor NP 446062.1 22165 3.7E-07 3 1 14-17 (1) 8 9 9
Phosphatidylethanolamine binding protein NP 058932.1 20788 4.6E-11 2 2 17-28 (2) 9 8 9
Phosphoglycerate mutase 2 (muscle) NP 059024.1 28737 1.6E-08 3 5 28-38 (5) 9 9 9
Prohibitin 2 NP 001013053.1 33292 1.6E-08 7 7 28-38 (7) 9 9 9
Proliferating cell nuclear antigen NP 071776.1 28730 2.9E-12 6 9 28-38 (9) 9 9 9
Proteasome (prosome, macropain) subunit, alpha type 4 NP 058977.1 29479 1.0E-06 3 7 28-38 (7) 9 9 9
Proteasome (prosome, macropain) subunit, alpha type 7 NP 001008218.1 27839 3.5E-09 5 5 28-38 (5) 9 9 9
RAN, member RAS oncogene family NP 445891.1 24408 2.4E-08 4 11 17-28 (6), 28-38 (5) 9 9 9
Rho GDP dissociation inhibitor (GDI) alpha NP 001007006.1 23393 4.7E-12 5 14 17-28 (6), 28-38 (8) 9 9 9
Ribosomal protein L11 NP 001020910.1 19012 5.8E-06 3 3 17-28 (3) 9 8 9
Ribosomal protein S3 NP 001009239.1 26657 4.6E-12 13 11 6-14 (1), 28-38 (10) 9 9 9  
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Table 16 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
Number of gel 
sections 
detected in
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myoblasts
Detected in 
treated 
myoblasts
Also detected 
in myotubes
Mw range 28-38kDa continued
Secreted protein, acidic, cysteine-rich (osteonectin) NP 036788.1 34274 6.3E-10 2 1 38-49 (1) 8 9 9
Solute carrier family 25, member 5 NP 476443.1 32880 2.2E-07 3 2 98-198 (1), 28-38 (1) 9 9 9
Splicing factor, arginine/serine-rich 10 NP 476460.1 33646 2.4E-06 2 1 38-49 (1) 9 8 8
Splicing factor, arginine/serine-rich 2 NP 001009720.1 25461 1.3E-04 2 6 28-38 (6) 9 9 9
Splicing factor, arginine/serine-rich 7 NP 001034124.1 17880 3.5E-10 3 3 28-38 (3) 9 9 9
Stathmin 1 NP 058862.1 17278 5.2E-05 3 3 14-17 (3) 8 9 9
Transgelin NP 113737.1 22588 3.3E-07 6 12 14-17 (1), 17-28 (11) 9 9 9
Transgelin 2 NP 001013145.1 22379 2.4E-06 2 5 14-17 (1), 17-28 (4) 9 9 9
Tropomyosin 1, alpha isoform c NP 001029242.1 32828 2.9E-07 8 9 28-38 (4), 38-49 (5) 9 9 9
Tropomyosin 1, alpha isoform h NP 001029246.1 28679 2.1E-09 13 20 28-38 (12), 38-49 (8) 9 9 9
Tropomyosin 2 NP 001019516.1 32938 4.4E-08 11 20 28-38 (9), 38-49 (11) 9 9 9
Tropomyosin 3, gamma isoform 1 NP 476556.2 28692 1.6E-08 10 12 28-38 (12) 9 9 9
Tropomyosin 3, gamma isoform 2 NP 775134.1 29017 1.6E-06 2 6 28-38 (6) 9 9 8
Tropomyosin 4 NP 036810.1 28492 4.3E-11 14 12 28-38 (12) 9 9 9
Tyrosine 3-monooxgenase/tryptophan 5-monooxgenase 
activation protein, beta polypeptide
NP_062250.1 28037 4.6E-09 3 3 28-38 (3) 9 9 9
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein
NP_113791.1 29103 2.6E-05 5 6 28-38 (6) 9 9 9
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, eta polypeptide
NP_037184.1 28194 5.6E-04 4 2 28-38 (2) 8 9 9
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, gamma polypeptide
NP_062249.1 28285 1.4E-11 4 9 28-38 (9) 9 9 9
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, theta polypeptide
NP_037185.1 27761 5.1E-10 3 6 28-38 (6) 9 9 9
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide
NP_037143.2 27754 1.4E-12 8 13 17-28 (1), 28-38 (12) 9 9 9
Ubiquitin-conjugating enzyme E2N NP 446380.1 17113 1.6E-06 2 2 14-17 (2) 9 9 9
Voltage-dependent anion channel 1 NP 112643.1 30737 1.3E-06 3 2 28-38 (2) 9 9 9
Voltage-dependent anion channel 2 NP 112644.1 31726 3.4E-06 4 7 28-38 (7) 9 9 9
V-set domain containing T cell activation inhibitor 1 NP 001019415.1 30644 3.4E-04 2 1 38-49 (1) 9 8 8
Mw range 38-49kDa
Actin, alpha 1, skeletal muscle NP_062085.1 42024 9.0E-13 17 60 >198 (10), 75-98 (10), 98-198 
(12), 49-62 (1), 28-38 (6), 38-49 
(12), 14-17 (2), 6-14 (7)
9 9 9
Aldolase A-like 1 NP 001013965.1 39467 1.1E-08 8 12 38-49 (12) 9 9 9  
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Table 16 continued  
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
Number of gel 
sections 
detected in
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myoblasts
Detected in 
treated 
myoblasts
Also detected 
in myotubes
Mw range 38-49kDa continued
Annexin A1 NP 037036.1 38805 2.3E-12 20 13 28-38 (1), 38-49 (12) 9 9 9
Annexin A2 NP_063970.1 38654 3.1E-11 20 27 >198 (2), 6-14 (2), 28-38 (11), 38-
49 (12)
9 9 9
ARP2 actin-related protein 2 homolog NP 001009268.1 44705 6.2E-06 2 1 38-49 (1) 9 8 8
Calreticulin NP 071794.1 47966 1.8E-07 4 4 49-62 (4) 9 9 8
Eukaryotic translation initiation factor 4A2 NP 001008336.1 46373 3.4E-10 5 12 38-49 (12) 9 9 9
Fructose-bisphosphate aldolase A NP 036627.1 39327 1.0E-30 4 12 38-49 (12) 9 9 9
Glutamate oxaloacetate transaminase 2 NP 037309.1 47284 4.1E-06 2 1 38-49 (1) 9 8 9
Heterogeneous nuclear ribonucleoprotein A3 isoform a NP 937765.1 39628 4.1E-07 5 3 28-38 (1), 38-49 (2) 9 8 8
Heterogeneous nuclear ribonucleoprotein F NP 001032362.1 45701 8.9E-10 4 3 38-49 (3) 9 9 9
Keratin 13 NP_001004021.1 47699 6.2E-07 5 8 >198 (3), 14-17 (1), 75-98 (1), 98-
198 (1), 3-6 (2)
9 9 9
Keratin 15 NP_001004022.1 48840 2.7E-06 4 10 >198 (2), 75-98 (1), 62-75 (1), 38-
49 (1), 14-17 (1), 3-6 (3), 6-14 (1)
9 9 9
Keratin 19 NP 955792.1 44609 2.3E-04 3 4 3-6 (3), 6-14 (1) 9 9 8
Nucleosome assembly protein 1-like 4 NP 001012170.1 43890 6.0E-07 2 1 49-62 (1) 9 8 8
Phosphoglycerate kinase 2 NP 001012130.1 44981 4.6E-11 3 6 38-49 (6) 9 9 9
Poly(rC) binding protein 2 NP 001013241.1 38556 4.1E-04 3 3 38-49 (3) 9 8 8
Protein disulfide isomerase-associated 6 NP 001004442.1 48730 2.1E-10 6 12 38-49 (12) 9 9 9
RAB3A interacting protein (rabin3)-like 1 NP 599238.1 41881 4.4E-04 2 1 62-75 (1) 9 8 8
Serine (or cysteine) peptidase inhibitor, clade H, member NP 058869.1 46488 2.1E-13 10 19 75-98 (7), 38-49 (12) 9 9 9
Mw range 49-62kDa
Aldehyde dehydrogenase 3A1 NP 114178.1 50307 1.6E-09 12 21 49-62 (9), 38-49 (12) 9 9 9
Apoptosis antagonizing transcription factor NP 446172.1 59461 8.2E-04 2 1 75-98 (1) 8 9 8
ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit 1, cardiac muscle
NP_075581.1 59717 2.1E-09 8 14 49-62 (10), 28-38 (4) 9 9 9
Caldesmon 1 NP 037278.1 60548 2.0E-11 9 12 75-98 (12) 9 9 9
Cathepsin F NP 001029282.1 51796 4.1E-05 2 2 75-98 (2) 9 9 8
Chaperonin containing TCP1, subunit 2 (beta) NP 001005905.1 57422 1.6E-06 4 6 49-62 (6) 9 9 9
Chaperonin containing TCP1, subunit 3 (gamma) NP 954522.1 60608 3.7E-06 5 6 62-75 (6) 9 9 9
Chaperonin containing TCP1, subunit 5 (epsilon) NP 001004078.1 59499 9.3E-07 4 2 62-75 (2) 9 8 9
Chaperonin containing Tcp1, subunit 6A (zeta 1) NP 001028856.1 57981 4.8E-08 8 9 49-62 (9) 9 9 9
Chaperonin subunit 4 (delta) NP 877966.1 58063 3.5E-07 4 8 49-62 (8) 9 9 9
Cortactin isoform B NP 068640.2 56907 8.4E-05 3 2 75-98 (2) 9 9 8
Dihydropyrimidinase-like 3 NP 037066.1 61928 8.1E-09 4 11 75-98 (11) 9 9 9
Eukaryotic translation elongation factor 1 alpha 2 NP_036792.2 50422 9.4E-07 7 27 >198 (2), 98-198 (2), 49-62 (7), 
28-38 (4), 38-49 (12)
9 9 9
Glucose-6-phosphate dehydrogenase NP 058702.1 59338 4.3E-06 2 1 49-62 (1) 9 8 8  
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Table 16 continued  
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
Number of gel 
sections 
detected in
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myoblasts
Detected in 
treated 
myoblasts
Also detected 
in myotubes
Mw range 49-62kDa continued
Glutamate dehydrogenase 1 NP 036702.1 61377 6.2E-10 6 9 49-62 (9) 9 9 9
Heterogeneous nuclear ribonucleoprotein K NP 476482.1 50944 3.7E-11 5 10 49-62 (10) 9 9 9
HLA-B associated transcript 1 NP 579834.2 49004 4.1E-04 2 2 38-49 (2) 9 8 8
Keratin 10 NP_001008804.1 56471 2.4E-10 10 52 >198 (10), 75-98 (2), 98-198 (6), 
49-62 (5), 62-75 (1), 28-38 (5), 
38-49 (1), 14-17 (6), 3-6 (10), 6-
9 9 9
Keratin 14 NP 001008751.1 52651 2.6E-06 2 1 >198 (1) 9 8 9
Keratin 4 NP_001008806.1 57631 1.1E-04 5 24 >198 (3), 75-98 (1), 49-62 (3), 28-
38 (6), 38-49 (3), 14-17 (1), 17-
28 (2), 3-6 (3), 6-14 (2)
9 9 9
Keratin 42 NP_001008816.1 50182 1.6E-06 7 22 >198 (3), 75-98 (1), 98-198 (1), 
49-62 (2), 38-49 (2), 14-17 (3), 3-
6 (8), 6-14 (2)
9 9 9
Keratin 5 NP 899162.1 61889 6.4E-06 7 3 14-17 (1), 98-198 (1), 38-49 (1) 9 9 9
Keratin 77 NP_001008807.1 57220 1.0E-08 7 120 >198 (11), 75-98 (11), 98-198 
(12), 49-62 (12), 62-75 (11), 28-
38 (11), 38-49 (11), 14-17 (9), 17-
28 (9) 3-6 (12) 6-14 (11)
9 9 9
Mitochondrial aldehyde dehydrogenase 2 NP 115792.1 56453 9.9E-10 2 1 49-62 (1) 8 9 9
Mitochondrial ATP synthase beta subunit NP 599191.1 56319 2.2E-10 7 12 49-62 (11), 38-49 (1) 9 9 9
PCTAIRE protein kinase 1 isoform b NP 112339.1 52490 1.6E-05 2 1 49-62 (1) 8 9 8
Phenylalanyl-tRNA synthetase 2, mitochondrial NP 001013157.1 55130 2.8E-04 2 1 28-38 (1) 8 9 8
Prolyl 4-hydroxylase, beta polypeptide NP 037130.1 56829 5.1E-11 19 12 49-62 (12) 9 9 9
Prosaposin NP 037145.1 61084 5.1E-04 2 1 6-14 (1) 8 9 9
Protein disulfide-isomerase A3 NP 059015.1 56554 2.0E-08 17 12 49-62 (12) 9 9 9
Pyruvate kinase, muscle NP 445749.1 57781 2.1E-11 15 14 49-62 (12), 62-75 (2) 9 9 9
Ribonuclease/angiogenin inhibitor 1 NP 620805.1 49873 1.1E-08 3 3 38-49 (3) 9 9 8
Solute carrier family 3, member 2 NP 062156.1 58036 3.5E-06 2 1 75-98 (1) 8 9 8
Tubulin, beta 5 NP 775125.1 49639 4.5E-10 2 18 49-62 (6), 38-49 (12) 9 9 9
Vimentin NP_112402.1 53700 4.9E-12 32 48 3-6 (12), 6-14 (12), 49-62 (12), 
38-49 (12)
9 9 9
Mw range 62-70kDa
Alpha-fetoprotein NP 036625.1 68341 3.1E-04 2 2 38-49 (2) 9 9 8
Calnexin NP 742005.1 67213 1.6E-13 3 12 75-98 (12) 9 9 9
Eukaryotic translation initiation factor 4B NP 001008325.1 69023 5.1E-07 6 6 75-98 (6) 9 9 9
Ezrin NP 062230.1 69348 1.5E-08 3 1 75-98 (1) 8 9 8  
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Table 16 continued  
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
Number of gel 
sections 
detected in
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myoblasts
Detected in 
treated 
myoblasts
Also detected 
in myotubes
Mw range 62-70kDa continued
Fragile X mental retardation 1 NP 434691.1 65591 4.8E-04 2 1 62-75 (1) 9 8 8
Keratin 2 NP_001008899.1 69085 9.9E-10 7 16 >198 (5), 98-198 (2), 49-62 (1), 
62-75 (1), 38-49 (2), 14-17 (2), 3-
6 (1), 6-14 (2)
9 9 9
Keratin 75 NP 001008828.1 62130 2.3E-05 3 2 >198 (2) 9 9 8
Mw range 70-98kDa
Moesin NP 110490.1 67697 1.9E-04 7 4 75-98 (4) 9 9 9
Radixin NP 001005889.2 68501 2.9E-09 8 16 75-98 (12), 62-75 (4) 9 9 9
WD repeat domain 1 NP 001014157.1 66140 8.5E-06 3 3 62-75 (3) 9 8 9
Cd44 molecule NP 037056.2 85865 5.9E-05 2 1 62-75 (1) 9 8 9
Dynein cytoplasmic 1 intermediate chain 2 NP 446332.1 71134 3.9E-04 2 1 75-98 (1) 9 8 8
Eukaryotic translation elongation factor 1 delta NP 001013122.1 72083 3.4E-09 5 11 28-38 (11) 9 9 9
Eukaryotic translation elongation factor 2 NP 058941.1 95223 1.6E-13 20 17 75-98 (12), 98-198 (5) 9 9 9
F-box protein 11 NP 853662.1 93983 7.1E-05 2 1 38-49 (1) 8 9 8
Gelsolin NP 001004080.1 86014 2.4E-07 4 6 75-98 (6) 9 9 9
Heat shock 105kDa/110kDa protein 1 NP 001011901.1 96357 5.2E-06 2 5 75-98 (5) 9 9 9
Heat shock 70kD protein 1-like NP 997711.1 70505 2.1E-11 7 21 75-98 (9), 62-75 (12) 9 9 9
Heat shock protein 4 NP 705893.1 93997 2.1E-06 4 2 75-98 (2) 9 8 9
Heat shock protein 5 NP 037215.1 72303 1.2E-10 17 21 75-98 (10), 62-75 (11) 9 9 9
Heat shock protein 8 NP 077327.1 70827 4.7E-11 12 21 75-98 (9), 62-75 (12) 9 9 9
Heat shock protein 90, alpha (cytosolic), class A member 
1
NP_786937.1 84762 5.2E-13 17 12 75-98 (12) 9 9 9
Lamin A isoform C2 NP 001002016.1 71856 5.3E-07 17 19 75-98 (12), 49-62 (2), 62-75 (5) 9 9 9
Neural cell adhesion molecule 1 NP 113709.1 94599 1.4E-07 4 9 98-198 (9) 9 9 9
Neurolysin (metallopeptidase M3 family) NP 446422.2 80231 8.2E-04 2 1 38-49 (1) 9 8 8
Nuclear RNA export factor 1 NP 067590.1 70318 9.9E-05 2 1 6-14 (1) 9 8 8
Poly(A) binding protein, cytoplasmic 1 NP 599180.1 70656 3.0E-05 4 4 75-98 (4) 9 9 9
Protein disulfide isomerase-associated 4 NP 446301.1 72761 1.2E-05 4 8 75-98 (8) 9 9 9
RAD17 homolog NP 001019949.1 77233 4.0E-04 2 1 >198 (1) 8 9 8
Ribonucleotide reductase M1 NP 001013254.1 90236 9.7E-04 2 1 75-98 (1) 9 8 8
Signal transducer and activator of transcription 5A NP 058760.1 90776 7.5E-04 3 1 >198 (1) 9 8 8
TNF receptor-associated protein 1 NP 001034090.1 80411 1.1E-08 4 5 75-98 (5) 9 9 9
Transferrin NP 001013128.1 76346 2.5E-04 2 2 75-98 (2) 8 9 8
Transient receptor potential cation channel, subfamily C, 
member 1
NP_446010.1 87561 9.3E-04 2 1 75-98 (1) 8 9 8
Transketolase NP 072114.1 71141 2.1E-06 4 1 62-75 (1) 9 8 9
Valosin-containing protein NP 446316.1 89293 1.8E-08 14 12 75-98 (12) 9 9 9  
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Table 16 continued  
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
Number of gel 
sections 
detected in
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myoblasts
Detected in 
treated 
myoblasts
Also detected 
in myotubes
Mw range 98-198kDa continued
Actinin, alpha 1 NP 112267.1 102896 3.2E-12 23 15 75-98 (12), 98-198 (3) 9 9 9
Aldehyde oxidase 3 NP 001008527.1 146656 1.1E-05 2 1 38-49 (1) 9 8 8
Alpha actinin 4 NP 113863.2 104849 2.8E-10 21 12 75-98 (12) 9 9 9
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 2
NP_036965.1 173273 4.1E-04 2 1 49-62 (1) 8 9 8
Clathrin, heavy chain (Hc) NP 062172.1 191476 8.5E-08 17 10 98-198 (10) 9 9 9
Coatomer protein complex, subunit beta 1 NP 542959.1 106943 6.0E-05 2 1 75-98 (1) 8 9 8
Coatomer protein complex, subunit beta 2 (beta prime) NP 068533.1 102486 2.7E-06 3 5 75-98 (4), 98-198 (1) 9 9 9
Collagen, type I, alpha 2 NP 445808.1 129486 8.7E-13 18 12 98-198 (12) 9 9 9
Collagen, type II, alpha 1 NP 037061.1 134488 1.5E-05 3 1 98-198 (1) 9 8 8
Collagen, type III, alpha 1 NP 114474.1 138851 1.6E-09 9 6 98-198 (6) 9 9 9
Cullin-associated and neddylation-dissociated 1 NP 446456.1 136275 1.7E-06 9 6 98-198 (6) 9 9 9
Exportin 1, CRM1 homolog NP 445942.1 122959 1.2E-04 2 1 28-38 (1) 9 8 8
Fibronectin type III domain containing 1 NP 001033704.1 188873 1.0E-04 2 1 3-6 (1) 9 8 8
Glutamyl-prolyl-tRNA synthetase NP 001019409.1 166675 3.7E-12 3 2 98-198 (2) 8 9 8
Golgi apparatus protein 1 NP 058907.1 133469 6.7E-04 3 1 98-198 (1) 9 8 9
Inter-alpha trypsin inhibitor, heavy chain 3 NP 059047.1 99036 5.7E-04 2 1 98-198 (1) 8 9 8
Kinesin family member 5B NP 476550.1 109463 1.8E-06 2 1 98-198 (1) 8 9 9
Leucine-rich PPR-motif containing NP 001008519.1 156553 5.1E-08 2 1 98-198 (1) 9 8 9
Leucyl-tRNA synthetase NP 001009637.1 134192 9.1E-05 3 2 98-198 (2) 9 8 8
Microtubule-associated protein 4 NP 001019449.1 110233 5.7E-07 5 4 98-198 (4) 9 9 9
Phosphoinositide-3-kinase, class 3 NP 075247.1 101470 2.2E-04 3 1 49-62 (1) 9 8 8
Pregnancy-zone protein NP 665722.1 167053 3.2E-04 2 1 >198 (1) 8 9 8
Rho-associated coiled-coil containing protein kinase 1 NP 112360.1 159526 8.9E-04 2 1 98-198 (1) 8 9 8
SEC31 homolog A NP 148981.1 135266 5.7E-07 5 5 98-198 (5) 9 9 9
Staphylococcal nuclease domain containing 1 NP 073185.2 101889 9.6E-09 8 7 75-98 (7) 9 9 9
TAO kinase 3 NP 001019425.1 105408 1.9E-04 2 1 28-38 (1) 8 9 8
Thrombospondin 1 NP 001013080.1 129588 1.0E-05 3 3 98-198 (3) 9 9 9
Ubiquitin-activating enzyme E1 NP 001014102.1 117713 6.1E-06 2 2 75-98 (2) 9 8 9  
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Table 16 continued  
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
Number of gel 
sections 
detected in
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myoblasts
Detected in 
treated 
myoblasts
Also detected 
in myotubes
Mw range >198kDa
A-kinase anchor protein 6 NP 072140.1 254192 3.4E-04 2 1 75-98 (1) 9 8 8
Alpha-spectrin 2 NP 741984.2 284418 4.3E-08 13 5 >198 (5) 9 9 9
ATP-binding cassette, sub-family A (ABC1), member 2 NP 077372.1 270753 4.1E-04 2 1 75-98 (1) 8 9 8
Cadherin, EGF LAG seven-pass G-type receptor 3 
(flamingo homolog, Drosophila)
NP_112610.1 359128 4.0E-04 2 1 38-49 (1) 8 9 8
Fatty acid synthase NP 059028.1 272477 2.9E-09 8 13 >198 (10), 98-198 (3) 9 9 9
HLA-B associated transcript 2 NP 997627.1 228905 6.9E-04 2 1 >198 (1) 9 8 8
Inositol 1,4,5-triphosphate receptor, type 2 NP 112308.1 306861 6.8E-04 2 1 62-75 (1) 9 8 8
Kalirin, RhoGEF kinase NP 114451.1 336374 3.3E-04 2 1 14-17 (1) 9 8 9
Multiple PDZ domain protein NP 062069.1 218455 6.7E-04 2 1 6-14 (1) 8 9 8
Myosin, heavy chain 10, non-muscle NP 113708.1 228823 1.5E-07 5 9 98-198 (9) 9 9 9
Myosin, heavy chain 9, non-muscle NP 037326.1 226196 7.2E-12 42 22 >198 (10), 98-198 (12) 9 9 9
Nestin NP 037119.1 198625 8.2E-12 8 7 >198 (7) 9 9 9
Piccolo isoform 1 NP 064483.1 552380 1.6E-04 2 1 >198 (1) 8 9 8
Plectin 1 NP 071796.1 533214 1.5E-12 118 15 >198 (12), 98-198 (3) 9 9 9
Spectrin repeat containing, nuclear envelope 1 NP 001025080.1 918957 1.8E-04 2 1 >198 (1) 9 8 9
Spectrin, beta, non-erythrocytic 1 NP 001013148.1 273415 8.3E-05 6 3 >198 (2), 28-38 (1) 9 9 9  
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Table 17: Proteins identified in rat L6 myotubes 
Myotubes were cultured (section 2.1) and cell homogenates were analysed by 1DE (section 2.7.1). Separated skeletal muscle cell samples were then 
divided into Mw regions in the resulting gel and peptides were generated by trypsin digestion. Peptides detected, measured and identified by LC-
MS/MS are shown here (section 2.7.3). Only proteins identified reliably by two or more peptides are included. 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range 3-6kDa
ATP synthase, H+ transporting, mitochondrial F1 
complex, epsilon subunit
NP_620799.1 5763 1.8E-04 2 3-6 (4) 9 9 8
Mw range 6-14kDa
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit E
NP_536729.1 8249 5.0E-06 2 6-14 (5), 3-6 (5) 9 9 9
D-dopachrome tautomerase NP 077045.1 13125 6.0E-06 3 6-14 (3) 9 9 9
Heat shock 10 kDa protein 1 NP 037098.1 10869 2.5E-11 6 6-14 (12) 9 9 9
Prothymosin alpha NP 068508.1 12375 7.0E-10 5 14-17 (12) 9 9 9
S100 calcium-binding protein A4 NP 036750.1 11769 8.3E-06 4 6-14 (12), 3-6 (9) 9 9 9
Thioredoxin NP 446252.1 11666 2.5E-07 6 6-14 (11) 9 9 9
Vesicle-associated membrane protein 2 NP 036795.1 12683 6.9E-06 3 6-14 (1), 14-17 (1) 8 9
Mw range 14-17kDa
Calmodulin 3 NP 036650.1 16827 2.6E-13 3 14-17 (11) 9 9 9
Epididymal secretory protein E1 NP 775141.1 16353 4.3E-04 2 14-17 (1) 9 8 8
Eukaryotic translation initiation factor 5A NP 001028853.1 16821 2.6E-05 3 14-17 (2) 9 9 8
Histone cluster 1, H2aa NP_068611.1 14275 1.5E-08 5 >198 (1), 17-28 (6), 28-38 (2), 6-
14 (11), 14-17 (12), 3-6 (2)
9 9 9
Lectin, galactoside-binding, soluble, 1 NP 063969.1 14847 2.1E-09 6 6-14 (12) 9 9 9
Phosphoprotein enriched in astrocytes 15A NP 001013249.1 15031 6.0E-04 2 14-17 (1) 9 8 8
Profilin 1 NP 071956.2 14948 1.3E-10 5 6-14 (7) 9 9 9
Profilin 2 NP 110500.1 16104 3.6E-09 2 6-14 (1) 9 8 8
Ribosomal protein S14 NP 073163.1 16249 1.8E-09 4 14-17 (12) 9 9 9
Ribosomal protein S19 NP 001032423.1 16076 8.0E-05 6 14-17 (10) 9 9 9
Ribosomal protein S23 NP 511172.1 15798 4.4E-05 3 14-17 (5) 9 9 8
Superoxide dismutase 1, soluble NP 058746.1 15902 3.7E-10 5 14-17 (12) 9 9 9
X-linked eukaryotic translation initiation factor 1A NP 001008773.2 16502 8.3E-04 2 14-17 (1) 9 8 8  
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Table 17 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range 17-28kDa
Adenine phosphoribosyl transferase NP 001013079.1 19533 4.6E-05 2 17-28 (2) 9 9 8
Adenylate kinase 1 NP 077325.2 21570 1.3E-10 3 17-28 (11) 9 9 8
Adenylate kinase 3 NP 037350.1 25422 1.5E-06 7 17-28 (12) 9 9 8
ADP-ribosylation factor 5 NP 077063.1 20517 1.1E-05 2 14-17 (10) 9 9 9
ATP synthase, H+ transporting, mitochondrial F1 
complex, delta subunit precursor
NP_620806.1 17584 4.1E-08 2 14-17 (4) 9 9 8
Chloride intracellular channel 1 NP 001002807.1 26964 1.2E-13 3 28-38 (2) 9 9 9
Cofilin 1 NP 058843.1 18521 5.2E-13 4 17-28 (12) 9 9 9
Crystallin, alpha B NP 037067.1 20076 1.5E-04 3 6-14 (4) 8 9 8
Cysteine and glycine-rich protein 1 NP 058844.1 20600 2.0E-07 3 17-28 (5) 9 9 8
Cysteine and glycine-rich protein 2 NP 803174.2 20912 1.2E-10 3 17-28 (9) 9 9 8
Cytidine monophosphate (UMP-CMP) kinase 1, 
cytosolic
NP_001020826.1 25816 1.0E-04 3 17-28 (1) 9 8 8
Cytochrome c oxidase subunit IV isoform 1 NP 058898.1 19502 1.1E-06 2 6-14 (4) 9 9 8
Glutathione S-transferase omega 1 NP 001007603.1 27665 3.4E-07 2 28-38 (1) 9 8 9
Mitochondrial ATP synthase, O subunit NP 620238.1 23383 5.1E-10 5 17-28 (5) 9 9 8
Myosin light chain, phosphorylatable, fast skeletal 
muscle
NP_036737.1 18957 5.4E-12 12 17-28 (2), 14-17 (12) 9 9 8
Non-metastatic cells 2, protein (NM23B) 
expressed in
NP_114021.2 17272 1.8E-07 4 14-17 (11) 9 9 9
Parkinson disease protein 7 NP 476484.1 19961 2.0E-05 4 17-28 (4) 9 9 8
Peptidylprolyl isomerase A (cyclophilin A) NP 058797.1 17863 1.5E-10 6 14-17 (12) 9 9 9
Peptidylprolyl isomerase B NP 071981.1 22788 1.7E-09 5 17-28 (12) 9 9 9
Peroxiredoxin 1 NP 476455.1 22095 6.5E-08 6 17-28 (12) 9 9 9
Peroxiredoxin 2 NP 058865.1 21770 1.3E-06 4 17-28 (11) 9 9 9
Peroxiredoxin 5 precursor NP 446062.1 22165 1.8E-11 4 14-17 (12) 9 9 9
Peroxiredoxin 6 NP 446028.1 24803 5.6E-06 4 17-28 (3) 9 9 8
Phosphatidylethanolamine binding protein NP 058932.1 20788 4.1E-14 4 17-28 (12) 9 9 9
Proteasome (prosome, macropain) subunit, alpha 
type 5
NP_058978.1 26374 1.4E-05 2 17-28 (2) 9 8
Proteasome (prosome, macropain) subunit, alpha 
type 7
NP_001008218.1 27839 3.0E-08 6 28-38 (7) 9 9 9
Proteasome (prosome, macropain) subunit, beta 
type 1
NP_446042.1 26462 1.0E-05 3 17-28 (4) 9 9 8
Proteasome (prosome, macropain) subunit, beta 
type 6
NP_476440.2 25273 7.5E-08 2 17-28 (12) 9 9 8
Proteasome beta 3 subunit NP 058981.1 22949 8.7E-08 2 17-28 (2) 9 8 8
RAB11a, member RAS oncogene family NP 112414.1 24378 1.6E-08 3 17-28 (5) 9 9 8
RAB7A, member RAS oncogene family NP 076440.1 23489 4.8E-10 7 17-28 (11) 9 9 8
RAN, member RAS oncogene family NP 445891.1 24408 7.6E-09 5 17-28 (4), 28-38 (6) 9 9 9  
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Table 17 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range 17-28kDa continued
Rho GDP dissociation inhibitor (GDI) alpha NP 001007006.1 23393 4.9E-12 4 17-28 (8), 28-38 (10) 9 9 9
Ribosomal protein L11 NP 001020910.1 19012 6.1E-10 5 17-28 (12) 9 9 9
Ribosomal protein S3 NP 001009239.1 26657 3.4E-08 7 28-38 (8), 6-14 (1), >198 (1) 9 9 9
Splicing factor, arginine/serine-rich 2 NP 001009720.1 25461 1.2E-04 2 28-38 (7) 9 9 9
Splicing factor, arginine/serine-rich 7 NP 001034124.1 17880 1.0E-06 2 28-38 (1) 9 8 9
Stathmin 1 NP 058862.1 17278 4.4E-06 3 14-17 (12) 9 9 9
Stathmin-like 2 NP 445892.1 20743 1.4E-05 2 14-17 (3) 9 9 8
Superoxide dismutase 2 NP 058747.1 24659 1.6E-07 6 17-28 (12) 9 9 8
Transgelin NP 113737.1 22588 8.1E-07 10 17-28 (12) 9 9 9
Transgelin 2 NP 001013145.1 22379 3.8E-05 3 17-28 (8) 9 9 9
Transmembrane emp24 protein transport domain 
containing 9
NP_001009703.1 27011 2.9E-05 2 17-28 (1) 9 8 8
Troponin C type 1 (slow) NP 001029277.1 18409 6.6E-10 4 14-17 (10) 9 9 8
Trypsin 10 precursor NP 001004097.1 26109 3.2E-06 2 49-62 (1), 62-75 (2) 9 9 8
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, theta 
polypeptide
NP_037185.1 27761 1.1E-09 2 28-38 (6) 9 9 9
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide
NP_037143.2 27754 2.6E-13 9 17-28 (1), 28-38 (12) 9 9 9
Ubiquitin-conjugating enzyme E2N NP 446380.1 17113 1.4E-06 3 14-17 (11) 9 9 9
Mw range 28-38kDa
Aldo-keto reductase family 1, member A1 
(aldehyde reductase)
NP_112262.1 36483 2.6E-07 5 28-38 (5) 9 9 8
Aldo-keto reductase family 1, member C-like 2 NP 001008343.1 34478 2.6E-04 3 28-38 (2) 9 8 9
Annexin A4 NP 077069.3 35871 5.3E-09 6 28-38 (5) 9 9 9
Annexin A5 NP 037264.1 35722 1.9E-07 13 17-28 (3), 28-38 (12) 9 9 9
Calponin 3, acidic NP 062232.1 36412 2.8E-04 2 38-49 (1) 9 8 8
Calumenin isoform b NP 001029070.1 37124 1.6E-08 2 38-49 (10) 9 9 9
Chloride intracellular channel 4 (mitochondrial) NP 114006.1 28615 1.9E-05 2 28-38 (1) 8 9 9
Diaphorase (NADH/NADPH) NP 058696.2 30927 1.0E-09 8 28-38 (11) 9 9 9
Dimethylarginine dimethylaminohydrolase 2 NP 997697.1 29669 5.0E-04 2 28-38 (1) 9 8 8
Electron-transfer-flavoprotein, alpha polypeptide NP 001009668.1 34929 5.2E-04 3 28-38 (3) 9 8 8
Endoplasmic reticulum protein 29 NP 446413.1 28557 4.1E-07 5 17-28 (2), 28-38 (3) 9 9 8
F-actin capping protein beta subunit NP 001005903.1 30609 1.1E-05 4 28-38 (4) 9 9 9
Guanine nucleotide binding protein, beta 
polypeptide 2-like 1
NP_570090.1 35073 5.4E-09 3 28-38 (11) 9 9 9
Heterogeneous nuclear ribonucleoprotein A1 NP 058944.1 34191 1.7E-11 8 38-49 (4), 28-38 (8) 9 9 9
Laminin receptor 1 NP 058834.1 32803 1.1E-15 6 38-49 (8), 28-38 (5) 9 9 9  
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Table 17 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range 28-38kDa continued
L-lactate dehydrogenase B NP 036727.1 36589 3.0E-09 4 28-38 (6) 9 9 9
Malate dehydrogenase 1, NAD (soluble) NP 150238.1 36460 1.2E-09 8 28-38 (10) 9 9 9
Malate dehydrogenase, mitochondrial NP 112413.2 35661 1.0E-30 11 28-38 (11) 9 9 9
PDZ and LIM domain 1 NP 059061.1 35503 1.4E-10 3 38-49 (8) 9 9 9
Peroxiredoxin 3 NP 071985.1 28303 7.1E-07 4 17-28 (8) 9 9 8
Peroxiredoxin 4 NP 445964.1 30988 1.5E-06 3 17-28 (12) 9 9 9
Phosphoglycerate mutase 2 (muscle) NP 059024.1 28737 1.5E-08 4 28-38 (10) 9 9 9
Prohibitin 2 NP 001013053.1 33292 4.2E-09 6 28-38 (8) 9 9 9
Proliferating cell nuclear antigen NP 071776.1 28730 9.8E-11 3 28-38 (4) 9 9 9
Protease (prosome, macropain) 28 subunit, alpha NP 058960.2 28617 2.4E-05 3 28-38 (5) 9 9 8
Proteasome (prosome, macropain) subunit, alpha 
type 3
NP_058976.1 28401 3.3E-06 2 28-38 (1) 8 9 8
Proteasome (prosome, macropain) subunit, alpha 
type 4
NP_058977.1 29479 1.5E-07 2 28-38 (9) 9 9 9
Ribosomal protein S6 NP 058856.1 28663 2.5E-04 3 3-6 (3) 9 9 8
Secreted protein, acidic, cysteine-rich 
(osteonectin)
NP_036788.1 34274 1.2E-11 3 38-49 (4) 9 8 9
Solute carrier family 25, member 5 NP 476443.1 32880 4.8E-05 2 >198 (1) 8 9 9
Tropomyosin 1, alpha isoform c NP 001029242.1 32828 1.4E-08 9 38-49 (9), 28-38 (11) 9 9 9
Tropomyosin 1, alpha isoform h NP 001029246.1 28679 4.3E-10 14 38-49 (9), 28-38 (12) 9 9 9
Tropomyosin 2 NP 001019516.1 32938 1.7E-08 11 38-49 (11), 28-38 (7) 9 9 9
Tropomyosin 3, gamma isoform 1 NP 476556.2 28692 2.4E-08 10 28-38 (10) 9 9 9
Tropomyosin 4 NP 036810.1 28492 9.0E-11 11 28-38 (11) 9 9 9
Troponin T type 2 (cardiac) NP 036808.1 35709 2.2E-07 2 38-49 (1) 9 8 8
Troponin T type 3 (skeletal, fast) NP 113720.1 30338 6.8E-07 2 28-38 (3) 9 9 8
Tyrosine 3-monooxgenase/tryptophan 5-
monooxgenase activation protein, beta 
polypeptide
NP_062250.1 28037 1.9E-09 3 28-38 (6) 9 9 9
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein
NP_113791.1 29103 4.4E-09 9 28-38 (11) 9 9 9
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta 
polypeptide
NP_037184.1 28194 7.0E-05 3 28-38 (3) 8 9 9
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, gamma 
polypeptide
NP_062249.1 28285 5.2E-11 4 28-38 (11) 9 9 9
Voltage-dependent anion channel 1 NP 112643.1 30737 8.7E-09 3 28-38 (10) 9 9 9
Voltage-dependent anion channel 2 NP 112644.1 31726 1.0E-07 5 28-38 (10) 9 9 9  
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Table 17 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range 38-49kDa
Actin, alpha 1, skeletal muscle NP_062085.1 42024 4.9E-13 18 98-198 (11), >198 (5), 75-98 
(11), 38-49 (12), 49-62 (4), 17-28 
(8), 28-38 (11), 6-14 (12), 14-17
9 9 9
Aldolase A-like 1 NP 001013965.1 39467 9.8E-09 6 38-49 (12) 9 9 9
Annexin A1 NP 037036.1 38805 1.0E-13 18 38-49 (12), 28-38 (11) 9 9 9
Annexin A2 NP 063970.1 38654 1.5E-10 17 38-49 (12), 28-38 (11), >198 (2) 9 9 9
Dynactin 2 NP 001004239.1 44121 4.9E-04 2 38-49 (1) 8 9
Eukaryotic translation initiation factor 4A2 NP 001008336.1 46373 4.8E-08 3 38-49 (3) 9 9 9
Farnesyl diphosphate synthase (farnesyl 
pyrophosphate synthetase, 
dimethylallyltranstransferase, gera
NP_114028.1 40778 9.3E-10 2 38-49 (1) 8 9 8
Fructose-bisphosphate aldolase A NP 036627.1 39327 1.0E-30 5 38-49 (8) 9 9 9
Glutamate oxaloacetate transaminase 2 NP 037309.1 47284 2.5E-07 4 38-49 (4) 9 9 9
Heterogeneous nuclear ribonucleoprotein F NP 001032362.1 45701 3.2E-09 3 38-49 (7) 9 9 9
Integrin-linked kinase-associated serine/threonine 
phosphatase 2C
NP_072128.1 42718 6.7E-04 2 49-62 (1) 9 8 8
Isocitrate dehydrogenase 3 (NAD+) alpha NP 446090.1 39588 8.3E-07 2 38-49 (1), 28-38 (3) 9 9 8
Keratin 13 NP 001004021.1 47699 1.4E-05 2 98-198 (1), 14-17 (1) 8 9 9
Keratin 15 NP_001004022.1 48840 1.9E-06 3 17-28 (1), 3-6 (2), 6-14 (1), >198 
(1), 14-17 (1)
9 9 9
Lysosomal-associated membrane protein 1 NP 036989.1 43941 4.9E-04 2 75-98 (1) 9 8 8
Phosphoglycerate kinase 2 NP 001012130.1 44981 2.2E-10 3 38-49 (2) 9 9 9
Protein disulfide isomerase-associated 6 NP 001004442.1 48730 3.5E-12 6 38-49 (12) 9 9 9
Pyruvate dehydrogenase (lipoamide) beta NP 001007621.1 38957 1.3E-10 2 28-38 (1) 9 8 8
Septin 2 NP 476489.1 41566 1.2E-04 2 38-49 (1) 8 9 8
Serine (or cysteine) peptidase inhibitor, clade H, 
member 1
NP_058869.1 46488 8.5E-14 8 38-49 (12), 49-62 (2), 6-14 (2) 9 9 9
Serum deprivation response NP 001007713.1 46358 1.7E-11 2 49-62 (2) 9 9 8
Ubiquinol cytochrome c reductase core protein 2 NP 001006971.1 48366 1.5E-04 2 38-49 (1) 9 8 8
Mw range 49-62kDa
Aldehyde dehydrogenase 3A1 NP_114178.1 50307 2.9E-11 18 38-49 (12), 49-62 (11), 17-28 (1), 
75-98 (1)
9 9 9
Aldehyde dehydrogenase 9A1 NP 071609.2 54015 2.0E-06 5 49-62 (7) 9 9 8
Ankyrin repeat, SAM and basic leucine zipper 
domain containing 1
NP_570106.1 53107 4.6E-05 2 14-17 (1) 8 9 8
Annexin A11 NP 001011918.1 54126 4.7E-08 2 49-62 (3) 8 9 8
ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit 1, cardiac muscle
NP_075581.1 59717 4.4E-12 14 49-62 (12), 28-38 (10) 9 9 9
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Table 17 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range 49-62kDa continued
Caldesmon 1 NP 037278.1 60548 8.9E-12 18 62-75 (12) 9 9 9
Chaperonin containing TCP1, subunit 2 (beta) NP 001005905.1 57422 8.9E-10 8 49-62 (9) 9 9 9
Chaperonin containing TCP1, subunit 3 (gamma) NP 954522.1 60608 3.8E-06 6 49-62 (10) 9 9 9
Chaperonin containing TCP1, subunit 5 (epsilon) NP 001004078.1 59499 8.2E-07 6 49-62 (7) 9 9 9
Chaperonin containing Tcp1, subunit 6A (zeta 1) NP 001028856.1 57981 2.4E-12 7 49-62 (6) 9 9 9
Chaperonin subunit 4 (delta) NP 877966.1 58063 2.7E-06 6 49-62 (3) 9 8 9
Dihydropyrimidinase-like 3 NP 037066.1 61928 3.6E-07 6 62-75 (11) 9 9 9
Dipeptidylpeptidase 7 NP 114179.1 55079 2.3E-06 3 49-62 (4) 9 9 8
Dynein, cytoplasmic 1 light intermediate chain 2 NP 112288.1 54711 4.5E-05 2 49-62 (1) 8 9 8
EH-domain containing 4 NP 647540.1 61429 1.6E-04 2 49-62 (1) 9 8 8
Enabled homolog NP 001012150.1 58792 7.8E-05 3 62-75 (4) 9 9 8
Eukaryotic translation elongation factor 1 alpha 2 NP 036792.2 50422 2.9E-07 7 38-49 (12), 49-62 (1), 98-198 (1) 9 9 9
Glutamate dehydrogenase 1 NP 036702.1 61377 2.5E-10 9 49-62 (12) 9 9 9
Heterogeneous nuclear ribonucleoprotein K NP 476482.1 50944 1.4E-11 7 49-62 (11) 9 9 9
Katanin p60 subunit A-like 1 NP 001006957.1 55166 2.2E-04 2 38-49 (1) 9 8 8
Keratin 10 NP_001008804.1 56471 2.0E-07 7 98-198 (3), >198 (5), 75-98 (2), 
49-62 (1), 17-28 (2), 28-38 (2), 6-
14 (3), 14-17 (2), 3-6 (12)
9 9 9
Keratin 14 NP 001008751.1 52651 1.3E-08 3 6-14 (1), >198 (1), 3-6 (1) 9 9 9
Keratin 4 NP_001008806.1 57631 2.9E-05 4 98-198 (1), 75-98 (2), 17-28 (2), 
28-38 (2), 6-14 (6), 14-17 (1), 3-6 
9 9 9
Keratin 42 NP_001008816.1 50182 8.6E-06 4 6-14 (2), 3-6 (2), 98-198 (2), 
>198 (6), 75-98 (1)
9 9 9
Keratin 5 NP 899162.1 61889 3.6E-05 3 3-6 (2) 9 9 9
Keratin 77 NP_001008807.1 57220 3.7E-09 6 98-198 (11), >198 (10), 62-75 
(9), 75-98 (7), 38-49 (11), 49-62 
(10), 17-28 (9), 28-38 (10), 6-14 
(12) 14-17 (12) 3-6 (12)
9 9 9
Mitochondrial aldehyde dehydrogenase 2 NP 115792.1 56453 3.9E-11 7 49-62 (7) 9 9 9
Mitochondrial ATP synthase beta subunit NP 599191.1 56319 1.0E-10 10 38-49 (6), 49-62 (11) 9 9 9
Myosin binding protein H NP 114001.1 52624 7.1E-05 2 49-62 (2) 9 9 8
PC4 and SFRS1 interacting protein 1 NP 786941.1 59603 3.8E-04 2 38-49 (1) 9 8 8
Plasma glutamate carboxypeptidase NP 113828.1 51937 6.3E-09 3 49-62 (9) 9 9 8
Procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), alpha 
polypeptide I
NP_742059.2 60860 4.1E-04 3 49-62 (2) 9 9 8
Prolyl 4-hydroxylase, beta polypeptide NP 037130.1 56829 4.4E-15 22 49-62 (12), 6-14 (1) 9 9 9
Prosaposin NP 037145.1 61084 6.1E-07 3 6-14 (11), 3-6 (1) 9 9 9
Protein disulfide-isomerase A3 NP 059015.1 56554 1.1E-09 17 49-62 (12) 9 9 9  
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Table 17 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range 49-62kDa continued
Pyruvate kinase, muscle NP 445749.1 57781 1.0E-30 19 49-62 (12) 9 9 9
T-complex 1 NP 036802.1 60322 4.8E-12 4 49-62 (2) 9 8 8
Trimethyllysine hydroxylase, epsilon NP 596878.2 50884 5.9E-04 2 49-62 (1) 8 9 8
Tubulin, beta 5 NP 775125.1 49639 5.6E-10 3 38-49 (11), 49-62 (4) 9 9 9
Tubulin, beta 6 NP 001020846.1 50027 2.6E-04 3 49-62 (2) 8 9 8
Vimentin NP_112402.1 53700 1.9E-13 38 >198 (3), 75-98 (5), 38-49 (12), 
49-62 (12), 6-14 (11), 3-6 (12)
9 9 9
Mw range 62-70kDa
Alpha isoform of regulatory subunit A, protein 
phosphatase 2
NP_476481.1 65281 1.5E-04 2 49-62 (1) 8 9 8
Calnexin NP 742005.1 67213 5.9E-12 4 62-75 (10), 75-98 (4) 9 9 9
Eukaryotic translation initiation factor 4B NP 001008325.1 69023 2.0E-09 6 75-98 (8) 9 9 9
FK506 binding protein 9 NP 001007647.1 63087 4.7E-05 2 62-75 (1) 8 9 8
Glucose phosphate isomerase NP 997475.1 62787 1.1E-06 2 49-62 (2) 8 9 8
Inner membrane protein, mitochondrial NP 001030100.1 67135 3.2E-09 3 75-98 (4) 9 9 8
Kelch repeat and BTB (POZ) domain containing 
10
NP_476539.1 68170 1.0E-06 4 62-75 (3) 9 9 8
Keratin 2 NP_001008899.1 69085 4.4E-09 3 28-38 (1), 6-14 (1), >198 (2), 62-
75 (1), 3-6 (1)
9 9 9
Lamin B1 NP 446357.1 66566 2.3E-07 9 62-75 (9) 9 9 8
Matrix metalloproteinase 14 (membrane-inserted) NP 112318.1 66038 4.3E-05 2 38-49 (1) 9 8 8
Moesin NP 110490.1 67697 2.1E-11 5 62-75 (9) 9 9 9
PDZ and LIM domain 5 NP 445778.1 63161 1.3E-04 2 62-75 (4) 9 9 8
Radixin NP 001005889.2 68501 7.8E-08 10 28-38 (1), 62-75 (11), 75-98 (1) 9 9 9
REC8 homolog NP 001011916.1 67832 8.9E-04 2 75-98 (1) 9 8 8
Spermatogenesis associated 18 NP 955406.2 63844 9.0E-04 2 6-14 (1) 9 8 8
WD repeat domain 1 NP 001014157.1 66140 1.2E-14 4 49-62 (2) 9 8 9
X-prolyl aminopeptidase (aminopeptidase P) 1, 
soluble
NP_571988.1 69613 6.0E-06 3 62-75 (6) 9 9 8
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Table 17 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range 70-98kDa
Aconitase 2, mitochondrial NP 077374.2 85380 3.3E-11 11 75-98 (11) 9 9 8
Acyl-Coenzyme A dehydrogenase, very long 
chain
NP_037023.1 70705 7.1E-04 2 62-75 (1) 9 8 8
ATP-binding cassette, sub-family B, member 7, 
mitochondrial precursor
NP_997683.1 82506 7.1E-04 2 28-38 (2) 8 9 8
Cadherin 13 NP 620244.1 78037 6.7E-05 5 75-98 (3) 9 9 8
Cd44 molecule NP 037056.2 85865 2.8E-06 2 62-75 (2) 9 9 9
Coiled-coil domain containing 33 NP 001014113.1 87710 2.2E-04 2 98-198 (1) 9 8 8
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 NP 445866.1 82445 4.7E-04 2 75-98 (1) 8 9 8
Eukaryotic translation elongation factor 1 delta NP 001013122.1 72083 8.1E-09 4 28-38 (11) 9 9 9
Eukaryotic translation elongation factor 2 NP 058941.1 95223 1.0E-14 18 98-198 (1), 75-98 (11) 9 9 9
Gelsolin NP 001004080.1 86014 1.1E-10 11 75-98 (10) 9 9 9
Heat shock 105kDa/110kDa protein 1 NP 001011901.1 96357 5.7E-06 3 75-98 (2) 8 9 9
Heat shock 70kD protein 1-like NP 997711.1 70505 1.8E-11 8 62-75 (12) 9 9 9
Heat shock protein 4 NP 705893.1 93997 3.2E-08 5 75-98 (5) 9 9 9
Heat shock protein 5 NP 037215.1 72303 1.1E-16 31 62-75 (12) 9 9 9
Heat shock protein 8 NP 077327.1 70827 1.1E-14 17 62-75 (12) 9 9 9
Heat shock protein 90, alpha (cytosolic), class A 
member 1
NP_786937.1 84762 7.2E-14 19 75-98 (11) 9 9 9
KH-type splicing regulatory protein (FUSE binding 
protein 2)
NP_598286.1 74181 1.2E-07 3 75-98 (1) 8 9 8
Lamin A isoform C2 NP_001002016.1 71856 1.3E-13 33 49-62 (10), 98-198 (1), 62-75 
(12), 75-98 (8)
9 9 9
Major vault protein NP 073206.2 95739 3.8E-04 2 75-98 (1) 9 8 8
Neural cell adhesion molecule 1 NP 113709.1 94599 1.3E-07 12 98-198 (11), 75-98 (1) 9 9 9
Nexilin (F actin binding protein) isoform b NP 631977.1 71899 1.7E-05 4 75-98 (2) 9 9 8
Nucleolar protein 10 NP 001014098.1 80188 6.6E-04 3 49-62 (1), 3-6 (1) 9 9 8
Plasticity related gene 1 NP 001001508.1 83309 3.8E-04 2 >198 (1) 8 9 8
Poly(A) binding protein, cytoplasmic 1 NP 599180.1 70656 5.5E-09 9 62-75 (11) 9 9 9
Procollagen-lysine 1, 2-oxoglutarate 5-
dioxygenase 1
NP_446279.1 83560 1.6E-07 2 75-98 (1) 8 9 8
Protein disulfide isomerase-associated 4 NP 446301.1 72761 1.1E-07 5 62-75 (8), 75-98 (9) 9 9 9
Protein phosphatase 1, regulatory subunit 10 NP 075240.1 92771 4.9E-04 2 75-98 (1) 9 8 8
Signal transducer and activator of transcription 3 NP 036879.1 87983 9.2E-05 2 14-17 (2) 9 9 8
Squamous cell carcinoma antigen recognized by 
T cells
NP_113784.1 90984 9.3E-04 2 62-75 (1) 8 9 8
TNF receptor-associated protein 1 NP 001034090.1 80411 4.4E-09 2 75-98 (5) 9 9 9
Transducin (beta)-like 3 NP 001008278.1 88316 3.0E-04 3 62-75 (1) 8 9 8
Transketolase NP 072114.1 71141 2.1E-11 10 62-75 (10) 9 9 9
Valosin-containing protein NP 446316.1 89293 2.8E-11 21 75-98 (11) 9 9 9
Zinc finger protein 111 NP 579857.1 85367 8.1E-05 2 38-49 (1) 9 8 8  
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Table 17 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range 98-198kDa
Actinin, alpha 1 NP 112267.1 102896 3.5E-12 30 98-198 (7), 75-98 (11) 9 9 9
Adaptor-related protein complex 1, beta 1 subunit NP 058973.1 104522 7.8E-04 2 75-98 (1) 8 9 8
Alpha actinin 4 NP 113863.2 104849 2.0E-11 24 98-198 (3), 75-98 (11) 9 9 9
Clathrin, heavy chain (Hc) NP 062172.1 191476 1.9E-09 20 98-198 (11) 9 9 9
Coatomer protein complex, subunit beta 2 (beta 
prime)
NP_068533.1 102486 2.2E-11 3 >198 (2) 8 9 9
Collagen, type I, alpha 2 NP 445808.1 129486 2.9E-09 16 98-198 (7) 9 9 9
Collagen, type III, alpha 1 NP 114474.1 138851 1.2E-11 11 98-198 (7) 9 9 9
Cullin-associated and neddylation-dissociated 1 NP 446456.1 136275 1.2E-06 4 98-198 (2) 9 9 9
Dynactin 1 NP 077044.1 141842 4.0E-04 2 98-198 (1) 9 8 8
Golgi apparatus protein 1 NP 058907.1 133469 1.7E-04 2 98-198 (1) 9 8 9
Integrin alpha 7 NP 110469.1 124117 1.5E-04 2 75-98 (1) 8 9 8
Kinesin family member 5B NP 476550.1 109463 1.3E-09 3 75-98 (3) 9 9 9
Mw range 98-198kDa continued
Lethal giant larvae homolog 1 NP 690057.1 112424 3.0E-06 2 75-98 (1) 9 8 8
Leucine-rich PPR-motif containing NP 001008519.1 156553 7.4E-07 4 98-198 (3) 9 8 9
LIM domain 7 NP 001001515.1 195450 1.0E-09 4 98-198 (4) 9 9 8
Methylenetetrahydrofolate dehydrogenase 1 NP 071953.1 100932 9.3E-04 2 75-98 (1) 9 8 8
Microtubule-associated protein 4 NP 001019449.1 110233 2.1E-06 9 98-198 (9) 9 9 9
Na+/K+ -ATPase alpha 1 subunit NP 036636.1 112982 2.1E-06 3 98-198 (2) 9 9 8
Proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 2
NP_001026809.1 100124 3.2E-08 3 75-98 (2) 8 9 8
SEC31 homolog A NP 148981.1 135266 1.8E-08 5 98-198 (3) 9 9 9
Staphylococcal nuclease domain containing 1 NP 073185.2 101889 2.6E-06 6 75-98 (6) 9 9 9
Thrombospondin 1 NP 001013080.1 129588 5.0E-05 3 98-198 (3) 9 8 9
Thyroid hormone receptor associated protein 3 NP 001009693.1 108188 1.0E-04 2 3-6 (1) 9 8 8
Ubiquitin-activating enzyme E1 NP 001014102.1 117713 2.6E-10 12 98-198 (2), 75-98 (11) 9 9 9  
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Table 17 continued 
Protein NCBI accession code Mw (Da) p value
Number of 
peptides used for 
identification
MW regions detected in (No. 
peptides in each region)
Detected in 
control 
myotubes
Detected in 
treated 
myotubes
Also detected 
in myoblasts
Mw range >198kDa
Acetyl-coenzyme A carboxylase alpha NP 071529.1 265023 3.0E-04 2 62-75 (1) 9 8 8
Alpha-spectrin 2 NP 741984.2 284418 9.3E-12 17 49-62 (1), >198 (5) 8 9 9
Citron (rho-interacting, serine/threonine kinase 
21)
NP_001025082.1 235161 4.2E-04 4 38-49 (1) 8 9 8
Fatty acid synthase NP 059028.1 272477 5.6E-09 9 >198 (5) 8 9 9
Insulin-like growth factor 2 receptor NP 036888.1 273220 3.7E-05 2 >198 (1) 8 9 8
Kalirin, RhoGEF kinase NP 114451.1 336374 8.2E-04 2 3-6 (1) 8 9 9
Myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 4
NP_037349.1 207548 7.6E-04 2 28-38 (1) 8 9 8
Myosin, heavy chain 10, non-muscle NP 113708.1 228823 2.6E-05 3 >198 (2) 8 9 9
Myosin, heavy chain 3, skeletal muscle, 
embryonic
NP_036736.1 223718 1.0E-30 62 98-198 (12), >198 (5) 9 9 8
Myosin, heavy chain 9, non-muscle NP 037326.1 226196 2.2E-13 33 98-198 (10), >198 (5) 9 9 9
Nestin NP 037119.1 198625 1.2E-11 25 >198 (5) 8 9 9
Phosphatidylinositol 4-kinase a NP 071637.1 231169 6.6E-04 2 >198 (1) 8 9 8
Phosphodiesterase 4D interacting protein NP 071777.1 261879 7.3E-04 2 75-98 (1) 8 9 8
Plectin 1 NP 071796.1 533214 3.4E-12 78 17-28 (4), 98-198 (8), >198 (5) 9 9 9
Sodium channel, voltage-gated, type III, alpha NP 037251.1 221241 2.4E-05 2 38-49 (1) 8 9 8
Spectrin repeat containing, nuclear envelope 1 NP 001025080.1 918957 3.1E-04 6 38-49 (2), 98-198 (1) 9 8 9
Spectrin, beta, non-erythrocytic 1 NP 001013148.1 273415 9.1E-11 6 >198 (1) 8 9 9
Sperm flagellar 2 NP 072142.1 200840 3.8E-04 2 38-49 (1) 8 9 8
ZUBR1 NP 001034115.1 573472 6.7E-04 2 62-75 (1) 9 8 8  
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3.5.2.1 Effect of TMPD-treatment on biological processes in myoblasts 
and myotubes 
Protein expression was investigated on a global level (using all the proteins 
identified using the srf files in Bioworks Browser). The nature of proteins 
expressed in control myoblasts was examined in order to appreciate the 
ongoing biological processes in untreated myoblasts. A list of proteins unique to 
control myoblasts was interrogated using the Panther classification tool 
available at www.pantherdb.org. Proteins present in treated myoblasts and 
those in control or treated myotubes were not considered at this stage of the 
analysis. 
From the analysis of control myoblasts, it was revealed that myoblasts were 
mainly involved in the biological processes of maintaining their shape and 
structure and also their motility (as evidenced by 45 out of 180 proteins 
examined in this analysis being involved in these functions). Myoblasts were 
also heavily involved in the essential process of protein metabolism and 
modification, which could involve protein synthesis, modification, or 
degradation, most likely as part of the growth and cell turnover processes that 
are typical of most proliferating cells (Figure 57). 
In myotubes, the main  biological processes that the cells were involved in were 
the same as described for myoblasts. In this case, however, protein metabolism 
and modification were the predominant processes as shown by 57 of 228 
proteins considered being involved. In the case of myotubes, 42/228 proteins 
were involved in maintaining cell structure and motility (Figure 58).  
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Figure 57: Normal biological processes in rat L6 myoblasts 
Myoblasts were grown (section 2.1) and the proteome of the cells was investigated using LC-MS/MS (section 2.7) in order to understand the normal 
biological processes ongoing within the cells. Out of 180 proteins investigated, 45 proteins were involved in maintaining the shape and structure of the 
cell, whilst 42 were involved in protein metabolism and modification. A total of 23 biological processes were identified that are natural to this cell type, 
although it was not possible to classify the function of all of the proteins examined (biological process unclassified). Biological processes for which >1 
protein could be associated with involved were included.  
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Figure 58: Normal biological processes in rat L6 myotubes 
Myotubes were differentiated from myoblasts (section 2.1) and their constituent proteins were measured using LC-MS/MS (section 2.7) in order to 
understand the normal biological processes characteristic of this cell type. Out of 228 proteins examined, 57 proteins were involved in protein 
metabolism and modification whilst 42 were involved in maintaining the shape and structure of the cell. A total of 24 biological processes were identified 
that are natural to this cell type although the function of some of the proteins was not clear (biological process unclassified). Biological processes with 
which <2 proteins could be associated with were not included in the analysis.  
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The biological processes ongoing in myoblasts and myotubes were compared 
directly in order to investigate the differences in the crucial biological processes 
in both cell types. The number of proteins involved in each of the biological 
processes already described were compared so that it could be determined 
whether cell differentiation resulted in (or from) changes in some of the 
processes already described. 
In the classification of the biological processes affected when myoblasts were 
matured into myotubes, biological processes such as lipid and fatty acid 
metabolism, cell proliferation and differentiation, electron transport and muscle 
contraction were increased in myotubes when compared to myoblasts (Figure 
59). Lipid and fatty acid metabolism is a common route for energy production in 
many biological systems302-304. In addition, skeletal muscle is an organ rich in 
mitochondria and this is a major site for fatty acid metabolism via the β-
oxidation of fatty acids and also via the electron transport chain (which was 
another upregulated biological process in myotubes)305,306.  
Cell proliferation and differentiation were classified together and it is likely that 
the increase in this biological process in myotubes was mainly due to an 
increase in the expression of proteins involved in the differentiation of myoblasts 
into myotubes. The differentiation of myoblasts into myotubes was further 
evidenced by the increase in the number of proteins involved in muscle 
contraction, which is a function more specific to mature skeletal muscle cells. 
This ties in with the presence of myofilaments in myotubes, as observed by EM 
(section 3.1, Figure 20). Apoptosis was downregulated in myotubes and this 
may be a consequence of a reduced amount of cell proliferation, which is more 
typical of undifferentiated myoblasts, and therefore a reduced turnover of cells 
in the corresponding cultures307. 
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Figure 59: Comparison of the normal biological process in myoblasts and myotubes 
Myoblasts and myotubes were cultured (section 2.1) and their protein expression was evaluated by LC-MS/MS (section 2.7) and the biological 
processes ongoing in myoblasts and myotubes were compared. The number of proteins involved in each of the biological processes (in myotubes) is 
shown relative to the number involved in myoblasts and processes such as lipid and fatty-acid metabolism, electron transport, cell differentiation and 
muscle contraction were upregulated. These processes could be considered to be typical of mature, mitochondria-rich skeletal muscle requiring energy 
for muscle contraction. 
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The effect of TMPD administration on the overall protein expression in 
myoblasts was also investigated by examining proteins that were uniquely 
expressed in either control myoblasts or in TMPD-treated myoblasts. For the 
most part, proteins that were reduced or absent in myoblasts as a result of 
TMPD-treatment were replaced by other proteins that were involved in the 
same biological processes (e.g. cell adhesion, cell structure and motility or 
immunity and defence).  
 
Changes in the expression of cell cycle proteins and those involved in apoptosis 
or lipid, fatty acid and steroid metabolism may have been a consequence of a 
proliferative response to drug treatment whereby programmed cell death was 
decreased and more cells were encouraged to enter the cell cycle in order to 
replace damaged or unhealthy cells. The increase in energy production (as 
evidenced by increased oxidation of fatty acids) may reflect an increased 
energy requirement in myoblasts treated low concentrations of TMPD (Table 
18). 
Chapter 3: Results 
 182
Table 18: Biological processes affected in TMPD-treated myoblasts 
Protein expression in cultured myoblasts (section 2.1) was investigated using LC-
MS/MS (section 2.7) in order to investigate TMPD-induced changes in the number of 
proteins involved in particular biological processes. The biological processes appeared 
to be unaffected but changes in apoptosis, lipid metabolism and cell cycle proteins 
resulted from TMPD treatment. 
Biological process No. of proteins Biological process
No. of 
proteins
Apoptosis 3 Reduced
Biological process unclassified 7 Biological process unclassified 2 Reduced
Blood circulation and gas exchange 2 Increased
Carbohydrate metabolism 2 Reduced
Cell adhesion 2 Cell adhesion 2 Unchanged
Cell cycle 3 Cell cycle 7 Increased
Cell proliferation and differentiation 2 Increased
Cell structure and motility 6 Cell structure and motility 6 Unchanged
Developmental processes 2 Developmental processes 2 Unchanged
Immunity and defense 5 Immunity and defense 4 Reduced
Intracellular protein traffic 5 Intracellular protein traffic 3 Reduced
Lipid, fatty acid and steroid metabolism 3 Increased
Neuronal activities 2 Reduced
Nucleoside, nucleotide and nucleic acid 
metabolism 11
Nucleoside, nucleotide and nucleic acid 
metabolism 3 Reduced
Other metabolism 3 Increased
Protein metabolism and modification 8 Protein metabolism and modification 9 Increased
Protein targeting and localization 2 Protein targeting and localization 2 Unchanged
Signal transduction 6 Signal transduction 7 Increased
Transport 4 Transport 7 Increased
Proteins present in control myoblast only Proteins present in treated myoblast only
Response to 
treatment
 
 
The effect of TMPD administration on the overall protein expression in 
myotubes was also investigated. As with myoblasts, some biological processes 
were unaffected and homeostasis was maintained by proteins that were 
reduced as a result of treatment being replaced by other proteins (e.g. 
intracellular protein traffic). Increases in cell cycle proteins and those involved 
with cell structure and motility may again reflect increased cell proliferation to 
replace or repair damaged cells. With respect to this, the biological pathways 
behind the lack of a change in cell proliferation proteins and the decrease in 
those involved in protein metabolism may reflect the fact that the cell was able 
to cope adequately with the change in biological functions (Table 19). 
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Table 19: Biological processes affected in TMPD-treated myotubes 
Protein expression in cultured myotubes (section 2.1) was investigated by LC-MS/MS 
(section 2.7) in order to investigate changes in the number of proteins involved in 
specific biological processes. Changes in cell cycle and cell structure proteins may be 
a consequence of increased cell proliferation in response to TMPD treatment. 
Biological process No, of proteins Biological process
No, of 
proteins
Biological process unclassified 9 Biological process unclassified 4 Reduced
Carbohydrate metabolism 2 Reduced
Cell adhesion 2 Increased
Cell cycle 2 Cell cycle 8 Increased
Cell proliferation and differentiation 2 Cell proliferation and differentiation 2 Unchanged
Cell structure and motility 3 Cell structure and motility 9 Increased
Developmental processes 4 Developmental processes 3 Reduced
Electron transport 2 Reduced
Immunity and defense 4 Reduced
Intracellular protein traffic 6 Intracellular protein traffic 7 Increased
Lipid, fatty acid and steroid metabolism 3 Lipid, fatty acid and steroid metabolism 5 Increased
Muscle contraction 3 Reduced
Neuronal activities 2 Neuronal activities 2 Unchanged
Nucleoside, nucleotide and nucleic acid 
metabolism 6
Nucleoside, nucleotide and nucleic acid 
metabolism 4 Reduced
Other metabolism 2 Increased
Protein metabolism and modification 13 Protein metabolism and modification 7 Reduced
Protein targeting and localization 2 Increased
Signal transduction 2 Signal transduction 9 Increased
Transport 2 Transport 6 Increased
Response to 
treatment
Proteins present in control myotube only Proteins present in treated myotube only
 
This approach to analysing this data was useful in representing an overall 
impression of the process in which both myoblasts and myotubes were involved 
with. Both myoblasts and myotubes are derived from the same cell and 
therefore closely related. This is reflected in the cells appearing to be involved 
in similar normal biological processes. In addition, the myotubes cultures 
contained a proportion of myoblasts (as described in section 3.1) and this may 
also have contributed to some of the similarities in the biological processes 
described for each cell type. 
This semi-quantitative approach to the analysis of all the LC-MS/MS data 
generated allowed a general appreciation of the overall changes in myoblasts 
and myotubes but a more detailed analysis looking into the levels of expression 
of particular proteins was required. The use of Decyder™ differential analysis 
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software was used to specifically detect, match and analyse protein levels in 
control and treated skeletal muscle cells and is described in the next section. 
 
3.5.3 Biomarker discovery in TMPD-treated skeletal muscle cells using LC-
MS/MS 
Decyder™ MS software was used in combination with Bioworks Browser to 
compare the relative levels of peptides from different samples (based on 
retention time and m/z). The use of the aforementioned software allowed the 
comparison of the relative intensities of peptides between control and treated 
samples. 
 
3.5.3.1 Optimisation of Decyder™ MS peptide detection settings 
Following LC-MS/MS analysis of skeletal muscle cells, the PepDetect module of 
Decyder™ MS software was used to detect a consistent number of peptides 
across the spectra generated (as described in section 2.7.4). Chemical or 
electrical noise can interfere with the interpretation of MS data, and so different 
detection settings were investigated so that a maximal number of ions could be 
included without including excessive background noise.  
 
Using data generated following the LC-MS/MS analysis of peptides generated 
from the >198kDa Mw region of a control myoblasts sample in a 1D gel, 
PepDetect settings were adjusted so that ions were detected using a range of 
S/N settings between 0.1 and 2 during the detection. This range was selected 
as using a S/N setting of 0.1 may tend to include too many ions (including 
spectral noise) due to the filtering criteria being relatively relaxed. Alternatively, 
a setting of 2 may exclude some useful ions due to its high stringency for the 
acceptance of ions. 
 
A suitable S/N (to exclude) setting of 1.1 was selected for the PepDetect 
module of the Decyder™ MS software as this appeared to be the setting at 
which a maximal number of peptides could be detected before the setting was 
changed to 1.2 and the stringency of the setting became exclusive of some ions 
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that may prove useful. The setting at 1.1 reduces the risk of including peptides 
that may be unreliable (Figure 60).  
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Figure 60: Optimisation of detection settings in the PepDetect module of 
Decyder™ MS software 
Myoblasts were cultured (section 2.1) and proteins in the sample were separated by 
1DE (section 2.7.1). Peptides were then generated from sections of the 1D gel and 
detected by LC-MS/MS (sections 2.7.2 and 2.7.3). In order to determine suitable 
settings for peptide detection in the PepDetect module of Decyder™ MS software, 
settings were adjusted so that the S/N of ions excluded ranged from 0.1 to 2. A S/N 
setting of 1.1 was used in subsequent experiments, as a setting of 2 was too stringent, 
leading to the possible exclusion of some potentially useful ions whilst a setting of 0.1 
may lead to the inclusion of ions that were affected by chemical or electrical noise. S/N 
= signal to noise ratio. 
 
3.5.3.2 Comparison of enzyme activity and protein levels 
In order to verify the TMPD-induced changes observed biochemically, changes 
observed using the assays described in section 3.3 were compared with 
changes in their protein levels as measured by LC-MS/MS. However, this 
comparison was only possible for CK, ALD and parvalbumin in myoblasts 
(Table 20) and only for CK, ALT, AST, ALD, sTnI and Myl3 in myotubes (Table 
21). In doing this, only the peptides used in the quantification of ALD (in 
myoblasts) and for ALD and AST (in myotubes) were based on reliable 
identifications of the protein (based on 2 or more peptides with a p value of 
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<0.05) and these proteins are also listed in Table 16. The remaining 
comparisons were either based on proteins identified using only 1 peptide or 
peptides in which the confidence in the identification was unacceptable 
(p>0.05). As such, these comparisons are only a guide and may serve as 
further confirmation of the changes observed using biochemical assays. 
 
In comparing changes in the biochemical levels of markers in myoblasts with 
the protein levels measured by LC-MS/MS, only 1 peptide was significantly 
reduced in its levels. However, a 2 fold decrease in the levels of a peptide used 
to quantify CK (K.SQEEYPDLSK.H) was not backed up by changes in the other 
peptide used in its measurement (-.MPFGNTHNKFK.L), despite the fact that 
biochemical measure of CK did demonstrate that this marker was decreased 
following treatment with 25μM TMPD. As a result of the conflicting changes in 
peptides from the same protein, this measurement cannot be relied on. Also, 
the peptides used were not identified with a high level of confidence (p>0.05) 
making it possible that even the peptides used in the quantitation may have 
been incorrectly identified (Table 20). 
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Table 20: Comparison of biochemical levels with protein levels in 
myoblasts 
Changes in the levels of biochemical markers in myoblasts treated with TMPD (Figure 
30) were compared with changes observed in the corresponding proteins using data 
generated by LC-MS/MS. Only the comparisons in the levels of ALD are based on 
reliable identifications (based on >1 peptide with a p value of <0.05). Only a change in 
the level of one of the peptides used to measure CK was observed (-
.MPFGNTHNKFK.L) and this was not backed up by the changes seen in the other 
peptide used to quantify CK (K.SQEEYPDLSK.H). No significant reduction in the levels 
of CK were observed biochemically in cells treated with 25μM TMPD (Student’s t-test, 
p<0.05). 
Description NCBI MW Peptide used for quantitation
No. peptides 
used in 
quantitation 
(control/treated)
Fold change 
compared to 
control
Muscle creatine kinase NP_036662.1 42992 -.MPFGNTHNKFK.L 4/4 1.4
K.SQEEYPDLSK.H 3/3 0.5
L-lactate dehydrogenase A NP_058721.1 36427 Insufficient peptides for quantitation - -
Glutamic-pyruvate transaminase (alanine 
aminotransferase)
NP_112301.1 55074 Insufficient peptides for quantitation - -
Glutamic-oxaloacetic transaminase 1, 
soluble (aspartate aminotransferase)
NP_036703.1 46299 Insufficient peptides for quantitation - -
Fructose-bisphosphate aldolase A NP_036627.1 39327 K.ELADIAHR.I 5/5 1.0
K.ADDGRPFPQVIK.S 6/4 0.8
Troponin I type 1 (skeletal, slow) NP_058880.1 21711 Insufficient peptides for quantitation -
Parvalbumin NP_071944.1 11918 K.GFSSDARDLSAK.E 6/6 0.1
Myosin, light chain 3, alkali; ventricular, 
skeletal, slow
NP_036738.1 22142 Insufficient peptides for quantitation - -
Fatty acid binding protein 3, muscle and 
heart
NP_077076.1 14766 Insufficient peptides for quantitation - -
 
 
No significant changes were observed by LC-MS/MS in the levels of the 
candidate markers in myotubes (Student’s t-test, p<0.05). This reflects what 
was observed when the intracellular levels of each marker was measured more 
specifically using the biochemical assays. The comparisons made here 
between the biochemical levels and the measured proteins levels perhaps 
suggest that there was increased sensitivity with the biochemical assays when 
measuring these candidate biomarkers (Table 21).  
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Table 21: Comparison of biochemical levels with protein levels in 
myotubes 
Changes in the levels of biochemical markers in myotubes treated with TMPD were 
compared with changes observed in the corresponding proteins using data generated 
by LC-MS/MS. Only the comparisons in the levels of AST and ALD are based on 
reliable identifications (based on >1 peptide with a p value of <0.05). None of the 
changes observed were significant, and this reflects what was observed biochemically 
despite the fact that both CK and ALD were observed to be reduced in cells treated 
with 25μM TMPD when measured more specifically (Student’s t-test, p<0.05). 
Description NCBI MW Peptide used for quantitation
No. peptides 
used in 
quantitation 
(control/treated)
Fold change 
compared to 
control
Muscle creatine kinase NP_036662.1 42992 K.GGDDLDPNYVLSSR.V 5/4 0.9
L-lactate dehydrogenase A NP_058721.1 36427 Insufficient peptides for quantitation - -
Glutamic-pyruvate transaminase (alanine 
aminotransferase)
NP_112301.1 55074 K.LMSVRLCPPVPGQALMDMVVS
PPTPSEPSFK.Q
5/3 0.8
Glutamic-oxaloacetic transaminase 1, 
soluble (aspartate aminotransferase)
NP_036703.1 46299 R.IAATILTSPDLR.K 3/3 0.8
Fructose-bisphosphate aldolase A NP_036627.1 39327 K.ADDGRPFPQVIK.S 6/6 1.3
K.ELADIAHR.I 3/4 1.3
Troponin I type 1 (skeletal, slow) NP_058880.1 21711 R.KNVEAMSGMEGR.K 2/2 1.6
Parvalbumin NP_071944.1 11918 Insufficient peptides for quantitation - -
Myosin, light chain 3, alkali; ventricular, 
skeletal, slow
NP_036738.1 22142 K.ITYGQCGDVLR.A 6/6 1.3
Fatty acid binding protein 3, muscle and 
heart
NP_077076.1 14766 Insufficient peptides for quantitation - -
 
 
 
Comparing the activity of the candidate biomarkers measured in section 3.3 
with the protein levels measured by LC-MS/MS was not useful as it would 
appear as if the majority of the parameters measured biochemically (and more 
specifically) were either more suitable for detection or measurement using the 
specific assays described earlier. It is also possible that the effect of treatment 
was on the activity of the enzymes measured and not their proteins levels. 
Here, it was not possible to verify the changes observed biochemically using 
LC-MS/MS data. 
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3.5.3.3 Selection of putative biomarkers of TMPD-induced myopathy in 
myoblasts 
At least 2 peptides with a p value <0.05 were required to ensure confidence in 
the conclusive identification of proteins (as described in section 3.5.2). Whilst it 
was acceptable for the peptides used in the identification to be detected in only 
one sample, this would not provide a sufficient number of samples from which a 
reliable quantitation of the protein could be made. As such, in a first pass filter 
of Decyder™ MS software output, the identification of proteins was considered 
separately from the measurement of peptides.  
 
The levels of proteins were only compared if the constituent peptides were 
observed on at least 50% (6/12) of the total number of observable occasions. 
This meant that a sufficient number of peptides could be measured to facilitate 
a reliable assessment of TMPD-induced changes and significant changes in the 
levels of the peptides could then be identified (Student’s t-test, p<0.05). 
Consideration was also given to consistency in the response of all the peptides 
chosen for measurement to TMPD-treatment across different samples, in terms 
of the magnitude of change and also in terms of whether the peptides were 
increased or decreased.  
The levels of individual peptides were also examined in order to ensure the 
accuracy of peptide selection by the PepDetect module of the Decyder™ MS 
software. This was performed so that peptides were not selected erroneously 
and also so that peptide matches were not overlooked due to slight shifts in the 
retention time or in the measured m/z of peptides. In such instances, peptides 
that should have been matched were manually selected, deselected or their 
charge assignment corrected manually in order to accurately reflect the true 
nature of the measured peptides.  
Using this relatively strict approach to putative biomarker selection, 8 proteins (4 
up-regulated and 4 down-regulated) ranging in Mw from 15-919kDa were 
differentially expressed in myoblasts as a result of treating the cells with TMPD. 
The magnitude of the changes ranged from 1.2 to 5.6-fold. The responsive 
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proteins were diverse in their biological functions and classified as being 
involved in biological processes such as cell structure and motility (2), 
metabolism (1), protein metabolism and modification (3) and signal transduction 
(2) (Table 22). 
Chapter 3: Results 
 191
Table 22: Identified myoblasts cell proteins that showed differential expression following treatment with TMPD  
Myoblasts were cultured and treated with TMPD for 24h (section 2.1). Proteins within the samples were then separated by 1DE (section 
2.7.1) before the resulting gel was divided into sections. Peptides generated from these sections were analysed by LC-MS/MS in order to 
determine any TMPD-induced changes in the expression of proteins in myoblasts. Proteins (8) were shown to differ significantly in their 
expression as a result of TMPD-treatment (Student’s t-test, p<0.05). Of these proteins, the levels of 4 were increased and 4 were 
decreased.  
Proteins Peptides used for quantitation
No. ions measured in 
control/treated
Fold 
change Probability
Overall fold 
change ± SEM 
(CV)
Cell structure and motility
Keratin 2 (KRT2) NP_001008899.1  Cytoplasm 69a) 98-198 7b) R.GFSSGSAVVSGGSR.R (+2) 4.36 5/5 +1.6 0.009 +1.6
Keratin 19  (KRT19) NP_955792.1  Cytoplasm 45a) 14-17 3b) R.LAADDFR.T (+1) 2.22 6/4 +5.5 0.04 +5.6 ±0.1
R.LASYLDKVR.A (+2) 3.32 6/4 +5.7 0.004  (3%)
Metabolism
Aldehyde dehydrogenase family 3, 
member A1  (ALDH3A1)
NP_114178.1  Cytoplasm 50 38-49 12b) K.SLLNEEAHK.A (+2) 2.33 6/6 -1.5 0.04 -1.5 ±0.1
R.EKPLALYVFSNNEK.V (+3) 4.42 6/6 -1.4 0.02 (11%)
Subcellular location
Comparison between control and TMPD-treated
Name (gene name) NCBI accession code
Mean 
Xcorr
Peptide (charge)Mw (kDa)
Mw region 
(kDa) 
identified in
No. of unique 
peptide ions 
used in 
identification
 
a) There was a discrepancy between the calculated Mw and the region of the gel in which the protein was detected. It is possible that a post-translational modification to the protein may have 
occurred or that the protein may have been fragmented or digested prior to detection. 
b) More peptides were used in the identification of these proteins but some of the peptides were below the level of quantitation. Therefore, only peptides suitable for measurement were used 
in determining the levels of the protein. 
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Table 22 continued 
Proteins Peptides used for quantitation
No. ions measured in 
control/treated
Fold 
change Probability
Overall fold 
change ± SEM 
(CV)
Protein  metabolism and modification
Serine [or cysteine] proteinase inhibitor, 
clade H (SERPINH1)
NP_058869.1  Extracellular Space 47 38-49 10b) K.HLAGLGLTEAIDK.N (+2) 3.04 6/5 -1.7 0.0009 -1.8 ±0.2
K.KPVEAAAPGTAEK.L (+3) 4.12 5/5 -2.0 0.03 (13%)
Eukaryotic translation initiation factor 4B     
(EIF4B)
NP_001008325.1  Cytoplasm 69a) 6-14 6b) K.DETKVDGVSTTK.G (+2) 2.21 6/6 -1.4 0.03 -1.4
Spectrin repeat containing, nuclear 
envelope 1 (SYNE1)
NP_001025080.1  Nucleus 919a) 75-98 2b) K.LSEFVVTK.I (+2) 2.25 6/6 +1.2 0.02 +1.2
Signal transduction
Rho GDP dissociation inhibitor [GDI] alpha 
(ARHGDIA)
NP_001007006.1  Cytoplasm 23 28-38 5b) R.VAVSADPNVPNVIVTR.L (+2) 4.75 6/6 +2.0 0.03 +2.1 ±0.1
K.SIQEIQELDKDDESLRK.Y (+2) 4.36 4/5 +2.2 0.04  (7%)
Lectin, galactose binding, soluble 1 
(LGALS1)
NP_063969.1  Extracellular Space 15 6-14 6b) K.VRGELAPDAK.S (+2) 2.69 6/6 -2.0 0.004 -1.7 ±0.2
K.SFVLNLGK.D (+2) 2.7 5/6 -1.4 0.01 (17%)
K.DSNNLCLHFNPR.F (+3) 3.61 5/5 -1.7 0.03
Mean 
Xcorr
Comparison between control and TMPD-treated
Mw region 
(kDa) 
identified in
No. of unique 
peptide ions 
used in 
identification
Peptide (charge)Name (gene name) NCBI accession code Subcellular location
Mw 
(kDa)
 
 
a) There was a discrepancy between the calculated Mw and the region of the gel in which the protein was detected. It is possible that a post-translational modification to the protein may have 
occurred or that the protein may have been fragmented or digested prior to detection. 
b) More peptides were used in the identification of these proteins but some of the peptides were below the level of quantitation. Therefore, only peptides suitable for measurement were used 
in determining the levels of the protein. 
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After finding a reliable profile of proteins whose levels were changed following 
the treatment of myoblasts with TMPD (Table 22), data generated by LC-
MS/MS was examined further in order to reveal a single protein that might be 
suitable for further investigation of the protein levels using an alternative method 
to LFQP. In doing this, the certainty in the identification (as evidenced by the 
number of peptides used in the identification and the mean Xcorr value) and the 
magnitude of change was taken into consideration.  
 
Rho GDP dissociation inhibitor (GDI) alpha (NP_001007006.1) was selected as 
the calculated Mw (23kDa) correlated well with the Mw region in which the 
protein was measured (28-38kDa). Two peptides were used to quantify the 
protein, and the observation that levels of the peptides in individual samples 
correlated well with each other, increased the certainty in the measurement of 
the protein levels. In addition, an overall 2.1-fold increase in the levels of the 
protein was observed in response to TMPD treatment (Figure 61). An example 
of the mass spectra obtained is shown in Figure 62. 
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Figure 61: Relative levels of peptides used to quantify Rho GDP 
dissociation factor Inhibitor (GDI) alpha 
Myoblasts were grown and treated with 25μM TMPD for 24h (section 2.1). Proteins in 
cell homogenates were separated by 1DE and peptides were generated from sections 
of the 1D gel (section 2.7). The levels of Rho GDI were increased significantly (2.1-fold) 
in response to treatment (Student’s t-test, p<0.05). The individual sample identities are 
displayed on the graph to show the correlation between the different peptide levels in 
each individual sample.  
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Figure 62: Example spectrum obtained following the MS/MS analysis of a peptide from Rho GDI 
Myoblasts were cultured and treated with 25μM TMPD (section 2.1). a) In combination, the 2 peptides used in the quantitation of Rho GDI covered 20% 
of the total protein and b) The example MS/MS spectrum shown is from 1 of 2 peptides used to quantify the protein. Identified b-ions and y-ions in the 
spectrum and the corresponding table are coloured blue and red, respectively, and this spectrum was typical of the spectra used to sequence this 
peptide. Pos, position; AA, Amino acid; Rev pos, reverse sequence position. 
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TMPD-induced increases in the level of Rho GDI observed by LC-MS/MS were 
confirmed by immunoblotting in order to verify the changes seen. Homogenates 
from myoblasts treated with a range of concentrations of TMPD (0-25μM) were 
probed specifically for Rho GDI myoblasts using a polyclonal antibody raised in 
rabbits. Rho GDI was significantly increased 1.4 and 1.6 times in myoblasts 
treated with 12.5 and 25μM TMPD, respectively (Figure 63).  
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Figure 63: TMPD-induced changes in the levels of Rho GDI in myoblasts 
Myoblasts were cultured and treated with a range of concentrations of TMPD (section 
2.1). TMPD-induced increases in the levels of Rho GDI originally observed by LC-
MS/MS were confirmed by immunoblotting using a polyclonal antibody measuring Rho 
GDI (section 2.7.5). Increases of 1.4 and 1.6-fold in this protein were observed 
following treatment with 12.5μM and 25μM TMPD, respectively. Error bars show ± 
SEM and significant changes are denoted by *p<0.05, **p<0.01. 
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The effect of other potential myotoxins on the levels of Rho GDI in myoblasts 
was also investigated. Treating myoblasts with 6.25, 12.5, 25 and 50μM GWδ 
had no significant effect on the levels of Rho GDI treated although it did 
increase (Students t-test; p<0.05). Myoblasts treated with pravastatin, which is 
another potentially myotoxic lipid-lowering compound were increased 2.6 and 
1.9-fold when cells were treated with 50 and 100μM of the compound (Figure 
64).  
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Figure 64: Rho GDI levels in myoblasts treated with GWδ or pravastatin 
Myoblasts were cultured and treated with a range of concentrations of GWδ or 
pravastatin (section 2.1). The levels of Rho GDI were investigated following the 
treatment of myoblasts with these test compounds in order to assess whether 
increases in the levels of Rho GDI were replicated using other potentially myotoxic 
compounds (section 2.7.5). Treating myoblasts with GWδ had no significant effect on 
the levels of Rho GDI but a 2.6 and 1.9-fold increase was observed when cells were 
treated with 50 and 100μM, respectively, of  pravastatin (Student’s t-test, p<0.05). Error 
bars show ± SEM and significant changes are denoted by *p<0.05, **p<0.01. 
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3.5.3.4 Selection of putative biomarkers of TMPD-induced myopathy in 
myotubes 
Using the same approach described for myoblasts in section 3.5.3.3, differential 
expression analysis of peptides generated from control and TMPD-treated rat 
L6 myotubes revealed that the levels of 10 proteins were differentially 
expressed in response to drug-treatment (Student’s t-test, p<0.05). Out of these 
proteins, 9 were measured at decreased levels in treated cells when compared 
to controls and 1 protein was up-regulated. The magnitude of the changes 
ranged from 1.3 to 2.6-fold. The proteins were classified according to their 
biological function and they included proteins that affected biological processes 
such as the cell cycle (3), electron transport (3), muscle contraction (1) and 
protein metabolism and modification (3) (Table 23). 
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Table 23: Identified myotubes cell proteins that showed differential expression following treatment with TMPD 
Myotubes were differentiated from myoblasts and treated with TMPD (section 2.1). Proteins within the samples were then separated by 
1DE before analysing peptides generated from different sections of the resulting gel by LC-MS/MS (section 2.7). Proteins (10) were 
shown to differ significantly in their expression as a result of TMPD-treatment (Student’s t-test, p<0.05). Of these proteins, the level of 1 
proteins was increased and 9 were decreased.  
Proteins Peptides used for quantitation
No. ions measured in 
control/treated
Fold 
change Probability
Overall fold 
change ± SEM 
(CV)
Cell cycle
Caldesmon 1 (CALD1) NP_037278.1  Cytoplasm 60 62-75 18b) R.LEQYTNAIEGTK.A (+2) 4.24 6/6 -1.3 0.04 -1.3
Proteasome 26S subunit, non-ATPase, 2 
(PSMD2)
NP_001026809.1  Cytoplasm 100a) 14-17 3b) R.ELDIMEPK.V (+2) 2.14 5/4 -1.7 0.006 -1.7
WD repeat domain 1 (WDR1) NP_001014157.1  Extracellular Space 66 49-62 4b) K.YAPSGFYIASGDISGK.L (+2) 4.96 6/6 +2.6 0.001 +2.6
Electron transport
ATP synthase, H+ transporting, 
mitochondrial F1 c (ATP5D)
NP_620806.1  Cytoplasm 18 14-17 2 K.AQSELSGAADEAAR.A (+2) 5.07 6/6 -1.7 0.004 -1.5 ±0.1
R.IEANEALVK.A (+2) 2.65 5/6 -1.4 0.04 (11%)
Cytochrome c oxidase subunit IV isoform 
1 (COX4I1)
NP_058898.1  Cytoplasm 19 6-14 2b) K.VNPIQGFSAK.W (+2) 2.78 6/6 -1.3 0.03 -1.3
Nucleoside diphosphate kinase B (NME2) NP_114021.2 17 14-17 4b) R.GDFCIQVGR.N (+2) 3.33 6/6 -2.0 0.003 -1.9 ±0.1
R.NIIHGSDSVESAEK.E (+2) 3.85 6/6 -1.7 0.04 (10%)
K.DRPFFPGLVK.Y (+2) 2.7 6/5 -2.0 0.01
Mean 
Xcorr
Comparison between control and TMPD-treatedNo. of unique 
peptide ions 
used in 
identification
Mw region 
(kDa) 
identified in
Peptide (charge)Name (gene name) NCBI accession code
Mw 
(kDa)Subcellular location
 
a) There was a discrepancy between the calculated Mw and the region of the gel in which the protein was detected. It is possible that a post-translational modification to the protein may have 
occurred or that the protein may have been fragmented or digested prior to detection. 
b) More peptides were used in the identification of these proteins but some of the peptides were below the level of quantitation. Therefore, only peptides suitable for measurement were used 
in determining the levels of the protein. 
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Table 23 continued. 
Proteins Peptides used for quantitation
No. ions measured in 
control/treated
Fold 
change Probability
Overall fold 
change ± SEM 
(CV)
Muscle contraction
Myosin, light polypeptide 2 (MYL2) NP_036737.1  Cytoplasm 19 14-17 12b) K.LKGADPEDVITGAFK.V (+3) 4.63 6/6 -2.5 0.02 -2.0 ±0.1
K.GADPEDVITGAFK.V (+2) 4.55 6/6 -2.0 0.03 (15%)
K.NICYVITHGDAKDQE.- (+3) 4.94 6/6 -2.0 0.006
R.FSQEEIK.N (+2) 2.54 6/5 -2.0 0.01
K.EAFTVIDQNR.D (+2) 4.37 6/6 -1.7 0.08
Protein metabolism and modification
Ribosomal protein S14 (RPS14) NP_073163.1  Cytoplasm 16 14-17 4b) K.TPGPGAQSALR.A (+2) 3.11 6/6 -1.7 0.005 -1.7
R.IEDVTPIPSDSTR.R (+2) 4.19 6/5 -1.7 0.004
Ribosomal protein S19 (RPS19) NP_001032423.1  Cytoplasm 16 14-17 6b) K.DVNQQEFVR.A (+2) 3.49 5/4 -1.7 0.009 -1.8 ±0.2 
R.VLQALEGLK.M (+1) 2.69 3/5 -2.0 0.001 (13%)
Ubiquitin-conjugating enzyme E2N 
(UBE2N)
NP_446380.1  Cytoplasm 17 14-17 3b) R.LLAEPVPGIK.A (+2) 2.46 6/6 -1.4 0.04 -1.4
Name (gene name) NCBI accession code Subcellular location
Mw 
(kDa) Peptide (charge)
Mw region 
(kDa) 
identified in
No. of unique 
peptide ions 
used in 
identification
Mean 
Xcorr
Comparison between control and TMPD-treated
 
a) There was a discrepancy between the calculated Mw and the region of the gel in which the protein was detected. It is possible that a post-translational modification to the protein may have 
occurred or that the protein may have been fragmented or digested prior to detection. 
b) More peptides were used in the identification of these proteins but some of the peptides were below the level of quantitation. Therefore, only peptides suitable for measurement were used 
in determining the levels of the protein. 
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In myotubes, the levels of myosin light chain polypeptide 2 (NP_036737.1) were 
decreased 2-fold in response to treatment with 25μM TMPD. There was also a 
reasonable degree of correlation between the calculated Mw (19kDa) and the 
gel slice in which the protein was measured (14-17kDa). In quantifying its 
levels, 5 peptides were used which increased the certainty that its levels were 
measured accurately. The correlation between the levels of the peptides used in 
the measurement of the protein in different samples was also good (Figure 65). 
 
In order to confirm the changes in the levels of myosin light chain 2 (Myl2) 
observed by LC-MS/MS, homogenates from myotubes treated with a range of 
concentrations of TMPD (0-25μM) were probed specifically for Myl2 using a 
rabbit polyclonal antibody to the protein. Myl2 was significantly decreased 2.4-
fold in cells treated with as low as 6.25μM TMPD (Student’s t-test, p<0.05). The 
levels of Myl2 were also reduced from control levels (2.3 and 2.4-fold) when 
myotubes were treated with 12.5μM and 25μM TMPD, respectively (Figure 67). 
An example of the mass spectra obtained is shown in Figure 66. 
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Figure 65: Relative levels of peptides used to quantify myosin light chain 
polypeptide 2 in myotubes 
Myotubes were differentiated from myoblasts and treated with 25μM TMPD for 24h 
(section 2.1). Proteins in myotubes were separated by 1DE and peptides were 
generated from fractions of the gel (section 2.7). The levels of Myl2 were decreased 
significantly (2-fold) in response to treatment (Student’s t-test, p<0.05). 5 different 
peptides contributed to the quantitation of the protein and the identity of each sample is 
displayed on the graph to show the correlation between the 5 different peptide levels in 
each individual sample.  
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Figure 66: Example spectrum obtained following the MS/MS analysis of a peptide from Myl2  
Myotubes were cultured and treated with 25μM TMPD (section 2.1). a) In combination, the 5 peptides used in the quantitation of Myl2 covered 34% of 
the total protein. a) The example MS/MS spectrum shown is from 1 of 5 peptides used to quantify Myl2. Identified b-ions and y-ions in the spectrum and 
the corresponding table are coloured blue and red, respectively, and this spectrum was typical of the spectra used to sequence the peptide.  
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Figure 67: TMPD-induced changes in the levels of myosin light chain 2 in 
myotubes 
Myotubes were differentiated from myoblasts and treated with a range of 
concentrations of TMPD (section 2.1). Reductions in the levels of Myl2 originally 
observed by LC-MS/MS were confirmed by immunoblotting using a rabbit polyclonal 
antibody to Myl2 (section 2.7.5). The sensitivity of the myotubes to TMPD was 
demonstrated by a 2.4-fold reduction in the levels of Myl2 when cells were treated with 
a low concentration of the compound (6.25μM). Significant reductions of 2.3 and 2.4-
fold in the levels of this protein compared to control samples were also observed 
following treatment with 12.5μM and 25μM TMPD, respectively (Student’s t-test; 
p<0.05). Error bars show ± SEM and significant changes are denoted by *p<0.05, 
**p<0.01. 
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The levels of Myl2 in myotubes treated with a range of concentrations of other 
potential myotoxins (GWδ and pravastatin) were also investigated. There were 
no statistically significant changes in the levels of this protein in cells treated 
with 12.5, 25 and 50μM GWδ (Students t-test; p<0.05). This was also true of 
myotubes treated with 25, 50 or 100μM pravastatin (Figure 68).  
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Figure 68: Myosin light chain 2 levels in myotubes following treatment 
with GWδ or Pravastatin 
Myotubes were grown and treated with a range of concentrations of GWδ or 
pravastatin (section 2.1). The levels of Myl2 were investigated following the treatment 
of myotubes with these test compounds in order to assess whether TMPD-induced 
decreases in the levels of Myl2 were replicated using other potentially myotoxic 
compounds (section 2.7.5). Myotubes were insensitive to the effects of both test 
compounds as demonstrated by the absences of statistically significant changes in the 
levels of Myl2 following treatment with GWδ or pravastatin. Error bars show ± SEM 
where visible. 
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The use of Decyder™ MS software allowed the semi-automated detection, 
identification, matching and measurement of peptides during these 
investigations. This, in turn, facilitated a more focused investigation into TMPD-
induced changes in the levels of peptides and proteins from a large dataset 
generated by LC-MS/MS that perhaps was not possible otherwise. However, 
the output from Decyder™ MS analysis is highly dependent on the settings used 
during its application. Due to the wide dynamic range of expression and the 
varied nature of the peptides measured, it was difficult to define settings that 
were suitable for all the peptides present. As such, it was decided to essentially 
over-detect peptides during the detection stage performed in the PepDetect 
module of the software and risk introducing peptides that might have been 
affected by electrical or chemical noise into the analysis. Some of this noise 
was then removed by using stringent criteria for the matching of peptides and 
also during the selection of putative biomarkers. 
 
A number of possible biomarkers of skeletal muscle toxicity were revealed and 
the treatment-induced changes in the levels of Rho GDI and Myl2 in myoblasts 
and myotubes, respectively, were confirmed by immunoblotting. In this way, any 
doubt in the authenticity of any changes revealed by LC-MS/MS were removed 
as they were confirmed when the proteins were measured more specifically. 
 
Technically, the use of LC-MS/MS is a more resource-demanding approach to 
biomarker discovery than using candidate biomarker screening (section 3.3) or 
the anonymous screening of protein ions (section 3.4). However, it results in 
useful data that can be interrogated to discover compound-induced changes in 
the levels of proteins and biomarkers of toxicity. The conclusive identification of 
each peptide and protein measured also allows the findings to be readily put 
into biological context. As a result of knowing the proteins that are responsive to 
treatment, the changes observed can then be measured more specifically using 
a more established or less technically demanding technique such as 
immunoblotting. 
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Chapter 4 
4. Discussion 
 
Evidence of skeletal muscle toxicity can occur in preclinical and clinical studies 
and can lead to the withdrawal of compounds, especially those belonging to the 
lipid-lowering class of drugs such as PPAR agonists or statins. Despite the 
incidence of myopathy being low in these studies, concerns over the safety of 
patients have led pharmaceutical companies and other sponsors to take this 
recurrent toxicology issue seriously. In addition, negative public perception and 
the threat of litigation are issues that regulatory authorities and research 
companies strive to address. For these reasons, skeletal muscle is a tissue that 
is usually monitored carefully when therapies for dyslipidaemia are being 
developed for clinical use63,68,85.  
 
CK is a biochemical marker that is often used to monitor the effects of drug-
treatment on skeletal muscle but, in most cases, it is not sensitive or specific 
enough and is only indicative of late-stage damage rather than being predictive 
of myopathy. Other biochemical markers of myopathy have, so far, performed 
little better and more novel biomarkers have yet to be fully validated for this 
purpose308,309. It was hypothesised that proteomics could be used to discover 
more useful biomarkers of myopathy using TMPD (an experimental myotoxin) 
and a potentially myotoxic PPAR-δ agonist (GWδ). Testing skeletal muscle cells 
with non-cytotoxic concentrations of the test compounds in vitro could also 
provide a suitable test system for discovering novel biomarkers of myopathy. In 
addition, it was proposed that this in vitro system might provide a way of 
screening novel compounds for their myopathic potential, prior to the selection 
of candidate drugs for development. 
 
In this study, the search for protein biomarkers of myopathy was conducted 
using a number of different strategies. A candidate biomarker approach was 
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used in which the value of markers associated with skeletal muscle was 
determined. MS based techniques were also used and this included an 
anonymous screening approach in which SELDI-TOF-MS was used to assess 
treatment related changes in the levels of protein ions in skeletal muscle cells 
treated with potentially myotoxic compounds. Biomarker discovery was also 
attempted using another MS based technique, which involved the combination 
of 1DE with LC-MS/MS. 
 
4.1 The use of rat L6 skeletal muscle cells 
The 3Rs (reduction, refinement and replacement) initiative encourages research 
institutions to use alternatives to animals, where possible and relevant, to 
assess the safety and efficacy of their compounds. In vitro alternatives are often 
sought due to ethical considerations surrounding the use of animals in drug 
research and the advantages of cost savings in terms of animal costs and 
animal husbandry101,310,311. In addition, there is sometimes a need to screen 
new molecules at the start of the drug discovery process in order to select 
molecules with the least potential of causing adverse effects in the latter stages 
of development. Along with reducing the costs of the large amounts of drug 
required for animal studies, this can reduce the costs of drug development by 
ensuring that compounds with a high liability are removed from the process thus 
reducing late-stage drug attrition due to unexpected findings312-316.  
 
Rat L6 skeletal muscle cells were used to determine the effects of test 
compounds selected for their ability to induce adverse effects on skeletal 
muscle in vivo and in vitro86,88,89,317. The rat L6 cell line closely mimics many 
aspects of skeletal muscle (both structurally and biochemically). Proliferating 
myoblasts are similar to myogenic satellite cells which, in vivo,  are involved in 
the growth, repair and maintenance of skeletal muscle tissue318-320. In culture, 
once they were attached to surface of the collagen-coated plate, they were 
shown to proliferate when grown in high serum conditions. EM examinations 
demonstrated that they existed as mononucleated single cells containing many 
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ribosomes and very few mitochondria, suggesting that the cells were 
undifferentiated, proliferating cells heavily involved in protein synthesis321. 
 
Myotubes were successfully differentiated from myoblasts after approximately 
10 days, as evidenced by the presence of cells with multiple nuclei. These cells 
were also elongated having been formed by the fusion of multiple myoblasts. It 
was also noted that, although the majority of cells in myotubes cultures were 
myogenic (>80%), there were still a proportion of myoblasts present 
(approximately 5-10%). This should be considered a desirable feature of the 
system making it more similar to skeletal muscle tissue. In vivo, immature 
muscle cells reside adjacent to mature cells in a quiescent state and are 
activated in the event of injury, functioning to repair or replace damaged skeletal 
muscle tissue107,109,322,323. 
 
The presence of myofilaments in myotubes provided further evidence of their 
differentiation from myoblasts. Myotubes also showed characteristic striations 
formed by light and thick bands (of myosin and actin, respectively), although the 
myofilaments were disorganised. During sample collection, cells were washed 
free of growth or differentiation medium and centrifuged in order to form a pellet 
so that the cells could be fixed in formaldehyde/gluteraldehyde for EM 
examinations. This procedure may have disrupted some of the fine structure 
present in the cells and subsequently the characteristic light and dark bands 
formed by the thin (actin) and thick (myosin) filaments that form the 
characteristic striations seen in muscle tissue in vivo (both of which are involved 
in the ATP driven procedure of muscle contraction under the influence of Ca2+). 
It is also possible that myofilaments were disorganised as the cells were non-
contracting in culture, in the absence of a suitable stimulus for contraction324,325.  
 
An initial assessment of the relative levels of the enzymes in myoblasts and 
myotubes showed that ALT, AST, CK, ALD and sTnI were detected at 
significantly higher levels in myotubes when compared to myoblasts. These 
higher basal levels of the markers in myotubes were due to the differentiated or 
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more “muscle-like” status of the mature cells. Previous researchers have used 
CK as a marker of differentiation in myotubes although the use of the other 
markers for this purpose has not been widely reported322,326-331. CK is the most 
commonly used marker in studies involving skeletal muscle and was the most 
responsive biochemical marker to the differentiation of myoblasts to myotubes. 
skeletal troponin I (sTnI) is a less well characterised marker for assessing the 
status of skeletal muscle and was also increased when myoblasts were 
differentiated88,92,93.  
 
Myoblasts were simpler to cultivate in vitro, as myotubes required the additional, 
time-consuming step of cell-differentiation. As such, myoblasts may be more 
suitable in a high-throughput screen for testing the myotoxic potential of NCEs. 
The length of time required for the differentiation of the myotubes might be 
considered to be a potential barrier to the use of myotubes in a high-throughput 
routine screen, although the growth and differentiation characteristics are very 
predictable and experiments could be planned accordingly so that this need not 
be a bottleneck in the process. Despite this, both systems were responsive to 
treatment with the test compounds and could help in elucidating the mechanism 
of toxicity of NCEs. 
 
4.2 The assessment of drug-induced cytotoxicity 
TMPD was selected for its ability to cause skeletal muscle toxicity, along with a 
highly selective PPAR-δ agonist (GWδ) for which incidents of myopathy have 
been reported86-90,332-336. Methods commonly used for the assessment of 
cytotoxicity in vitro (such as the visualisation of cells by microscopy, total 
intracellular protein and MTT reduction) were used to determine concentrations 
of the test compounds at which cellular function was compromised or at which 
the membrane integrity of myoblasts or myotubes was adversely affected337,338. 
These methods were used also to select non-overtly cytotoxic concentrations of 
TMPD or GWδ with which to conduct differential protein expression 
investigations.  
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Ultrastructural changes in cells (observed by EM and LM) were indicative of 
compound-induced effects. The levels at which these changes were observed 
also correlated well with the concentrations at which significant reductions in 
total intracellular protein and changes in the ability of the mitochondria of cells 
to convert a tetrazolium salt (MTT) to a formazan dye were observed. These 
cells displayed swollen mitochondria, disorganised cristae and the presence of 
vacuoles or lipid droplets within the cells. However, these alterations in the 
morphology and function of the cells were only evident at concentrations at 
which adverse effects had already been observed by relatively unsophisticated 
methods such as LM. This demonstrated the lack of sensitivity of these 
commonly used methods for assessing the effects of test compounds and the 
need for more sensitive methods or biomarkers for assessing myopathy.  
 
During EM examinations, it was also noticed that there was a higher proportion 
of cells that displayed features typical of myoblasts within myotube cultures 
treated with toxic concentrations of TMPD than were observed in untreated 
cultures. This observation may correspond to the situation in vivo where 
quiescent satellite cells are activated after injury to skeletal muscle and re-enter 
the cell cycle. Cells then divide and replicate before differentiating into 
myotubes and fusing with other myotubes to replace damaged skeletal muscle 
tissue. This indicated the potential to use markers of muscle differentiation as 
biomarkers of effect319,339,340. 
 
Taken together, these results demonstrated that both in vitro systems (using 
myoblasts and myotubes) were responsive to treatment and therefore suitable 
for biomarker discovery experiments. These results also allowed the selection 
of appropriate concentrations of the test compounds with which to treat skeletal 
muscle cells in differential protein expression experiments. In order to detect 
changes that were predictive of drug effects, subsequent experiments were 
performed on cells treated with concentrations of the test compounds that were 
not overtly cytotoxic. 
 
Chapter 4: Discussion  
 
 211
4.3 The candidate biomarker approach to biomarker discovery 
CK is found in several tissues but is detected at especially high levels in skeletal 
muscle, brain and heart tissue. An increase in the circulatory level of CK is 
usually used in toxicology experiments to indicate irreversible damage to the 
cell membrane of skeletal muscle cells332,341-343. It is often used in combination 
with other enzymes that are present in high concentrations in skeletal muscle 
(e.g. ALT, AST, LDH and ALD) that can help to clarify the origins of any 
changes in enzyme levels. Changes in the circulatory levels of these markers 
have been used extensively to monitor adverse effects on skeletal muscle in 
vivo. In spite of their routine use, it is widely recognised that these enzymes 
sometimes lack sensitivity to low levels of damage and also lack specificity for 
the site of injury unless specific isoenzymes such as CK-MM (specific to 
skeletal muscle) are measured95,98,286,344-348. As such, other more novel markers 
such as sTnI, Myl3, FABP3 and parvalbumin-α have been proposed and their 
usefulness was also assessed in this work. 
 
Enzyme leakage from cells into the circulation is commonly used for the 
assessment of damage to organs and therefore the leakage of enzymes from 
skeletal muscle cells in vitro was assessed. However, these markers were 
generally not of any additional value in these investigations. AST leaked from 
the cells of myoblasts and myotubes and the leakage of sTnI from myotubes 
were the most useful markers of TMPD-induced cytotoxicity in these 
investigations although these changes were observed at concentrations already 
known to be cytotoxic (as demonstrated by changes in microscopy, intracellular 
protein content and MTT reduction).   
 
Intracellular decreases in the levels of ALT, AST, CK and LDH in myoblasts 
treated with 100μM TMPD and an increase in the leaked levels of AST in 
myoblasts treated with 50μM TMPD demonstrated that there was no additional 
value in measuring candidate biomarkers in myoblasts. It was also noted that 
the levels of sTnI, Myl3, FABP3 and parvalbumin-α were, for the most part, 
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below the limit of detection for myoblasts due to the comparatively low levels 
detected in undifferentiated cells.  
 
In myotubes, the intracellular levels of ALD and CK were increased in cells 
treated with ≥ 6.25μM TMPD. All other changes were, again, only observed at 
levels already shown to be cytotoxic to myotubes. As with myoblasts, there 
appeared to be little additional value in measuring candidate biomarkers when 
compared to the more commonly used measures of cytotoxicity such as 
intracellular protein content and MTT reduction. The sensitivity of ALD and CK 
to the treatment of myotubes with TMPD was unexpected (and previously 
unreported) but may be useful for the in vitro assessment of the myotoxic 
potential of NCEs in myotubes. 
 
In interpreting the results from biochemical analyses, it was not possible to 
correlate changes in the intracellular levels or markers with leaked levels 
because some of the candidate biomarkers were detected in cells at low 
concentrations (especially myoblasts). For biochemical analyses, cells were 
lysed into 200μl of extraction buffer but 2ml of medium was collected, resulting 
in a greater dilution of the leaked levels of the markers. This resulted in a 
greater chance of their levels being below or near the limit of detection. It is also 
recognised that CK, for instance, is broken down or loses activity in the medium 
making it difficult to correlate intracellular and leaked levels of the marker88. In 
addition, it should be noted that the assays used for these investigations are 
normally aimed at human diagnostics and therefore at much higher 
concentrations of the markers than were evident in these experiments. 
 
4.4 SELDI-TOF-MS as a tool for biomarker discovery 
SELDI-TOF-MS is based on the same principles as MALDI-TOF-MS and 
enriches specific subsets of proteins from samples on the chromatographic 
surfaces of the ProteinChip® arrays used. By effectively limiting the proportion 
of the proteome viewed in a single analysis, a staggered analysis of the proteins 
in a sample can be performed. This is a similar principle to using LC to 
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introduce samples into a mass spectrometer, and usually leads to a reduction in 
ion-suppression, which might occur when highly abundant proteins are present 
or many proteins co-elute from an HPLC column during LC-MS analyses. 
SELDI-TOF-MS can also be technically less demanding than some of the other 
MS based techniques and has the additional benefit of generating a large 
quantity of data in a high-throughput manner164,231,233,234,349,350.  
 
Protein profiling investigations were aimed at identifying compound-induced 
differences in protein expression when control cells and treated cells were 
compared. Control cells were compared with those treated with a concentration 
of the test compounds at which cytotoxicity was not evident, as monitored by 
more established methods of screening cell status. At these concentrations, 
putative biomarkers were likely to be predictive of treatment effects and 
indicative of the mechanism by which cytotoxicity would eventually occur with 
increased exposure of the cells to the test compounds. 
 
Separation between control and treated myoblasts and myotubes following PCA 
analysis of SELDI-TOF-MS data demonstrated that both TMPD and GWδ-
treatment caused changes in the levels of protein ions that could be revealed 
using this technique. PCA is usually the first stage of such analyses and natural 
separation between control and treated groups usually indicates that PLS-DA is 
a valid next step in the analysis. PLS-DA is commonly used to force the 
separation between groups so that the variables responsible for the separation 
can be established. However, the inclusion of a large number of variables can 
lead to complicated loadings plots in which it is difficult to interpret which are the 
most important variables in the analysis. The use of VIP plots can help in this 
interpretation but, in these investigations, too many ions resulted. The use of 
false discovery rates was also attempted but the methods used (BH-FDR and 
the Bonferroni correction) are widely recognised to be too conservative and this 
proved to be the case in these investigations295. 
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It was recognised during these SELDI-TOF-MS investigations that the 
reproducibility of the compound-induced changes observed was a critical factor 
that determines the usefulness of any biomarkers discovered. Issues with 
reproducibility in this technique originate from a number of sources such as the 
preparation of ProteinChip® arrays or pulse-to-pulse variation in the laser 
source of the mass spectrometer. However, these are issues that are inherent 
in MS (and other techniques) and not all of them (apart from the ProteinChip® 
arrays) are unique to SELDI-TOF-MS297,351-353. Some of these variations arise 
during the application of EAM solution or from residual buffer solutions left on 
ProteinChip® arrays during their preparation (chemical noise). Electrical noise 
generally emanates from the internal machinery of the mass spectrometer and, 
along with chemical noise, can also affect mass spectra. This is managed 
during the processing of SELDI-TOF-MS data using the BMW incorporated into 
Ciphergen Peaks software. The BMW not only allows the clustering of protein 
ions that can be compared to each other in differential protein expression 
experiments, but it also ensures that appropriate peaks are selected for analysis 
with the minimal inclusion of peaks that might have been adversely affected by 
noise. The possibility of selecting variable ions was reduced by using 
appropriate settings for the BMW (section 3.4.1)288-290.  
 
In these investigations, issues with reproducibility were also addressed by 
repeating experiments. The initial findings from the statistical analysis of two 
repeat experiments of a training dataset were tested in an independent, smaller 
test dataset. Markers that responded consistently to treatment with the test 
compounds were then considered as putative biomarkers. SELDI-TOF-MS 
revealed a protein expression profile consisting of 16 protein ions that were able 
to discriminate between control and TMPD-treated myoblasts in a training 
dataset, although not all of these ions were validated successfully in the test 
dataset. In myotubes, a similar profile of 12 protein ions was discovered whose 
levels changed in response to treatment with the same test compounds. Some 
researchers have proposed that the conclusive identification of proteins may not 
be necessary and that protein fingerprints that are capable of distinguishing 
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between control and treated samples may be sufficient162,164,234,354,355. Although 
a combination of biomarkers could potentially be useful in the prediction of 
disease or toxicity, a specific combination of a number of variables may be 
difficult to reproduce in independent repeat experiments. It is therefore more 
difficult to produce fully validated assays. There is also a possibility of 
statistically over-fitting the data when a complex protein profile is considered in 
this way.  
 
It is often preferable to discover the most reproducible changes and to 
conclusively identify them, so that the response of the marker observed using 
MS can be validated using another technique356,357. Despite this, SELDI-TOF-
MS demonstrated that ions at m/z 5743 and 5298 might have been the most 
robust markers in myoblasts and myotubes, respectively, due to them being 
highlighted following corrections for multiple testing and also in repeat 
experiments. The fact that some of the ions previously shown in the profile were 
reproducible in training dataset, but not in the test dataset, highlights the risk of 
using a specific profile or “fingerprint”. This demonstrated that whilst some of 
the ions previously selected in the training dataset showed reasonable intra-
experimental reproducibility, they were variable when considered inter-
experimentally.  
 
Following the discovery of proteins ions that proved useful in the distinguishing 
between control and treated samples, proteins were identified on the basis on 
Mw information and their response to drug treatment. Data generated by LC-
MS/MS was used in combination with the TagIdent protein identification tool 
available via the ExPASy proteomics database, which searches the UniProt 
consortium knowledgebase for possible protein matches based on m/z 
information, and a user defined mass accuracy (0.1% of the measured m/z). 
The response of proteins to drug treatment, as measured by LC-MS/MS, was 
also compared to the response of the SELDI-TOF-MS protein ions in an attempt 
to identify proteins conclusively, but was of little additional value in this exercise. 
It was not possible to conclusively identify the protein ions of interest although 
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these methods of searching gave an idea of some possible identities for 
unknown proteins. Protein ions found using SELDI-TOF-MS ultimately remained 
unidentified, making it difficult to consider the effect of the changes biologically. 
The difficulty in obtaining conclusive identifications using SELDI-TOF-MS is, in 
part, due to the difficulty in isolating proteins that may have been retained on 
the chip surface. Furthermore, the relatively low resolution of the Ciphergen 
PBS IIc mass spectrometer usually prevents the identification of interesting 
proteins based on an accurate Mw assignment. This is combined with the 
possibility that protein ions detected at certain molecular weights could actually 
be multiple charges of the protein of interest358,359.  
 
Other approaches to the identification of proteins discovered by SELDI-TOF-MS 
include prefractionation of the sample to allow isolation of the specific proteins 
in order to allow specific proteins of interest to be characterised more easily. 
The use of magnetic beads designed to mimic the chemistries available on the 
ProteinChip® surface would also facilitate the isolation of interesting proteins 
from the beads, perhaps after they have been characterised on SELDI-TOF-MS 
ProteinChip® arrays. Antibody arrays designed to specifically probe for 
candidate biomarkers could also be potentially useful360-365. The approach of 
using ProteinChip® arrays as a target in higher resolution mass 
spectrophotometers has also been attempted and may increase the possibility 
of a conclusive identification366,367. Despite some limitations, SELDI-TOF-MS is 
still a useful tool for investigating protein expression, but the lack of a conclusive 
identification of responsive proteins means that it is difficult to fully validate 
putative biomarkers and, therefore, using them preclinically or clinically could be 
questionable.  
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4.5 The label-free approach to biomarker discovery 
LC-MS/MS was combined with 1DE during the LFQP analysis of control and 
treated skeletal muscle cells. The prefractionation of samples using 1DE 
allowed the complexity of samples to be reduced prior to enzymatically 
digesting the proteins and generating peptides, which could then be measured 
by LC-MS/MS. This in turn allowed more peptides to be detected (and therefore 
more proteins) with the increased possibility of discovering protein biomarkers 
of treatment effect. At this sample preparation stage, some researchers have 
been able to focus subsequent analyses on specific areas of the gel, if clear 
differences in protein expression were observed236. In this study, no changes in 
the protein expression profile were visible by 1DE so it was not possible to 
focus on any specific areas of the 1D-gel.  
 
In this study, 6 replicate control and 6 replicate TMPD-treated samples 
effectively became 132 samples when each lane of the gel was divided into 11 
Mw regions. Whilst dividing the gel into multiple sections reduced the 
complexity of the samples, it resulted in an increased number of samples and 
therefore an increase in the complexity of the data analysis. In addition, for a 
reliable comparison of expressed protein levels to be made between control and 
drug-treated samples, the accuracy of gel slicing was essential during sample 
processing. 
 
LC-MS/MS analysis of the peptides generated from the gel pieces was a time-
consuming process with each sample taking 70min to analyse. In practice, two 
traps and columns were run in parallel in order to increase sample throughput 
and samples that were to be compared to each other were analysed on the 
same column in order to minimise any variation in the retention times of eluted 
peptides. Although the data used was truncated to between 15 and 45 min (as 
the excluded regions contained a minimal number of peptides), MS analysis 
resulted in a large dataset containing 2100 peptides, which contributed to the 
identification of 217 proteins in myoblasts and 269 proteins in myotubes.  
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Intracellular levels of candidate biomarkers measured biochemically were 
compared to the levels of the corresponding proteins measured by LC-MS/MS. 
This analysis proved not to be useful at this level and this was mainly due to the 
fact that most of the peptides used in these comparison were not reliably 
identified (based on 1 peptide with a p value>0.05). In some instances, the 
peptides used may have been suitable for the identification of the protein but 
were not expressed at sufficiently high levels to facilitate a reliable quantitation 
of their levels. It should be noted, however, that this exercise essentially meant 
comparing specifically measured and sensitive enzyme activity with the protein 
levels of these markers. 
 
Myoblasts and myotubes were involved in very similar cellular processes when 
the global protein expression was considered and this is perhaps not surprising 
as 155 of the total number of proteins identified in skeletal muscle cells were 
common to both cell types. In a comparison between the normal biological 
processes, myotubes were shown to be highly involved in processes such as 
lipid, fatty acid and steroid metabolism, cell differentiation and muscle 
contraction, which are more likely to occur in skeletal muscle in vivo.  
 
Conversely, the process of apoptosis was comparatively higher in myoblasts 
when compared to myotubes and it would appear as if this is a common finding 
in vivo. In vivo macrophages have  frequently been found in close proximity with 
developing muscle tissue and the process of cellular proliferation was apparent 
bearing in mind the nature of the cells used in this work307,339,368. The remaining 
processes were those that are typical of a highly metabolic tissue with a high 
energy requirement, such as skeletal muscle.  
 
A profile of 8 proteins whose levels were responsive to TMPD treatment was 
revealed when the peptides levels were examined more specifically using 
Decyder™ MS software (4 increased and 4 decreased). In myotubes, 10 
proteins were discovered that were similarly responsive to treatment with TMPD 
(9 decreased and 1 increased in its levels). In contrast to the anonymous 
Chapter 4: Discussion  
 
 219
approach using SELDI-TOF-MS, this method proved to be advantageous in that 
nearly all of the peptides detected were routinely identified during MS analysis. 
This allowed changes in the levels of the proteins to be considered in terms of 
the affected cellular processes for both myoblasts and myotubes.  
 
The use of Decyder™ MS software allowed the automation of some aspects of 
the complex data analysis procedures involved with such a large dataset. In the 
PepDetect module of the software peptides were detected automatically (based 
on user settings) although peptide detection was rigorously checked for any 
inconsistencies so that occasional errors in feature selection could be corrected 
manually. This was critical to the matching of peptides, as errors here would 
lead to errors in data analysis. Peptide matching was performed in the 
PepMatch portion of the Decyder™ MS software and allowed peptides to be 
considered together for proteins and also allowed their response to drug-
treatment to be assessed. 
 
A number of proteins associated with cell proliferation, growth, structure and 
intracellular signalling were responsive to TMPD. In particular, many appeared 
to be directly involved with the reorganisation of the actin cytoskeleton, which 
plays an important role in many essential biological processes within the cell. 
Rho GDI is an important protein involved in signal transduction processes within 
the cell, including the reorganisation of the actin cytoskeleton369,370. This occurs 
via the interaction between Rho GDI and the family of small guanosine 
triphosphatases (GTPases) and guanosine diphosphatases (GDPases). GTP 
and GDP are key molecular switches of many cellular processes and they are, 
in turn, influenced by the binding of Rho GDI which was increased in this 
study371-374. Rho GDI has also been associated with the nuclear hormone 
receptor estrogen receptor β (ESR2)375 which was also increased, although it 
was not included in Table 16 as the confidence in the identification was 
insufficient (based on <2 peptides). The levels of several structural proteins 
such as Keratin 2 and 19 were also increased in myoblasts as a response to 
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treatment with TMPD and these proteins form part of the intermediate filament 
and are therefore involved with the actin cytoskeleton376-378.  
 
Some of the responsive proteins were also involved with myoblast 
differentiation. Increases in the levels of Rho GDI have been linked with a 
negative effect on cell differentiation in skeletal muscle cells, regulating the 
expression of myogenic regulatory factors such as myogenin and myocyte 
enhancing factor 2 (MEF2)379. Nuclear envelope spectrin repeat protein 1 (also 
known as nesprin 1) is a protein that is believed to maintain the structural 
integrity of the nucleus during myoblast differentiation and an increase in its 
levels may reflect an effect on cell differentiation380. Lectin galactose binding 
soluble 1 is another protein closely linked with cell differentiation and decreases 
in its levels support the suggestion that cell differentiation was discouraged 
(perhaps in preference to cell proliferation) in response to treatment with 
TMPD381-384. Lectin has also been associated with apoptosis385 and, in 
conjunction with decreases in the levels of serine [or cysteine] proteinase 
inhibitor (which is involved in proteolysis386-388) this may provide additional 
evidence for an increase in cell proliferation. 
 
The majority of the proteins that were differentially expressed in treated 
myotubes were reduced in their levels, which might suggest an adverse effect 
of TMPD treatment. These included proteins involved with metabolism and 
transport, intracellular signalling, protein synthesis, and cell structure. The levels 
of ubiquitin-conjugating enzyme E2N (UBE2N) were decreased and this protein 
is responsible for binding to and targeting other proteins for degradation. It is 
also known to act in conjunction with proteasome 26S subunit, non-ATPase, 2 
(PSMD2) in defining the fate of cells and this was also decreased389. Together, 
these results may suggest that protein synthesis was increased although the 
reasons for reductions in the levels of cytoplasmic ribosomal proteins 
(ribosomal protein s14 and ribosomal protein s19), which are important proteins 
involved in protein biosynthesis, are not yet clear but may well reflect a transient 
change in their levels. EM examinations in these investigations (section 3.1) 
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demonstrated that myotubes were actually a mixture of differentiated skeletal 
muscle cells (approximately 80%) with a small population of myoblasts 
(approximately 10%) and this may be reflected in the sometimes complex 
cellular responses of “myotubes” to treatment with TMPD. 
 
Myl2 is an important contractile protein and reductions in its levels may reflect a 
TMPD-induced change from the mature form of skeletal muscle cells to the 
undifferentiated proliferative form in order to address the potentially harmful 
effects of treatment with the test compound390-392. ATP synthase and 
cytochrome c oxidase are electron transport proteins, found in the mitochondria 
of mature skeletal muscle cells, and these also were reduced which might 
support a cell type switch to the proliferative immature form of the cells. 
 
Amongst the changes observed in both myoblasts and myotubes, increases in 
the levels of Rho GDI in myoblasts and a reduction in the level of Myl2 were the 
most consistent changes and their response to drug-treatment was confirmed 
by immunoblotting. An increase in Rho GDI was also observed following the 
treatment of myoblasts with similar concentrations of GWδ and pravastatin. 
Although, Myl2 was not decreased following the treatment of myotubes with 
GWδ, there were decreases in its level observed following treatment with 
pravastatin. It is possible that GWδ did not cause structural changes to 
myotubes (as might be evidenced by changes in Myl2). 
 
Despite being technically more demanding and having a much lower throughput 
than SELDI-TOF-MS, the vast amount of information generated by the powerful 
combination of electrophoresis, LC and MS/MS is a definite advantage during 
biomarker discovery. As discussed previously, the conclusive identification of 
proteins of interest is a key aspect of biomarker validation as it allows biological 
understanding to be applied to the findings. Despite the advantage of being able 
to generate a large amount of data quickly and relatively easily, the lack of 
conclusive identifications of the proteins observed is a major shortfall of the 
SELDI-TOF-MS approach. Although attempts were made to identify the 
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responsive proteins seen by SELDI-TOF-MS, the mass accuracy of the 
technique does not allow for conclusive identification of the proteins. In addition, 
the limited mass range of SELDI-TOF-MS (<20kDa) meant that large proteins 
were not observed using this technique. However, the technique was shown in 
this study to be capable of discovering protein biomarkers of myopathy in the 
form of responsive protein ions. Other researchers have shown that 
identification of these putative biomarkers is possible through the use of on-chip 
or off-chip fractionation, modification of existing LC-MS/MS technology to 
integrate with ProteinChip® arrays or via the use of antibody-based 
ProteinChip® arrays174,367.  
 
LFQP provides an alternative method for discovering protein biomarkers that 
has advantages over the labelling techniques such as ITRAQ or ICAT, in that 
the use of expensive reagents or reagents with a limited availability is avoided. 
However, the vast amount of data produced can be difficult and time-consuming 
to analyse. It should be noted that the identifications provided by LFPQ should 
be considered with caution. Confidence in the identifications routinely provided 
LC-MS/MS (in combination with database searching) should be considered 
based on the number of peptides and the confidence in the identification (as 
indicated by the p value or the mean Xcorr value)197. In this work, although all 
proteins were considered, the most reproducible changes were focused on, 
based on protein identifications from multiple unique peptides (Table 22 and 
Table 23). It should be pointed out, however, that the proteins discovered in 
these investigations are likely to require further validation prior to use as 
biomarkers of myopathy in preclinical or clinical studies. 
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4.6 Summary 
During these investigations, a number of proteins were discovered to be 
responsive to the treatment of skeletal muscle cells with TMPD or GWδ. During 
these studies, TMPD was used in all experiments and results obtained using 
this compound allowed a comparison to be made between all the different 
approaches to biomarker discovery used in these investigations (Figure 69). 
 
Methods of assessing compound effects on cells, such as measuring total 
intracellular protein, MTT reduction or the visualisation of cells using microscopy 
were useful in determining the cytototoxic potential of the test compounds in the 
test system. They were therefore useful for defining the concentrations at which 
biomarker discovery investigations could be conducted. However, these 
methods were only able to describe overt cytotoxicity caused by the test 
compounds and, when lower concentrations of the test compounds were used, 
they were unable to predict the effects at higher concentrations of the 
compounds. In general, candidate markers provided no additional value over 
the previously mentioned cytotoxicity markers although intracellular levels of 
ALD and CK proved to be sensitive markers of TMPD-induced myopathy in 
myotubes. 
 
SELDI-TOF-MS was also used to search for protein biomarkers of myopathy 
and the levels of a number of protein ions were changed in response to 
treatment with 25μM TMPD in both myoblasts and myotubes. Although the 
putative biomarkers discovered using this approach were more sensitive to 
treatment than total intracellular protein, MTT reduction, microscopy and the 
candidate markers, they were not responsive to <25μM TMPD. In addition, it 
was not possible to obtain conclusive identifications for the proteins discovered, 
making it difficult to fully understand the biological nature of the changes. 
Background variation in the levels of some of the SELDI-TOF-MS ions meant 
that, as is often the case with MS experiments, the analysis of a large number 
of samples was required in order to generate statistical confidence in the 
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robustness of the changes found. This often means that experiments are 
designed in order to overcome potential issues with reproducibility, which 
sometimes limits the number of different types of experiment that can be 
performed.  
 
A similar limitation to the design of experiments was true of the LFQP approach 
in that, although sensitivity was improved using an ion-trap mass spectrometer 
and the reproducibility was as would be expected for MS experiments, the 
analysis was low-throughput. Despite this, the combination of electrophoresis, 
MS/MS and immunoblotting was still the most useful approach to the discovery 
of biomarkers as it facilitated the discovery, identification and quantitation of 
sensitive protein biomarkers of myopathy in both myoblasts and myotubes.  
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Figure 69: Summary of protein changes in myoblasts and myotubes 
Myoblasts and myotubes were cultured and treated with a range of concentrations of 
TMPD (section 2.1). A number of approaches to discovering protein biomarkers of 
myopathy were attempted and their effectiveness in a) myoblasts and b) myotubes is 
summarised here. TMPD was overtly cytotoxic to myoblasts and myotubes at 50μM 
and filled boxes represent the concentration at which the levels of markers where 
changed significantly in response to treatment (Student’s t-test, p<0.05). Grey boxes 
represent the concentrations at which the markers were unresponsive to TMPD-
treatment when tested, and the hatched boxes represent where Rho GDI and Myl2 
were measured by immunoblotting. The assessment of endpoints commonly used to 
assess cell viability were only changed significantly at concentrations in which overt 
cytotoxicity was already evident (Student’s t-test, p<0.05) and intracellular levels of CK 
and ALD (in myotubes) were the only candidate biomarkers that were responsive at 
low concentrations of TMPD. A number of SELDI-TOF-MS protein ions and proteins 
discovered using a combination of electrophoresis and MS/MS were discovered to be 
responsive to low concentrations of TMPD. Following the discovery of responsive 
proteins by LFQP, changes in Rho GDI and Myl2 were confirmed using immunoblotting 
and found to be the most sensitive biomarkers of myopathy.  
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Chapter 5 
5. Conclusions 
 
This work has demonstrated that an in vitro skeletal muscle cell system, using 
myoblasts or myotubes, can be established that is responsive to the test 
compounds included in this study (TMPD and GWδ). A candidate biomarker 
approach to biomarker discovery was attempted but was of little additional value 
to routinely used biochemical markers of cytotoxicity. Intracellular levels of ALD 
and CK proved to be useful markers of myopathy but other markers tested 
were, in general, non-responsive to the treatment of cells with low 
concentrations of the test compounds used. 
 
SELDI-TOF-MS was useful in discovering protein ions whose levels were 
changed in response to treatment, and these proteins may have been indicative 
of early changes in the status of skeletal muscle cells. Although SELDI-TOF-MS 
was amenable for high-throughput analysis, it was limited to the low Mw mass 
range, although this could also be considered useful due to the fact that other 
techniques sometimes neglect this mass range. Interesting proteins were not 
readily identified using this SELDI-TOF-MS and this made it difficult to fully 
understand the changes observed. Despite the label-free approach to 
biomarker identification being limited by its throughput, it proved to be a 
valuable method for identifying protein biomarkers of myopathy. Unlike SELDI-
TOF-MS, the conclusive identification of putative biomarkers was routinely 
achieved using this technique and this allowed the changes observed to be 
considered in their proper biological context.  
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These studies demonstrated that proteomics is a powerful tool that can be used 
to search for biomarkers or patterns of biomarkers of toxicity in an in vitro 
system utilising skeletal muscle cells. The use of such biomarkers could allow 
researchers to closely monitor the effects of test compounds on experimental 
animals in preclinical studies and thus prevent the late stage attrition of 
compounds in drug development. In clinical studies or for patients on long-term 
treatment for dyslipidaemia, the use of effective biomarkers of myopathy may 
permit the safety monitoring of patients for muscle disorders, so that treatment 
can be withdrawn or modified before permanent damage can occur.  
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